0001628280-21-021464.txt : 20211103 0001628280-21-021464.hdr.sgml : 20211103 20211103161148 ACCESSION NUMBER: 0001628280-21-021464 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 211375476 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 10-Q 1 auph-20210930.htm 10-Q auph-20210930
false2021Q3000160062012-3100016006202021-01-012021-09-30xbrli:shares00016006202021-11-02iso4217:USD00016006202021-09-3000016006202020-12-310001600620us-gaap:ProductMember2021-07-012021-09-300001600620us-gaap:ProductMember2020-07-012020-09-300001600620us-gaap:ProductMember2021-01-012021-09-300001600620us-gaap:ProductMember2020-01-012020-09-300001600620us-gaap:LicenseMember2021-07-012021-09-300001600620us-gaap:LicenseMember2020-07-012020-09-300001600620us-gaap:LicenseMember2021-01-012021-09-300001600620us-gaap:LicenseMember2020-01-012020-09-3000016006202021-07-012021-09-3000016006202020-07-012020-09-3000016006202020-01-012020-09-30iso4217:USDxbrli:shares0001600620us-gaap:CommonStockMember2021-06-300001600620us-gaap:AdditionalPaidInCapitalMember2021-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001600620us-gaap:RetainedEarningsMember2021-06-3000016006202021-06-300001600620us-gaap:CommonStockMember2021-07-012021-09-300001600620us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001600620us-gaap:CommonStockMember2021-09-300001600620us-gaap:AdditionalPaidInCapitalMember2021-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001600620us-gaap:RetainedEarningsMember2021-09-300001600620us-gaap:CommonStockMember2020-06-300001600620us-gaap:AdditionalPaidInCapitalMember2020-06-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001600620us-gaap:RetainedEarningsMember2020-06-3000016006202020-06-300001600620us-gaap:CommonStockMember2020-07-012020-09-300001600620us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001600620us-gaap:CommonStockMember2020-09-300001600620us-gaap:AdditionalPaidInCapitalMember2020-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001600620us-gaap:RetainedEarningsMember2020-09-3000016006202020-09-300001600620us-gaap:CommonStockMember2020-12-310001600620us-gaap:AdditionalPaidInCapitalMember2020-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001600620us-gaap:RetainedEarningsMember2020-12-310001600620us-gaap:CommonStockMember2021-01-012021-09-300001600620us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300001600620us-gaap:RetainedEarningsMember2021-01-012021-09-300001600620us-gaap:CommonStockMember2019-12-310001600620us-gaap:AdditionalPaidInCapitalMember2019-12-310001600620us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001600620us-gaap:RetainedEarningsMember2019-12-3100016006202019-12-310001600620us-gaap:CommonStockMember2020-01-012020-09-300001600620us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300001600620us-gaap:RetainedEarningsMember2020-01-012020-09-30auph:segmentauph:reportingUnitxbrli:pure0001600620us-gaap:SalesRevenueNetMemberauph:SpecialtyPharmacyOneMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001600620us-gaap:SalesRevenueNetMemberauph:SpecialtyPharmacyTwoMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001600620auph:CashableGuaranteedInvestmentCertificatesMember2021-09-300001600620auph:CashableGuaranteedInvestmentCertificatesMember2020-12-310001600620auph:ShortTermCorporateDebtSecuritiesMember2021-09-300001600620auph:ShortTermCorporateDebtSecuritiesMember2020-12-310001600620us-gaap:CommercialPaperMember2021-09-300001600620us-gaap:CommercialPaperMember2020-12-310001600620us-gaap:USTreasuryBillSecuritiesMember2021-09-300001600620us-gaap:USTreasuryBillSecuritiesMember2020-12-310001600620us-gaap:USTreasuryBondSecuritiesMember2021-09-300001600620us-gaap:USTreasuryBondSecuritiesMember2020-12-310001600620auph:YankeeBondMember2021-09-300001600620auph:YankeeBondMember2020-12-310001600620us-gaap:CorporateBondSecuritiesMember2021-09-300001600620us-gaap:CorporateBondSecuritiesMember2020-12-310001600620us-gaap:PatentsMember2021-09-300001600620us-gaap:IntellectualPropertyMember2021-09-300001600620us-gaap:ComputerSoftwareIntangibleAssetMember2021-09-300001600620us-gaap:PatentsMember2020-12-310001600620us-gaap:IntellectualPropertyMember2020-12-310001600620us-gaap:ComputerSoftwareIntangibleAssetMember2020-12-310001600620us-gaap:ConstructionInProgressMember2021-09-300001600620us-gaap:ConstructionInProgressMember2020-12-310001600620us-gaap:LeaseholdImprovementsMember2021-09-300001600620us-gaap:LeaseholdImprovementsMember2020-12-310001600620us-gaap:OfficeEquipmentMember2021-09-300001600620us-gaap:OfficeEquipmentMember2020-12-310001600620us-gaap:ComputerEquipmentMember2021-09-300001600620us-gaap:ComputerEquipmentMember2020-12-31utr:sqft0001600620auph:VictoriaBritishColumbiaMember2020-12-310001600620auph:VictoriaBritishColumbiaMember2021-09-300001600620auph:VictoriaBritishColumbiaMember2020-08-310001600620auph:RockvilleMarylandMember2020-03-31auph:extension_option0001600620auph:RockvilleMarylandMember2020-03-012020-03-310001600620auph:RockvilleMarylandMember2021-09-300001600620auph:RockvilleMarylandMember2020-12-310001600620auph:RockvilleMarylandMember2020-01-012020-12-310001600620auph:RockvilleMarylandMember2020-03-1200016006202021-02-012021-02-280001600620us-gaap:FairValueInputsLevel1Memberus-gaap:DemandDepositsMember2021-09-300001600620us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel2Member2021-09-300001600620us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel3Member2021-09-300001600620us-gaap:DemandDepositsMember2021-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-09-300001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2021-09-300001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-09-300001600620us-gaap:MoneyMarketFundsMember2021-09-300001600620us-gaap:FairValueInputsLevel1Member2021-09-300001600620us-gaap:FairValueInputsLevel2Member2021-09-300001600620us-gaap:FairValueInputsLevel3Member2021-09-300001600620us-gaap:FairValueInputsLevel1Memberus-gaap:DemandDepositsMember2020-12-310001600620us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel2Member2020-12-310001600620us-gaap:DemandDepositsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001600620us-gaap:DemandDepositsMember2020-12-310001600620us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2020-12-310001600620us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310001600620us-gaap:MoneyMarketFundsMember2020-12-310001600620us-gaap:FairValueInputsLevel1Member2020-12-310001600620us-gaap:FairValueInputsLevel2Member2020-12-310001600620us-gaap:FairValueInputsLevel3Member2020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:RiptideBioscienceIncMember2021-08-172021-08-170001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-172020-12-170001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-170001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMembersrt:MinimumMember2020-12-170001600620srt:MaximumMemberus-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-170001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-12-012020-12-310001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2021-01-012021-09-300001600620us-gaap:LicenseAgreementTermsMemberauph:OtuskaPharmaceuticalCoLtdMember2020-10-012020-12-310001600620us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001600620us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001600620us-gaap:PerformanceSharesMember2021-01-012021-09-300001600620us-gaap:PerformanceSharesMember2020-01-012020-09-300001600620us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001600620us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001600620us-gaap:WarrantMember2021-01-012021-09-300001600620us-gaap:WarrantMember2020-01-012020-09-300001600620auph:AmendedAndRestatedEquityIncentivePlanMember2021-06-012021-06-300001600620us-gaap:EmployeeStockMember2021-09-300001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2020-12-310001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2021-01-012021-09-300001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2021-09-300001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2020-10-232020-10-230001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2021-03-182021-03-180001600620auph:PerformanceShareSandRestrictedStockUnitsRSUsMembersrt:OfficerMember2021-08-062021-08-060001600620srt:OfficerMemberus-gaap:PerformanceSharesMember2021-07-012021-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001600620us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001600620us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001600620us-gaap:InventoriesMember2021-07-012021-09-300001600620us-gaap:InventoriesMember2020-07-012020-09-300001600620us-gaap:InventoriesMember2021-01-012021-09-300001600620us-gaap:InventoriesMember2020-01-012020-09-300001600620auph:MilestonePaymentMemberauph:ILJINMembersrt:AffiliatedEntityMember2021-01-012021-03-310001600620auph:ILJINMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001600620auph:ILJINMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-310001600620auph:MilestonePaymentMemberauph:ILJINMembersrt:AffiliatedEntityMember2021-09-300001600620auph:LegalFeesMembersrt:ManagementMember2020-07-012020-09-300001600620auph:LegalFeesMembersrt:ManagementMember2020-01-012020-09-300001600620auph:LonzaMember2021-01-012021-09-300001600620auph:LonzaMember2021-07-012021-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________________________________
FORM 10-Q
_____________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from_____________ to ________________
Commission file number: 001-36421
__________________________________________
Aurinia Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
__________________________________________
Alberta, Canada
(State or other jurisdiction of
incorporation or organization)
#1203-4464 Markham Street
Victoria, British Columbia V8Z 7X8
46-4129078
(Address of principal executive offices)(I.R.S. Employer
Identification Number)
(250) 708-4272
Registrant’s telephone number, including area code
_____________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x 
Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of November 2, 2021, the registrant had 129,670,345 of common shares outstanding.
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of exchange on which registered
Common shares, no par valueAUPHThe Nasdaq Global Market LLC


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
TABLE OF CONTENTS
Page


PART I—FINANCIAL INFORMATION
Item 1. Financial Statements
AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September 30, 2021December 31, 2020
(unaudited)
ASSETS
Current assets
Cash and cash equivalents$57,587 $272,350 
Short-term investments228,813 125,979 
Accounts receivable, net9,814 — 
Inventories, net19,293 13,927 
Prepaid expenses and other current assets13,712 7,171 
Total current assets329,219 419,427 
Non-current assets
Long-term investments— 24,380 
Other non-current assets11,838 247 
Property and equipment, net4,551 4,786 
Acquired intellectual property and other intangible assets, net8,926 9,332 
Right-of-use assets5,532 5,489 
Total assets360,066 463,661 
LIABILITIES
Current liabilities
Accounts payable and accrued liabilities29,970 24,797 
Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively)
6,456 6,412 
Operating lease liabilities1,111 788 
Total current liabilities37,537 31,997 
Non-current liabilities
Other non-current liabilities16,562 16,295 
Operating lease liabilities7,795 7,619 
Total liabilities61,894 55,911 
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY
Common shares - no par value, unlimited shares authorized, 129,570 and 126,725 shares issued and outstanding as at September 30, 2021 and December 31, 2020, respectively
967,159 944,328 
Additional paid-in capital54,607 39,383 
Accumulated other comprehensive loss(794)(805)
Accumulated deficit(722,800)(575,156)
Total shareholder’s equity298,172 407,750 
Total liabilities and shareholders’ equity$360,066 $463,661 
The accompanying notes are an integral part of these condensed consolidated financial statements.
1

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
Three months endedNine months ended
September 30,September 30,
2021202020212020
(unaudited)(unaudited)
Revenue
Product revenue, net$14,638 $— $22,113 $— 
License revenue29 29 88 88 
Total revenue14,667 29 22,201 88 
Operating expenses:
Cost of sales254 — 610 — 
Selling, general and administrative44,128 30,702 127,196 57,204 
Research and development20,066 12,243 39,990 37,154 
Amortization of intangible assets517 316 1,576 902 
Other (income) expense, net55 (917)859 1,066 
Total cost of sales and operating expenses65,020 42,344 170,231 96,326 
Loss from operations(50,353)(42,315)(148,030)(96,238)
Interest income106 170 420 1,381 
Net loss before income taxes(50,247)(42,145)(147,610)(94,857)
Income tax expense (benefit)8 (15)34 (251)
Net loss(50,255)(42,130)(147,644)(94,606)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale securities, net of tax of nil
(2)— 11 — 
Comprehensive loss$(50,257)$(42,130)$(147,633)$(94,606)
Basic and diluted loss per share$(0.39)$(0.34)$(1.15)$(0.82)
Weighted-average common shares outstanding used in computation of basic and diluted loss per share128,443 122,357 128,084 115,738 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(in thousands)
(unaudited)
Common Shares
Three Months Ended September 30, 2021SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2021128,396 $954,572 $51,022 $(792)$(672,545)$332,257 
Shares issued on exercise of stock options1,172 12,579 (3,505)— — 9,074 
Exercise of warrants2 8 (2)— — 6 
Share-based compensation— — 7,092 — — 7,092 
Other comprehensive income— — — (2)— (2)
Net loss— — — — (50,255)(50,255)
Balance at September 30, 2021129,570 $967,159 $54,607 $(794)$(722,800)$298,172 
Common Shares
Three Months Ended September 30, 2020SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at June 30, 2020112,705 $752,357 $31,098 $(805)$(524,952)$257,698 
Issue of common shares13,333 200,000 — — — 200,000 
Shares issued on exercise of stock options412 2,386 (861)— — 1,525 
Share issue costs— (12,268)— — — (12,268)
Shared-based compensation— — 4,611 — — 4,611 
Net loss— — — (42,130)(42,130)
Balance at September 30, 2020126,450 $942,475 $34,848 $(805)$(567,082)$409,436 
Common Shares
Nine Months Ended September 30, 2021SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2020126,725 $944,328 $39,383 $(805)$(575,156)$407,750 
Shares issued on exercise of stock options2,324 22,097 (6,745)— — 15,352 
Exercise of warrants521 734 (697)— — 37 
Share-based compensation— — 22,666 — — 22,666 
Other comprehensive income— — — 11 — 11 
Net loss— — — — (147,644)(147,644)
Balance at September 30, 2021129,570 $967,159 $54,607 $(794)$(722,800)$298,172 
Common Shares
Nine Months Ended September 30, 2020SharesAmountAdditional
paid in
capital		Accumulated
Other
Comprehensive
(Loss) Income		Accumulated
Deficit		Total
Shareholders'
Equity
Balance at December 31, 2019111,798 $746,487 $25,394 $(805)$(472,476)$298,600 
Shares issued on exercise of stock options1,318 8,254 (2,854)— — 5,400 
Issue of common shares13,333 200,000 — — — 200,000 
Share issue costs— (12,268)— — — (12,268)
Exercise of warrants1 2 (1)— — 1 
Shared-based compensation— — 12,309 — — 12,309 
Net loss— — — (94,606)(94,606)
Balance at September 30, 2020126,450 $942,475 $34,848 $(805)$(567,082)$409,436 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Nine Months Ended
September 30,
20212020
(unaudited)
Cash flows used in operating activities:
Net loss$(147,644)$(94,606)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation of property and equipment497 59 
Amortization of intangible assets1,576 902 
Upfront license and milestone expense10,000 — 
Share-based compensation expense22,666 12,309 
Other, net1,005 736 
Net changes in operating assets and liabilities
Accounts receivable(9,815)— 
Inventories(5,366)(471)
Prepaid expenses and other current assets(6,541)(3,725)
Non-current assets247 — 
Right of use assets(43)(5,576)
Accounts payable, accrued and other liabilities1,149 9,012 
Lease liabilities499 8,298 
Net cash used in operating activities (131,770)(73,062)
Cash flows used in investing activities:
Purchase of investments(342,831)(202,951)
Proceeds from investments263,752 30,779 
Upfront lease payment(11,838)— 
Upfront license payment(6,000)— 
Purchase of long-lived assets(262)(4,095)
Additions to internal use-software implementation costs(1,198)(982)
Capitalized patent costs(6)(83)
Net cash used in investing activities (98,383)(177,332)
Cash flows from financing activities
Proceeds from exercise of stock options15,353 5,400 
Proceeds from exercise of warrants37 1 
Net proceeds from issuance of common shares— 187,732 
Cash provided by financing activities 15,390 193,133 
Net decrease in cash and cash equivalents(214,763)(57,261)
Cash and cash equivalents, beginning of period272,350 306,019 
Cash and cash equivalents, end of period$57,587 $248,758 
Supplemental cash flow information
Cash received for interest$671 $891 
Cash paid for taxes$(236)$(62)
Cash paid for amounts included in the measurement of lease liabilities$(195)$(68)
Supplemental disclosure of noncash transactions
Initial recognition of operating lease right-of-use asset$419 $5,804 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4


AURINIA PHARMACEUTICALS INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1.Organization and Description of Business
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program.
On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN.
On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 is currently undergoing pre-clinical development with projected submission of an Investigational New Drug Application (IND) to the FDA by the end of 2022. It is anticipated that an IND for AUR300 is expected during the first half of 2023.
Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle, Rockville, Maryland, United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares traded on both the Nasdaq Global Market (Nasdaq) under the symbol AUPH and on the Toronto Stock Exchange (TSX) under the symbol AUP until July 30, 2021. As of July 30, 2021, the Company's common shares no longer trade on the TSX following the voluntary delisting by the Company and are solely traded on the Nasdaq.
2.Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.
The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief executive officer makes decisions for the Company and its subsidiaries as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.
These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.
5


We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash and cash equivalents and investments of $286.4 million as of September 30, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued.
3.Summary of Significant Accounting Policies
Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Critical Accounting Estimates: The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial expenditures;
•Share-based compensation;
•Intangible assets;
•Leases; and
•Income taxes.
Concentration of Credit Risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.

The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 59% and 40% of the Company's total revenues for the three and nine months ended September 30, 2021. The Company monitors economic conditions, the
6

creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
Investments: The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the FASB ASC Topic 320, Investments — Debt Securities. Investments classified as held to maturity are carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method.
Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to two specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.
More specifically, these adjustments include the following:
Prompt pay discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Customer fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&A) expense.
Government rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.
7

Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
Co-payment assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.
License, Collaboration and Other Revenues
The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services and pass-through costs that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property (IP) is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Manufacturing supply services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.
Milestone payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-
8

evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.
Research, Development and/or Manufacturing Services. The Company’s agreements may include research and development (R&D) or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.
Cost of sales: Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.
Research and development expenses: R&D expenses are accounted for in accordance with ASC Topic 730, Research and Development, and are expensed as incurred. R&D costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, acquired licenses, subcontractors (such as contract research organizations) and materials used for R&D activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the R&D activities of the Company, including R&D conducted by others on behalf of the Company, shall be included in R&D costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers.
Selling, general and administrative expenses: The Company's SG&A expenses include commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These SG&A costs include corporate facility operating expenses and allocated depreciation; commercial, marketing, pharmacovigilance, publications, tradeshows, advisory boards, samples and operations in support of LUPKYNIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense SG&A expenses as they are incurred.
The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to two specialty pharmacies and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in SG&A expenses.
Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of September 30, 2021, accounts receivable, net are $9.8 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of September 30, 2021 and as of December 31, 2020.
Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date for all share-based payments related to stock options, performance awards, restricted stock units and purchases under the Company's Employee Stock Purchase Plan.
Recently adopted accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit
9

losses if fair value increases. The Company adopted the standard as of January 1, 2020 and did not have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement. Topic 820 requires to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.
10

4.    Investments
As of September 30, 2021 and December 31, 2020, the Company had $228.8 million and $nil and $126.0 million and $24.4 million of short and long-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of September 30, 2021, the Company classifies its investments as debt securities of which $21.5 million are held to maturity debt securities which are carried at amortized cost and are approximately equal to fair market value. As of September 30, 2021, $207.3 million are available-for-sale debt securities which are carried at fair market value and are approximately equal to amortized cost. As of December 31, 2020, $150.4 million were classified as held to maturity and $nil were available-for-sale.
(in thousands)September 30, 2021December 31, 2020
Cashable Guaranteed Investment Certificate$5,644 $2,000 
Corporate Bond25,435 40,372 
Commercial Paper197,734 67,747 
Treasury Bill— 7,999 
Treasury Bond— 5,045 
Yankee Bond— 2,816 
Total short-term investments228,813 125,979 
Corporate Bonds - total long-term investments— 24,380 
Total investments$228,813 $150,359 

Currently, the Company does not intend to sell investments that are classified as held-to-maturity and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of September 30, 2021 and December 31, 2020, accrued interest receivable from the investments were $0.1 million and $0.5 million, respectively. During the three and nine months ended September 30, 2021, the Company had $2 thousand and $11 thousand unrealized losses and gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. The Company's investments as of September 30, 2021 mature at various dates through September 2022.

5.    Inventories

Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For our product LUPKYNIS, the Company commenced capitalization of inventory once FDA approval was deemed to be probable, which occurred during the third quarter of 2020. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.

The components of inventory as of September 30, 2021 and December 31, 2020 are as follows:
(in thousands)September 30, 2021December 31, 2020
Raw materials$2,217 $— 
Work in process12,074 13,927 
Finished goods5,002 — 
Total inventories$19,293 $13,927 


11

6.Prepaid Expenses and Other Current Assets

The following table summarizes prepaid expenses and other current assets.

(in thousands)September 30, 2021December 31, 2020
Prepaid assets$5,871 $3,701 
Prepaid insurance2,524 2,054 
Other current assets728 1,018 
Prepaid deposits4,589 398 
Total prepaid expenses and other current assets$13,712 $7,171 

7.Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2021
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,471 $(1,152)$319 
Acquired intellectual property and reacquired rights15,125 (8,545)6,580 
Internal-use software implementation costs2,873 (846)2,027 
$19,469 $(10,543)$8,926 
December 31, 2020
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,651 $(1,203)$448 
Acquired intellectual property and reacquired rights15,126 (7,770)7,356 
Internal-use software implementation costs1,675 (147)1,528 
$18,452 $(9,120)$9,332 
Amortization expense for the three months ended September 30, 2021 and 2020 was $0.5 million and $0.3 million, respectively, and for the nine months ended September 30, 2021 and 2020 was $1.6 million and $0.9 million, respectively.

8.    Property and Equipment, net
Property and equipment as of September 30, 2021 and December 31, 2020 are as follows:
(in thousands)September 30, 2021December 31, 2020
Construction in progress$360 $4,467 
Leasehold improvements2,978 34 
Office equipment and furniture1,621 83 
Computer equipment265 381 
5,2244,965
Less accumulated depreciation(673)(179)
Property and equipment, net$4,551 $4,786 

12

Depreciation expense for the three month period ended September 30, 2021 and September 30, 2020 was $0.2 million and $nil, respectively, and for the nine months ended September 30, 2021 and 2020 was $0.5 million and $0.1 million. which is included in SG&A expenses in the condensed consolidated statements of operations.
9.    Lease Obligations
The Company has the following lease obligations:
Victoria, British Columbia
During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of September 30, 2021, the Company had $0.2 million right-of-use assets (ROU assets) and $0.2 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in SG&A expense in the condensed consolidated statement of operations. The incremental borrowing rate applied to the lease liabilities was 4.08% based on financial position, geographical region and terms of leases.
During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The lease term is expected to begin in 2022. The present value of the minimum lease payments for this lease are $2.7 million. As of September 30, 2021, the lease has not commenced and as a result there has been no accounting recognition associated with the lease.
Rockville, Maryland
During March 2020, the Company entered into a lease for its commercial office in Rockville, Maryland. The lease has a remaining term of approximately 11 years and has an option to extend for two five-year periods after the 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2021, the Company had a right-of-use asset of $5.3 million and lease liability of $8.7 million included in the condensed consolidated balance sheets. As of December 31, 2020, the Company had a right of use asset of $5.5 million and lease liability of $8.4 million included in the condensed consolidated balance sheets. During 2020, the Company received reimbursements for tenant leasehold improvements by the landlord in the amount of $2.3 million for the Maryland lease. The Company recorded these leasehold improvement incentives as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During the fourth quarter of 2020, the Company entered into an agreement to lease premises in Edmonton, Alberta, commencing on October 1, 2020 and ending September 30, 2021. During the third quarter of 2021, the lease was extended until September 30, 2022. The Company recognizes short-term leases on a straight-line basis and did not record a related lease asset or liability for the Edmonton lease. The Company recognized short-term rent expense for this lease, which is included in SG&A expense in the condensed consolidated statement of operations.
The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:
(in thousands)Balance Sheet ClassificationSeptember 30, 2021December 31, 2020
Assets
Operating lease right of-use assetsRight-of-use assets$5,532 $5,489 
Liabilities
Current operating lease liabilitiesCurrent operating lease liabilities1,111 788 
Non-current operating lease liabilitiesNon-current operating lease liabilities7,795 7,619 
Total lease liabilities$8,906 $8,407 
13


Beginning January 1, 2021, the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs for the three and nine month periods ended September 30, 2021. The following provides a summary of the components of leasing costs and rent for the three and nine month periods ended September 30, 2021 and September 30, 2020.
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)Consolidated Statement of Operations2021202020212020
Operating lease costs
Operating lease costsSelling, general and administrative$261 $196 $783 $456 
Short-term lease costs
Office BuildingSelling, general and administrative7 74 21 215 
Variable lease costs
Office buildingSelling, general and administrative44 1 124 3 
Total rent expense$312 $271 $928 $674 
The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2021:
As of September 30, 2021
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases9.685.20%
The following table provides a summary of operating lease liabilities maturities for the next five years and thereafter:
14

(in thousands)Operating Lease Payments
Remainder of 2021$281 
20221,143 
20231,061 
20241,085 
20251,109 
Thereafter6,773 
Total future minimum lease payments 11,452 
Less: lease imputed interest(2,546)
Total future minimum lease payments$8,906 
Finance Lease
On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
The first capital expenditure payment was made in February 2021 of $11.8 million which was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee.
The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $84.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.
10.Accounts Payable and Accrued Liabilities
The following table summarizes the Company's accounts payable and accrued liabilities.

(in thousands)September 30, 2021December 31, 2020
Trade payables$3,263 $2,635 
Other accrued liabilities8,322 6,616 
Accrued R&D projects3,865 4,185 
Employee accruals14,520 11,361 
Total accounts payable and accrued liabilities$29,970 $24,797 


11.Non-current Liabilities

The Company recorded other non-current liabilities of $16.6 million and $16.3 million as of September 30, 2021 and December 31, 2020, respectively. The balance as of September 30, 2021 and December 31, 2020 primarily included obligations that are the result of a resolution of the board of directors of the Company dated March 8, 2012 whereby certain executive officers at that time were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events.
15

12.Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short and long-term investments that are valued through third-party pricing services that use verifiable observable market data. The Company has no Level 3 instruments as of September 30, 2021 and December 31, 2020.
There were no transfers between Level 1, Level 2 and Level 3 instruments in the periods presented.
The following tables present the financial assets measured at fair value on a recurring basis:
September 30, 2021
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$35,070 $— $— $35,070 
Short-term highly liquid investments19,417 3,100 — 22,517 
Investments197,734 31,079 — 228,813 
Total$252,221 $34,179 $— $286,400 
December 31, 2020
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$130,807 $— $— $130,807 
Short-term highly liquid investments141,543 — — 141,543 
Investments69,746 80,613 — 150,359 
Total$342,096 $80,613 $— $422,709 
Refer to Note 4, “Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
13.License and Collaboration Agreements
Riptide License
On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated
16

statement of operations. Additional milestone payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during the first half of 2023.
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS for the treatment of patients with active LN in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.

As part of the agreement, Aurinia received an upfront cash payment of $50.0 million for the license agreement and has the potential to receive up to $50.0 million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, voclosporin will be provided to Otsuka under a cost-plus supply agreement.

The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional IP that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0 million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.

The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved, and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.

As of September 30, 2021, there has been no additional consideration earned or received since the upfront payment of $50.0 million during the fourth quarter of 2020.
14.Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2021202020212020
Net loss$(50,255)$(42,130)$(147,644)$(94,606)
Weighted average common shares outstanding128,443 122,357 128,084 115,738 
Net loss per common share (expressed in $ per share)$(0.39)$(0.34)$(1.15)$(0.82)
The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:

17

Nine months ended
September 30,
(in thousands)20212020
Stock options12,837 11,443 
Unvested performance awards857 — 
Unvested restricted units201 — 
Warrants1,012 1,690 
14,907 13,133 

15.Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of outstanding awards). Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code (the “Code”) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price.
As of September 30, 2021 and December 31, 2020, 129.6 million and 126.7 million, common shares were issued and outstanding.

Stock Options

The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average assumptions were used to estimate the fair value of the options granted during the nine month periods ended September 30, 2021 and September 30, 2020:
September 30, 2021September 30, 2020
Annualized volatility66 %43%
Risk-free interest rate0.38 %0.70 %
Expected life of options in years4.0 years3.0 years
Estimated forfeiture rate8.9 %12 %
Dividend rate0.0 %0.0%
Fair value per common share option$6.64 $5.05 

18

The following table summarizes the option award activity during the nine months ended September 30, 2021:

September 30, 2021
Number of shares (in thousands)Weighted average exercise price $
Outstanding - Beginning of Period14,047 11.35 
Granted2,059 13.42 
Exercised(2,324)6.60 
Cancelled/Forfeited(945)13.72 
Outstanding - End of Period12,837 12.37 
Vested and expected to vest - End of Period2,635 14.54 
Options exercisable - End of Period5,244 10.81 
Performance Awards and Restricted Stock Units
On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56.
On August 6, 2021, the Company granted approximately 619,000 PAs and restricted stock units (RSUs). The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vest on the employee's first anniversary of the grant date and the employee must achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs have no performance metrics and will vest on the one year anniversary of the grant.
The Company recorded approximately $0.7 million and $1.1 million of share-based compensation expense related to PAs and RSUs during the three and nine month periods ended September 30, 2021.
Compensation Expense
The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2021 and September 30, 2020 as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Research and development$1,038 $814 $3,201 $3,111 
Selling, general and administrative6,000 3,750 19,189 9,151 
Capitalized under inventories54 47 276 47 
Share-based compensation expense$7,092 $4,611 $22,666 $12,309 
As of September 30, 2021, there was $16.9 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.1 years.

16.Income Taxes

The effective tax rates for the three and nine months ended September 30, 2021 and September 30, 2020 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $8 thousand and $34 thousand for the three and nine months ended September 30, 2021, respectively, and an income tax benefit of $15 thousand and $251 thousand for the three and nine months ended September 30, 2020, respectively. The expense recognized for the three and nine months ended September 30,
19

2021 was a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.

The tax benefit recognized for the three and nine months ended September 30, 2020 was a result of a discrete tax benefit recorded in the U.S. pursuant to certain tax provisions provided under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in the United States on March 27, 2020. The CARES Act permits the Company to carry back net operating losses to offset taxable income generated in the five preceding years, some of which were taxed at a federal income tax rate higher than the current enacted rate.
17.Related Party Transactions
ILJIN is considered to be a related party due to their equity ownership of over 5%. The outstanding related party amount payable to ILJIN is the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the first quarter of 2021, Aurinia paid $4.0 million upon achievement of specific milestones. The amount payable to ILJIN of $2.0 million and $6.0 million as of September 30, 2021 and December 31, 2020 was recorded in other current liabilities, respectively. The final $2.0 million outstanding amount payable has been achieved and will be paid during the fourth quarter 2021.
Stephen P. Robertson was a partner at Borden Ladner Gervais LLP (BLG) and acted as our corporate secretary through October 2020. We incurred legal fees in the normal course of business to BLG of $0.1 million and $0.3 million for the three and nine months ended September 30, 2020. We had no ongoing contractual or other commitments as a result of engaging Mr. Robertson to act as our corporate secretary and Mr. Robertson received no additional compensation for acting as the corporate secretary. On November 2, 2020 we announced the appointment of Stephen Robertson as our Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.
18.Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's commitments and contingencies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Manufacturing Commitments
The Company has various manufacturing agreements to support our commercial and clinical product supply requirements.

We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial and clinical drug substance requirements. We have firm orders with Lonza, with remaining total non-cancellable future commitments of approximately $25.4 million through 2023 of which $3.5 million was paid during the second quarter of 2021. If we terminate certain firm orders with Lonza without cause, we will be required to pay for drug substance scheduled for manufacture under our arrangement.
20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this Quarterly Report. The information in this discussion contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Exchange Act, which are subject to the “safe harbor” created by those sections, as well as “forward-looking information” as defined in applicable Canadian securities laws. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans; objectives of management; the key potential benefits of LUPKYNIS; our belief that we have sufficient financial resources to fund our current plans for at least the next 12 months; and our potential to receive certain payments and royalties under our agreement with Otsuka. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “propose,” “intend,” “continue,” “potential,” “possible,” “foreseeable,” “likely,” “unforeseen” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: the accuracy of reported data from third party studies and reports; that our IP rights are valid and do not infringe the IP rights of third parties; our assumptions relating to the capital required to fund operations for the next 12 months; the assumption that our current good relationships with our suppliers, service providers and other third parties will be maintained; assumptions relating to the burn rate of our cash for operations; that our third party service providers will comply with their contractual obligations. Even though management believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. We discuss many of these risks, uncertainties and other factors in greater detail under the heading “Risk Factors” in Part I, Item 1A of our 2020 Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission on February 24, 2021 and with applicable Canadian securities regulatory authorities. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this discussion completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Overview
Aurinia is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. We have commercially launched LUPKYNIS in the United States for the treatment of adult patients with active LN, and continue to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program.
LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids, the current standard of care for LN (although not currently approved as such). By inhibiting calcineurin, LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. LUPKYNIS also potentially stabilizes podocytes, which can reduce proteinuria. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The mechanism of action of LUPKYNIS has been validated with certain earlier generation CNIs for the prevention of rejection in patients undergoing solid organ transplants and in several autoimmune indications, including uveitis, keratoconjunctivitis sicca, psoriasis, rheumatoid arthritis, and for LN in Japan. We believe that LUPKYNIS possesses pharmacologic properties with the potential to demonstrate best-in-class differentiation.
Earlier generation CNIs have demonstrated efficacy for a number of conditions, including transplant and other autoimmune diseases; however, side effects exist which can limit their long-term use and tolerability. Some clinical complications of earlier generation CNIs include hypertension, hyperlipidemia, diabetes, and both acute and chronic nephrotoxicity.
Based on published data, we believe the key potential benefits of LUPKYNIS in the treatment of adult patients with active LN versus marketed CNIs include:
•increased potency compared to cyclosporine A, allowing for lower dosing requirements and potentially fewer off
21

target effects;
•limited inter and intra patient variability, allowing for easier dosing without the need for monitoring blood levels for therapeutic drug monitoring;
•less cholesterolemia and triglyceridemia than cyclosporine A; and
•limited incidence of glucose intolerance and diabetes at therapeutic doses compared to tacrolimus.

Developments

•On January 22, 2021, the FDA approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN. As a condition of approval, we are required and are on track to conduct two pediatric studies (with reports due in 2025 and 2031), a milk only lactation study (with a report due in 2026), a drug-drug interaction study (with a report due in 2023) and submit a final study report on our AURORA-2 continuation study (by March 2022).
•On May 10, 2021, The Lancet, an international, peer-reviewed medical journal, published the results of the Company’s Phase 3 AURORA 1 study evaluating LUPKYNIS (voclosporin) in adults with LN.
•On May 20, 2021, we announced that the interim analysis of the AURORA 2 continuation study showed that subjects in the LUPKYNIS treatment arm sustained meaningful reductions in proteinuria, with no change in mean estimated glomerular filtration rate (eGFR) at 104 weeks of treatment.
•On June 7, 2021, our shareholders adopted and approved the Plan, which allows for the issuance of up to an additional 11.5 million shares. The purpose of the Plan is to advance the interests of the Company by encouraging equity participation in the Company through the acquisition of common shares. Also in June 2021, our shareholders adopted and approved the 2021 ESPP, which allows for the issuance of up to 2.5 million shares. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price.
•On June 14, 2021, we appointed Dr. Brinda Balakrishnan, M.D., Ph.D., to our Board of Directors effective June 14, 2021. Dr. Balakrishnan is Group Vice President, Corporate and Business Development of BioMarin Pharmaceutical Inc.
•On June 25, 2021, our licensing partner, Otsuka, filed an initial marketing authorization application with the European Medicines Agency seeking approval for the use of voclosporin for the treatment of adult patients with active LN in the European Union, as well as Norway, Iceland and Liechtenstein. Upon approval we would be eligible for up to an additional $30 million USD in approval related milestones, low double-digit royalties on sales, and additional revenues for the supply of product to Otsuka under a cost-plus arrangement.
•On July 16, 2021, we announced we will voluntarily delist the common shares from the TSX effective as of the close of trading on July 30, 2021. Our common shares will no longer be traded on the TSX but will continue to trade on the Nasdaq under the symbol AUPH.
•On August 17, 2021, we announced the addition of two novel pipeline assets AUR200 and AUR300. AUR200 is a Fc protein targeting BAFF/APRIL (B-cell Activating Factor, known as BAFF, and A Proliferation-Inducing Ligand known as APRIL). AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA by the end of 2022. AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cells) via the macrophage mannose receptor CD206. Dysregulation of M2 macrophages drives fibrosis. AUR300 acts to reduce M2 dysregulation and decrease inflammatory cytokines, and therefore may have significant clinical applications for autoimmune and fibrotic diseases. AUR300 IND filing is expected during the first half of 2023.
•On October 1, 2021, Aurinia’s licensing partner, Otsuka Pharmaceutical Co., Ltd., filed an initial marketing authorization application (MAA) with the Swiss Agency for Therapeutic Products (Swissmedic) seeking approval for the use of voclosporin for the treatment of adult patients with active LN. The Swiss filing was based on the June 24, 2021 MAA submission to the European Medicines Agency (EMA).
•Regulatory review of the EMA MAA remains on track with a CHMP opinion expected around mid-2022 followed by an EMA decision expected sometime in the third quarter of 2022. Additionally, Otsuka continues to work to finalize the timeline for the JNDA regulatory filing with PMDA to seek approval of voclosporin for the treatment of LN in Japan.

Impact of COVID-19 Pandemic

In the event of a prolonged disruption related to the COVID-19 pandemic, there could be detrimental impact to our ongoing and future clinical trials, our ongoing commercial launch and future commercialization activities for LUPKYNIS, and our ability to access capital markets. For further information, refer to Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020.
22

Critical Accounting Policies and Significant Judgments and Estimates
The preparation of our unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the revenues and expenses incurred during the reported periods. We base our estimates on historical experience and on various other factors that we believe are relevant under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We discussed accounting policies and assumptions that involve a higher degree of judgment and complexity in Note 2 to our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 and any updates in Item 1. Note 3 from our Summary of Significant Accounting Policies.
There have been no material changes to our critical accounting policies and estimates as compared to those disclosed in our Annual Report.
We believe that of our critical accounting policies, the most significant areas involving critical estimates, judgments and assumptions used in the preparation of our consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial expenditures;
•Share-based compensation;
•Intangible assets;
•Leases; and
•Income taxes.
23

Results of Operations
Three and Nine Month Periods ended September 30, 2021 compared to Three and Nine Month Periods ended September 30, 2020
The following table sets forth our results of operations for the three and nine month periods ended September 30, 2021 and September 30, 2020.
Three months ended September 30,Nine Months Ended September 30,
20212020Change20212020Change
(in thousands)(in thousands)
Revenue
Product revenue, net$14,638 $— $14,638 $22,113 $— $22,113 
License revenue29 29 — 88 88 — 
Total revenue14,667 29 14,638 22,201 88 22,113 
Operating expenses:— — 
Cost of sales254 — 254 610 — 610 
Selling, general and administrative44,128 30,702 13,426 127,196 57,204 69,992 
Research and development20,066 12,243 7,823 39,990 37,154 2,836 
Amortization of intangible assets517 316 201 1,576 902 674 
Other (income) expense, net55 (917)972 859 1,066 (207)
Total cost of sales and operating expenses65,020 42,344 22,676 170,231 96,326 73,905 
Loss from operations(50,353)(42,315)(8,038)(148,030)(96,238)(51,792)
Interest income106 170 (64)420 1,381 (961)
Net loss before income taxes(50,247)(42,145)(8,102)(147,610)(94,857)(52,753)
Income tax expense (benefit)8 (15)23 34 (251)285 
Net loss$(50,255)$(42,130)$(8,125)$(147,644)$(94,606)$(53,038)
Revenues
Total revenue was $14.7 million and $29 thousand for the three months ended September 30, 2021 and September 30, 2020, respectively. Total revenue was $22.2 million and $88 thousand for the nine months ended September 30, 2021 and September 30, 2020, respectively. Our revenues primarily consisted product revenue, net of adjustments, for LUPKYNIS following FDA approval in January 2021.
Cost of Sales
Cost of sales were $254 thousand and $nil for the three months ended September 30, 2021 and September 30, 2020, respectively. Cost of sales were $610 thousand and $nil for the nine months ended September 30, 2021 and September 30, 2020, respectively. The increase was primarily the result of commercial sales of LUPKYNIS. Gross margin for the three and nine months ended September 30, 2021 was approximately 98% and 97% respectively.
24

Selling, General and Administrative Expenses
SG&A expenses increased to $44.1 million for the three months ended September 30, 2021 compared to $30.7 million for the three months ended September 30, 2020. For the nine months ended September 30, 2021 and September 30, 2020, SG&A expenses were $127.2 million and $57.2 million, respectively. SG&A expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Salaries, incentive pay and employee benefits$19,981 $13,795 $58,723 $22,375 
Professional fees and services13,110 8,668 34,536 18,229 
Share-based compensation expense6,000 3,750 19,189 9,151 
Other public company costs, facility costs, insurance, information technology, amortization of property and equipment3,304 4,030 9,579 6,548 
Travel, trade shows and sponsorships1,733 459 5,169 901 
$44,128 $30,702 $127,196 $57,204 
The primary drivers for the increase for the three and nine months ended September 30, 2021 as compared to the same periods ended 2020 were an increase in salaries, incentive pay and employee benefits and share-based compensation expense related to the expansion of the commercial and administrative functions to support the launch of LUPKYNIS which ramped up during the third quarter of 2020. Also contributing was an increase in professional fees for activities such as patient assistance programs, consulting, recruiting, legal, market research and marketing.
Research and Development Expenses
R&D expenses were $20.1 million and $12.2 million for the three months ended September 30, 2021 and September 30, 2020, respectively. For the nine months ended September 30, 2021 and September 30, 2020, R&D expenses were $40.0 million and $37.2 million, respectively. R&D expenses consisted of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Contract research organizations (CRO) and developmental expenses$15,873 $5,581 $25,579 $18,928 
Clinical supply and distribution872 2,502 3,242 6,882 
Salaries, incentive pay and employee benefits2,070 2,976 7,807 7,351 
Share-based compensation expense1,038 814 3,201 3,111 
Travel, insurance, patent annuity fees, legal fees and other213 370 161 882 
$20,066 $12,243 $39,990 $37,154 
The primary driver for the increase for the three months ended September 30, 2021 as compared to the same period of 2020 was due to an upfront license and accrued milestone expense related to our recently acquired developmental programs AUR200 and AUR300. In accordance with U.S. GAAP, these transactions did not meet the definition of a business combination and therefore, were recorded as asset acquisitions. The Company expensed the cost of the assets as R&D expense at the acquisition dates. The increase was partially offset by a decrease in clinical supply and distribution costs due to our new drug application and voclosporin related clinical trial expenditures in 2020 not recurring in 2021. Also contributing was a decrease in salaries, incentive pay and employee benefits due to the allocation of costs related to post approval support of LUPKYNIS to SG&A.
The primary drivers for the increase for the nine months ended September 30, 2021 as compared to the same period of 2020 were due to the upfront license and accrued milestone expense related to our recently acquired developmental programs, AUR200 and AUR300 and higher CRO expenses related to our new clinical programs offset by a decrease in clinical supply and distribution costs following the approval of LUPKYNIS, including a reduction in new drug application preparation costs and termination of the dry eye trial during the fourth quarter of 2020.
25

Liquidity and Capital Resources
As of September 30, 2021, we had cash and cash equivalents and investments of $286.4 million compared to cash and cash equivalents and investments of $422.7 million at December 31, 2020. The decrease is primarily related to the commercial infrastructure spend to support the launch of LUPKYNIS, payments for inventory, an upfront payment made as part of a collaborative agreement with Lonza to build a dedicated manufacturing capability (or monoplant) and an upfront license payment related to our recently acquired developmental program. Cash and cash equivalents and investments are primarily held in U.S. dollars. As of September 30, 2021 and December 31, 2020, we had working capital of $291.7 million and $387.4 million, respectively.
We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the cash and cash equivalents and investments as of September 30, 2021, we believe that our cash position is sufficient to fund our current plans which include funding commercial activities, including our FDA related post approval commitments, manufacturing commercial drug supply, funding our supporting commercial infrastructure, conducting our planned R&D programs, investing in our pipeline and funding our supporting corporate and working capital for at least the next 12 months.

Cash Flow Summary
The following table summarizes our cash flows for the nine months ended September 30, 2021 and September 30, 2020:
Nine months ended September 30,
(in thousands)20212020
Net cash (used in) provided by:
Operating activities$(131,770)$(73,062)
Investing activities(98,383)(177,332)
Financing activities15,390 193,133 
Net decrease in cash and cash equivalents$(214,763)$(57,261)

Net cash used in operating activities was $131.8 million for the nine months ended September 30, 2021 compared to $73.1 million for the nine months ended September 30, 2020. The increase is primarily due to the commercial infrastructure spend to support the launch of LUPKYNIS, payments for inventory, and a one-time payment to a related party upon achievement of specific milestones partially offset by an increase in cash receipts. In the prior year, the Company was still in the development phase of LUPKYNIS.
Cash used in investing activities during the nine months ended September 30, 2021 was $98.4 million compared to cash used in investing activities of $177.3 million during the nine months ended September 30, 2020. Investing activities during the nine months ended September 30, 2021 consisted primarily of $342.8 million for purchases of investments, $11.8 million for an upfront lease payment and $6.0 million for an upfront license payment which was offset by $263.8 million of proceeds of maturities of investments. Cash used in investing activities of $177.3 million for the nine months ended September 30, 2020 was primarily attributable to purchases of short-term investments.
Cash provided by financing activities during the nine months ended September 30, 2021 was $15.4 million compared to cash provided by financing activities of $193.1 million during the nine months ended September 30, 2020. The decrease was primarily due to the public offering during the third quarter of 2020.
Off‑Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off‑balance sheet arrangements as such term is defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Act.
Contractual Obligations
26

There have been no material changes outside the ordinary course of business to our contractual obligations and commitments as described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2020.
Item 3. Quantitative and Qualitative Disclosures About Market Risks
Our activities can expose us to market risks which include interest rate risk, foreign currency risk, inflation risk and credit risk. Risk management is carried out by management under policies approved by our board of directors. Our overall risk management program seeks to minimize adverse effects on our financial performance.
Interest rate risk
Financial assets and financial liabilities with variable interest rates expose us to cash flow interest rate risk. We manage our interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis. Our investment portfolio includes cash and cash equivalents and investments that earn interest at market rates. Our investments held during the year were comprised of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. As of September 30, 2021, these instruments have a maturity of one year or less. Accounts receivable, accounts payable and accrued liabilities bear no interest. We do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.
Foreign currency risk
We are exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk for the Company is the risk variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar and Swiss franc, which could affect our operating and financial results. A 10% increase or decrease of the U.S. dollar would have no material effect assuming all other variables remained constant.
Inflation Risk
Inflation may generally affect us by increasing our cost of labor, commercial support and clinical trial expenditures. Inflation has not had a material effect on our business, financial condition or results of operations during the three and nine months ended September 30, 2021 and 2020.
Credit risk
Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of September 30, 2021, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
27

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
28

PART II—OTHER INFORMATION
Item 1. Legal Proceedings.
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Our management believes that there are currently no claims or actions pending against us, the ultimate dispositions of which could have a material adverse effect on our results of operations, financial condition or cash flows.
There are no material developments in respect of previously disclosed litigation to report.
Item 1A. Risk Factors.
Under Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 we identified important factors that could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report. There has been no material change in our risk factors subsequent to the filing of our prior reports referenced above. However, the risks described in our reports are not the only risks we face. Additional risks and uncertainties that we currently deem to be immaterial or not currently known to us, as well as other risks reported from time to time in our reports to the SEC, also could cause our actual results to differ materially from our anticipated results or other expectations.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
None.
Item 6. Exhibits.
The following exhibits are filed as part of this report:
29

Exhibit
Number		Description
3.1
3.2
3.3
31.1*
31.2*
32.1**
32.2**
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.
**Furnished herewith. Exhibits 32.1 and 32.2 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

30

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AURINIA PHARMACEUTICALS INC.
November 3, 2021By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer, Director
(Principal Executive Officer)
November 3, 2021By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)
31
 EX-31.1 2 auph-2021q3exx311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Peter Greenleaf, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 3, 2021By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-31.2 3 auph-2021q3exx312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a),
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Joseph Miller, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Aurinia Pharmaceuticals Inc..;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 3, 2021By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-32.1 4 auph-2021q3exx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peter Greenleaf, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 3, 2021By:/s/ Peter Greenleaf
Peter Greenleaf
Chief Executive Officer
(Principal Executive Officer)

 EX-32.2 5 auph-2021q3exx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Aurinia Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Miller, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 3, 2021By:/s/ Joseph Miller
Joseph Miller
Chief Financial Officer
(Principal Financial and Accounting Officer)

 EX-101.SCH 6 auph-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2104103 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2205201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2107104 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2110105 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2113106 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2116107 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2120108 - Disclosure - Property, Plant and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2321305 - Disclosure - Property, Plant and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 2422408 - Disclosure - Property, Plant and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 2123109 - Disclosure - Lease Obligations link:presentationLink link:calculationLink link:definitionLink 2324306 - Disclosure - Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 2425409 - Disclosure - Lease Obligations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) link:presentationLink link:calculationLink link:definitionLink 2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2129110 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2132111 - Disclosure - Non-current Liabilities link:presentationLink link:calculationLink link:definitionLink 2433414 - Disclosure - Non-current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2134112 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2335308 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2137113 - Disclosure - License and Collaboration Agreement link:presentationLink link:calculationLink link:definitionLink 2438416 - Disclosure - License and Collaboration Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2139114 - Disclosure - Net Loss per Common Share link:presentationLink link:calculationLink link:definitionLink 2340309 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2441417 - Disclosure - Net Loss per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2143115 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 2344310 - Disclosure - Share-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2445419 - Disclosure - Share-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2446420 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2447421 - Disclosure - Share-based Compensation - Performance Shares Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2448422 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2149116 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2450423 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2151117 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 2452424 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2153118 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 2454425 - Disclosure - Commitment and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 auph-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 auph-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 auph-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Proceeds from exercise of warrants Proceeds from Warrant Exercises Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Assets Operating Lease, Assets And Liabilities, Assets, Lessee [Abstract] Operating Lease, Assets And Liabilities, Assets, Lessee Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Leasehold improvements Leasehold Improvements [Member] Net loss Net loss Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Right-of-use assets Operating Lease, Right-of-Use Asset Exercise of warrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Employee accruals Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Tiered royalty percentages on future sales Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent Statistical Measurement [Domain] Statistical Measurement [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Entity Address, Address Line One Entity Address, Address Line One Cancelled/Forfeited, Weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Revenue from Contract with Customer [Abstract] Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Weighted average remaining lease term - operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Other non-current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Capitalized under inventories Inventories [Member] Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Expenses from related party Related Party Transaction, Expenses from Transactions with Related Party Document Fiscal Year Focus Document Fiscal Year Focus Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of intangible assets Amortization of Intangible Assets Variable lease costs Variable Lease, Cost Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Incremental borrowing rate Weighted average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Research and development Research and Development Expense [Member] Granted, Weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Performance Shares Activity Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block] Title of Individual [Domain] Title of Individual [Domain] Unrealized gain on available-for-sale securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Award Type [Domain] Award Type [Domain] Vested and expected to vest - End of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price ASSETS Assets [Abstract] Related Party Transactions [Abstract] Granted Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Concentration risk Concentration Risk, Percentage Entity Address, City or Town Entity Address, City or Town Accumulated Deficit Retained Earnings [Member] Area of property (in sqft) Area of Real Estate Property Non-current liabilities Liabilities, Noncurrent [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Upfront payments received Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Related Party [Axis] Related Party [Axis] Initial recognition of operating lease right-of-use asset Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Commitments and Contingencies Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Due to related parties Due to Related Parties Capital expenditure payments Finance Lease, Principal Payments Entity Interactive Data Current Entity Interactive Data Current Number of operating segments Number of Operating Segments Basic loss per share (expressed in $ per share) Basic loss per share (expressed in $ per share) Earnings Per Share, Basic 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three License and Collaboration Agreement Revenue from Contract with Customer [Text Block] Outstanding - Beginning of Period (in shares) Outstanding - End of Period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type Prepaid expenses and other current assets Prepaid Expense, Current Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Legal Fees Legal Fees [Member] Legal Fees Entity Current Reporting Status Entity Current Reporting Status Accounts receivable, net Accounts and Other Receivables, Net, Current Commercial Paper Commercial Paper [Member] Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Other, net Other Noncash Income (Expense) Research and development costs Research and Development Expense, Policy [Policy Text Block] Options exercisable - End of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price Plan Name [Axis] Plan Name [Axis] Assets: Assets, Fair Value Disclosure [Abstract] Total Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and shareholders’ equity Liabilities and Equity Other accrued liabilities Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Dividend rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Purchase of long-lived assets Payments to Acquire Other Productive Assets Payments to Acquire Other Productive Assets Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Milestone Payment Milestone Payment [Member] Milestone Payment Cash flows used in operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net Loss per Common Share Earnings Per Share [Text Block] Current Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee [Abstract] Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee Operating expenses: Operating Expenses [Abstract] Non-current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Shares issued on exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Potential regulatory milestone revenue Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount Affiliated Shareholder Affiliated Entity [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Annualized volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Trading Symbol Trading Symbol Cash received for interest Proceeds from Interest Received Current liabilities Liabilities, Current [Abstract] Issue of common shares Stock Issued During Period, Value, New Issues Lease liabilities Increase (Decrease) in Operating Lease Liability Upfront lease payment Payments to Acquire Lease Receivables Selling, general and administrative General and Administrative Expense Share-based Compensation Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Inventories Inventory Disclosure [Text Block] Specialty Pharmacy One Specialty Pharmacy One [Member] Specialty Pharmacy One Accounting Policies [Abstract] Issuance of common shares (in shares) Stock Issued During Period, Shares, New Issues ILJIN ILJIN [Member] ILJIN Total lease liabilities Total lease liabilities Total future minimum lease payments Operating Lease, Liability Non-cancellable future commitments Long-term Purchase Commitment, Amount Unrecognized share-based compensation expense weighted average recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) Outstanding, Weighted average exercise price - End of Period (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Unvested performance awards Performance Shares [Member] Commitments and contingencies (Note 18) Commitments and Contingencies Lease Obligations Lessee, Operating Leases [Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Remainder of 2021 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Schedule of Share-based Payment Award Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Document Period End Date Document Period End Date Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Treasury Bond US Treasury Bond Securities [Member] Total cost of sales and operating expenses Costs and Expenses Entity Registrant Name Entity Registrant Name Less: lease imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Work in process Inventory, Work in Process, Net of Reserves Upfront license fee Payments to Acquire Productive Assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Financial Instrument [Axis] Financial Instrument [Axis] Total revenues Revenues Revenue from Contract with Customer, Excluding Assessed Tax Otuska Otuska Pharmaceutical Co., Ltd. [Member] Otuska Pharmaceutical Co., Ltd. Office equipment and furniture Office Equipment [Member] Prepaid deposits Prepaid Rent and Prepaid Continuing Studies Prepaid Rent and Prepaid Continuing Studies Finished goods Inventory, Finished Goods, Net of Reserves Stock options Share-based Payment Arrangement, Option [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Share issue costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Common Shares Common Stock [Member] Loss from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating lease liabilities Current operating lease liabilities Operating Lease, Liability, Current Number of extension options Lessee, Operating Lease, Number of Extension Options Lessee, Operating Lease, Number of Extension Options Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Property, Plant and Equipment [Abstract] Share-based compensation expense Share-based Payment Arrangement, Noncash Expense Upfront license payment Payments to Acquire Other Investments Additional paid in capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation of property and equipment Depreciation Payments to related party Related Party Transaction, Amounts of Transaction Prepaid assets Prepaid Advertising Lease termination option term Lessee, Operating Lease, Lease Termination Term Lessee, Operating Lease, Lease Termination Term Prepaid insurance Prepaid Insurance Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively) Other Liabilities, Current Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Legal Entity [Axis] Legal Entity [Axis] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Accounts receivable Increase (Decrease) in Receivables Award Type [Axis] Award Type [Axis] Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total shareholder’s equity Balance Balance Stockholders' Equity Attributable to Parent Amended and Restated Equity Incentive Plan Amended and Restated Equity Incentive Plan [Member] Amended and Restated Equity Incentive Plan Common stock, issued (shares) Common Stock, Shares, Issued Accounts payable, accrued and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Management Management [Member] Goodwill and Intangible Assets Disclosure [Abstract] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Intangible Assets Intangible Assets Disclosure [Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Operating lease liabilities Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Minimum finance lease liability payments due Finance Lease, Liability, Payment, Due Cashable Guaranteed Investment Certificate Cashable Guaranteed Investment Certificates [Member] Cashable Guaranteed Investment Certificates Non-current assets: Assets, Noncurrent [Abstract] Riptide Bioscience, Inc. Riptide Bioscience, Inc. [Member] Riptide Bioscience, Inc. City Area Code City Area Code Accumulated deficit Retained Earnings (Accumulated Deficit) Unvested restricted units Restricted Stock Units (RSUs) [Member] Treasury Bill US Treasury Bill Securities [Member] Selling, general and administrative expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Statement of Stockholders' Equity [Abstract] Remaining lease term Lessee, Operating Lease, Remaining Lease Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Income Statement [Abstract] Amendment Flag Amendment Flag Options exercisable - End of Period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number Inventory Disclosure [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Related Party Transaction [Axis] Related Party Transaction [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax expense (benefit) Income tax (benefit) expense Income Tax Expense (Benefit) Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total current assets Assets, Current Acquired intellectual property and reacquired rights Intellectual Property [Member] Minimum lease payments Total Lessee, Operating Lease, Liability, to be Paid Concentration Risk Type [Domain] Concentration Risk Type [Domain] Cancelled/Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Inventories, net Total inventories Inventory, Net Entity File Number Entity File Number Statement of Financial Position [Abstract] Unrecognized share-based compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Product and Service [Axis] Product and Service [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Basis of Presentation Basis of Accounting [Text Block] Revenue Benchmark Revenue Benchmark [Member] Fair value per common share option (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Short-term lease costs Short-term Lease, Cost Unrealized gains on available-for-sale securities Debt Securities, Available-for-sale, Unrealized Gain (Loss) 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Statement [Line Items] Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accrued R&D projects Accrued Research, Current Accrued Research, Current Allocation of Share-Based Payments Share-based Payment Arrangement, Cost by Plan [Table Text Block] Debt Securities, Available-for-sale Debt Securities, Available-for-sale Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Entity Address, State or Province Entity Address, State or Province Purchase of investments Payments to Acquire Marketable Securities Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Entity [Domain] Entity [Domain] Customer [Axis] Customer [Axis] Critical Accounting Estimates Use of Estimates, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Net proceeds from issuance of common shares Proceeds from Issuance of Common Stock Total assets Assets Plan Name [Domain] Plan Name [Domain] Geographical [Domain] Geographical [Domain] Title of Individual [Axis] Title of Individual [Axis] Total investments Debt Securities, Current and Noncurrent Debt Securities, Current and Noncurrent Research and development Research and Development Expense Product and Service [Domain] Product and Service [Domain] Lease extension term Lessee, Operating Lease, Renewal Term Specialty Pharmacy Two Specialty Pharmacy Two [Member] Specialty Pharmacy Two Long-term investments Debt Securities, Noncurrent Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Lease, Cost Lease, Cost [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Corporate Bonds Corporate Bond Securities [Member] Geographical [Axis] Geographical [Axis] Weighted-average common shares outstanding used in computation of basic loss per share Weighted Average Number of Shares Outstanding, Basic Diluted loss per share (expressed in $ per share) Diluted loss per share (expressed in $ per share) Earnings Per Share, Diluted Due to related party, current Due to Related Parties, Current Product revenue, net Product [Member] Cash paid for taxes Income Taxes Paid, Net Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Cost of sales Cost of Revenue Investments Investment, Policy [Policy Text Block] Cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Related Party Transaction [Line Items] Related Party Transaction [Line Items] Short-term investments Debt Securities, Current Exercise of warrants (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Fair Value Measurements Fair Value Disclosures [Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Right of use assets Increase (Decrease) in Operating Lease, Right-of-Use Assets Increase (Decrease) in Operating Lease, Right-of-Use Assets Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Marketable Securities [Table] Marketable Securities [Table] Common stock, outstanding (shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Other (income) expense, net Other Operating Income (Expense), Net Financial Instruments [Domain] Financial Instruments [Domain] Net revenue: Revenues [Abstract] Cloud computing arrangements Computer Software, Intangible Asset [Member] Number of reporting units Number of Reporting Units Capitalized patent costs Payments to Acquire Intangible Assets Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Cash flows used in investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Yankee Bond Yankee Bond [Member] Yankee Bond Total lease costs Total rent expense Lease, Cost Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Proceeds from tenant improvements Payments for (Proceeds from) Tenant Allowance SHAREHOLDER’S EQUITY Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Investments Investments, Fair Value Disclosure Supplemental disclosure of noncash transactions Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Number of additional shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Corporate Bond Short-Term Corporate Debt Securities [Member] Short-Term Corporate Debt Securities Interest Receivable Interest Receivable Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Other non-current liabilities Other non-current liabilities Other Liabilities, Noncurrent Earnings Per Share [Abstract] Property, plant and equipment, gross Property, Plant and Equipment, Gross Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Cash and cash equivalents and investments Cash, Cash Equivalents and Debt Securities, Current Cash, Cash Equivalents and Debt Securities, Current Related Party Transaction [Domain] Related Party Transaction [Domain] Document Quarterly Report Document Quarterly Report Other Current Liabilities Other Current Liabilities [Member] Rockville, Maryland Rockville, Maryland [Member] Rockville, Maryland Warrants Warrant [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Patents Patents [Member] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Share-based compensation expense Share-based Payment Arrangement, Expense Cost of sales Cost of Goods and Service [Policy Text Block] Estimated forfeiture rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate Weighted average exercise price $ Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Non-current Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee [Abstract] Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee Counterparty Name [Axis] Counterparty Name [Axis] Proceeds from investments Proceeds from Sale and Maturity of Marketable Securities Payables and Accruals [Abstract] Construction in progress Construction in Progress [Member] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Current assets Assets, Current [Abstract] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Gross Carrying Value Finite-Lived Intangible Assets, Gross Interest income Interest Income (Expense), Nonoperating, Net Leases [Abstract] Entity Central Index Key Entity Central Index Key Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Security Exchange Name Security Exchange Name Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Shares issued on exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Weighted-average common shares outstanding used in computation of diluted loss per share Weighted Average Number of Shares Outstanding, Diluted Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Related Party [Domain] Related Party [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Deposits held with banks Demand Deposits [Member] Victoria, British Columbia Victoria, British Columbia [Member] Victoria, British Columbia License Agreement Terms License Agreement Terms [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Prepaid Expenses and Other Current Assets Other Current Assets [Text Block] Officer Officer [Member] Statement of Cash Flows [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Marketable Securities [Line Items] Marketable Securities [Line Items] Unrealized (loss) gain on available-for-sale securities, net of tax of nil Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Debt Securities, Held-to-maturity Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Vested, Weighted average exercise price (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Selling, general and administrative General and Administrative Expense [Member] Expected life of options in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Employee Stock Employee Stock [Member] Cash paid for amounts included in the measurement of lease liabilities Lease Obligation Incurred Lonza Lonza [Member] Lonza Upfront license and milestone expense Acquired Upfront License Payment Acquired Upfront License Payment Short-term highly liquid investments Money Market Funds [Member] Trade payables Accounts Payable, Trade, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Title of 12(b) Security Title of 12(b) Security Investments Marketable Securities [Table Text Block] Other current assets Other Assets, Current Statement [Table] Statement [Table] Recently adopted accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Non-current assets Increase (Decrease) in Other Noncurrent Assets Statistical Measurement [Axis] Statistical Measurement [Axis] Additions to internal use-software implementation costs Payments for Software Accounts receivable, net Accounts Receivable [Policy Text Block] Cover [Abstract] Acquired intellectual property and other intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net License revenue License [Member] Performance Share sand Restricted Stock Units (RSUs) Performance Share sand Restricted Stock Units (RSUs) [Member] Performance Share sand Restricted Stock Units (RSUs) Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Common shares - no par value, unlimited shares authorized, 129,570 and 126,725 shares issued and outstanding as at September 30, 2021 and December 31, 2020, respectively Common Stock, Value, Outstanding Operating lease costs Operating Lease, Cost Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Computer equipment Computer Equipment [Member] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Vested and expected to vest - End of Period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number EX-101.PRE 10 auph-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 auph-20210930_htm.xml IDEA: XBRL DOCUMENT 0001600620 2021-01-01 2021-09-30 0001600620 2021-11-02 0001600620 2021-09-30 0001600620 2020-12-31 0001600620 us-gaap:ProductMember 2021-07-01 2021-09-30 0001600620 us-gaap:ProductMember 2020-07-01 2020-09-30 0001600620 us-gaap:ProductMember 2021-01-01 2021-09-30 0001600620 us-gaap:ProductMember 2020-01-01 2020-09-30 0001600620 us-gaap:LicenseMember 2021-07-01 2021-09-30 0001600620 us-gaap:LicenseMember 2020-07-01 2020-09-30 0001600620 us-gaap:LicenseMember 2021-01-01 2021-09-30 0001600620 us-gaap:LicenseMember 2020-01-01 2020-09-30 0001600620 2021-07-01 2021-09-30 0001600620 2020-07-01 2020-09-30 0001600620 2020-01-01 2020-09-30 0001600620 us-gaap:CommonStockMember 2021-06-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001600620 us-gaap:RetainedEarningsMember 2021-06-30 0001600620 2021-06-30 0001600620 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001600620 us-gaap:CommonStockMember 2021-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001600620 us-gaap:RetainedEarningsMember 2021-09-30 0001600620 us-gaap:CommonStockMember 2020-06-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001600620 us-gaap:RetainedEarningsMember 2020-06-30 0001600620 2020-06-30 0001600620 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001600620 us-gaap:CommonStockMember 2020-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001600620 us-gaap:RetainedEarningsMember 2020-09-30 0001600620 2020-09-30 0001600620 us-gaap:CommonStockMember 2020-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001600620 us-gaap:RetainedEarningsMember 2020-12-31 0001600620 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0001600620 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0001600620 us-gaap:CommonStockMember 2019-12-31 0001600620 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001600620 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001600620 us-gaap:RetainedEarningsMember 2019-12-31 0001600620 2019-12-31 0001600620 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001600620 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001600620 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001600620 auph:SpecialtyPharmacyOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001600620 auph:SpecialtyPharmacyTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001600620 auph:CashableGuaranteedInvestmentCertificatesMember 2021-09-30 0001600620 auph:CashableGuaranteedInvestmentCertificatesMember 2020-12-31 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2021-09-30 0001600620 auph:ShortTermCorporateDebtSecuritiesMember 2020-12-31 0001600620 us-gaap:CommercialPaperMember 2021-09-30 0001600620 us-gaap:CommercialPaperMember 2020-12-31 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2021-09-30 0001600620 us-gaap:USTreasuryBillSecuritiesMember 2020-12-31 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2021-09-30 0001600620 us-gaap:USTreasuryBondSecuritiesMember 2020-12-31 0001600620 auph:YankeeBondMember 2021-09-30 0001600620 auph:YankeeBondMember 2020-12-31 0001600620 us-gaap:CorporateBondSecuritiesMember 2021-09-30 0001600620 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001600620 us-gaap:PatentsMember 2021-09-30 0001600620 us-gaap:IntellectualPropertyMember 2021-09-30 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-09-30 0001600620 us-gaap:PatentsMember 2020-12-31 0001600620 us-gaap:IntellectualPropertyMember 2020-12-31 0001600620 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-12-31 0001600620 us-gaap:ConstructionInProgressMember 2021-09-30 0001600620 us-gaap:ConstructionInProgressMember 2020-12-31 0001600620 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001600620 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001600620 us-gaap:OfficeEquipmentMember 2021-09-30 0001600620 us-gaap:OfficeEquipmentMember 2020-12-31 0001600620 us-gaap:ComputerEquipmentMember 2021-09-30 0001600620 us-gaap:ComputerEquipmentMember 2020-12-31 0001600620 auph:VictoriaBritishColumbiaMember 2020-12-31 0001600620 auph:VictoriaBritishColumbiaMember 2021-09-30 0001600620 auph:VictoriaBritishColumbiaMember 2020-08-31 0001600620 auph:RockvilleMarylandMember 2020-03-31 0001600620 auph:RockvilleMarylandMember 2020-03-01 2020-03-31 0001600620 auph:RockvilleMarylandMember 2021-09-30 0001600620 auph:RockvilleMarylandMember 2020-12-31 0001600620 auph:RockvilleMarylandMember 2020-01-01 2020-12-31 0001600620 auph:RockvilleMarylandMember 2020-03-12 0001600620 2021-02-01 2021-02-28 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001600620 us-gaap:DemandDepositsMember 2021-09-30 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-09-30 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-09-30 0001600620 us-gaap:MoneyMarketFundsMember 2021-09-30 0001600620 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001600620 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001600620 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001600620 us-gaap:DemandDepositsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001600620 us-gaap:DemandDepositsMember 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001600620 us-gaap:MoneyMarketFundsMember 2020-12-31 0001600620 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001600620 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001600620 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001600620 auph:RiptideBioscienceIncMember us-gaap:LicenseAgreementTermsMember 2021-08-17 2021-08-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-17 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MinimumMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember srt:MaximumMember us-gaap:LicenseAgreementTermsMember 2020-12-17 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-12-01 2020-12-31 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2021-01-01 2021-09-30 0001600620 auph:OtuskaPharmaceuticalCoLtdMember us-gaap:LicenseAgreementTermsMember 2020-10-01 2020-12-31 0001600620 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001600620 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001600620 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0001600620 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0001600620 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001600620 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001600620 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001600620 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001600620 auph:AmendedAndRestatedEquityIncentivePlanMember 2021-06-01 2021-06-30 0001600620 us-gaap:EmployeeStockMember 2021-09-30 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2020-12-31 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-09-30 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2020-10-23 2020-10-23 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-03-18 2021-03-18 0001600620 srt:OfficerMember auph:PerformanceShareSandRestrictedStockUnitsRSUsMember 2021-08-06 2021-08-06 0001600620 srt:OfficerMember us-gaap:PerformanceSharesMember 2021-07-01 2021-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001600620 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001600620 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001600620 us-gaap:InventoriesMember 2021-07-01 2021-09-30 0001600620 us-gaap:InventoriesMember 2020-07-01 2020-09-30 0001600620 us-gaap:InventoriesMember 2021-01-01 2021-09-30 0001600620 us-gaap:InventoriesMember 2020-01-01 2020-09-30 0001600620 auph:ILJINMember auph:MilestonePaymentMember srt:AffiliatedEntityMember 2021-01-01 2021-03-31 0001600620 auph:ILJINMember us-gaap:OtherCurrentLiabilitiesMember 2021-09-30 0001600620 auph:ILJINMember us-gaap:OtherCurrentLiabilitiesMember 2020-12-31 0001600620 auph:ILJINMember auph:MilestonePaymentMember srt:AffiliatedEntityMember 2021-09-30 0001600620 auph:LegalFeesMember srt:ManagementMember 2020-07-01 2020-09-30 0001600620 auph:LegalFeesMember srt:ManagementMember 2020-01-01 2020-09-30 0001600620 auph:LonzaMember 2021-01-01 2021-09-30 0001600620 auph:LonzaMember 2021-07-01 2021-09-30 shares iso4217:USD iso4217:USD shares auph:segment auph:reportingUnit pure utr:sqft auph:extension_option false 2021 Q3 0001600620 --12-31 10-Q true 2021-09-30 false 001-36421 Aurinia Pharmaceuticals Inc. Z4 #1203-4464 Markham Street Victoria BC V8Z 7X8 46-4129078 (250) 708-4272 Yes Yes Large Accelerated Filer false false false 129670345 Common shares, no par value AUPH NASDAQ 57587000 272350000 228813000 125979000 9814000 0 19293000 13927000 13712000 7171000 329219000 419427000 0 24380000 11838000 247000 4551000 4786000 8926000 9332000 5532000 5489000 360066000 463661000 29970000 24797000 2000000 6000000 6456000 6412000 1111000 788000 37537000 31997000 16562000 16295000 7795000 7619000 61894000 55911000 129570000 129570000 126725000 126725000 967159000 944328000 54607000 39383000 -794000 -805000 -722800000 -575156000 298172000 407750000 360066000 463661000 14638000 0 22113000 0 29000 29000 88000 88000 14667000 29000 22201000 88000 254000 0 610000 0 44128000 30702000 127196000 57204000 20066000 12243000 39990000 37154000 517000 316000 1576000 902000 -55000 917000 -859000 -1066000 65020000 42344000 170231000 96326000 -50353000 -42315000 -148030000 -96238000 106000 170000 420000 1381000 -50247000 -42145000 -147610000 -94857000 8000 -15000 34000 -251000 -50255000 -42130000 -147644000 -94606000 0 0 0 0 -2000 0 11000 0 -50257000 -42130000 -147633000 -94606000 -0.39 -0.39 -0.34 -0.34 -1.15 -1.15 -0.82 -0.82 128443000 128443000 122357000 122357000 128084000 128084000 115738000 115738000 128396000 954572000 51022000 -792000 -672545000 332257000 1172000 12579000 -3505000 9074000 2000 8000 -2000 6000 7092000 7092000 -2000 -2000 -50255000 -50255000 129570000 967159000 54607000 -794000 -722800000 298172000 112705000 752357000 31098000 -805000 -524952000 257698000 13333000 200000000 200000000 412000 2386000 -861000 1525000 12268000 12268000 4611000 4611000 -42130000 -42130000 126450000 942475000 34848000 -805000 -567082000 409436000 126725000 944328000 39383000 -805000 -575156000 407750000 2324000 22097000 -6745000 15352000 521000 734000 -697000 37000 22666000 22666000 11000 11000 -147644000 -147644000 129570000 967159000 54607000 -794000 -722800000 298172000 111798000 746487000 25394000 -805000 -472476000 298600000 1318000 8254000 -2854000 5400000 13333000 200000000 200000000 12268000 12268000 1000 2000 -1000 1000 12309000 12309000 -94606000 -94606000 126450000 942475000 34848000 -805000 -567082000 409436000 -147644000 -94606000 497000 59000 1576000 902000 10000000 0 22666000 12309000 -1005000 -736000 9815000 0 5366000 471000 6541000 3725000 -247000 0 43000 5576000 1149000 9012000 499000 8298000 -131770000 -73062000 342831000 202951000 263752000 30779000 11838000 0 6000000 0 262000 4095000 1198000 982000 6000 83000 -98383000 -177332000 15353000 5400000 37000 1000 0 187732000 15390000 193133000 -214763000 -57261000 272350000 306019000 57587000 248758000 671000 891000 236000 62000 195000 68000 419000 5804000 Organization and Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company has developed LUPKYNIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 is currently undergoing pre-clinical development with projected submission of an Investigational New Drug Application (IND) to the FDA by the end of 2022. It is anticipated that an IND for AUR300 is expected during the first half of 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle, Rockville, Maryland, United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares traded on both the Nasdaq Global Market (Nasdaq) under the symbol AUPH and on the Toronto Stock Exchange (TSX) under the symbol AUP until July 30, 2021. As of July 30, 2021, the Company's common shares no longer trade on the TSX following the voluntary delisting by the Company and are solely traded on the Nasdaq.</span></div> Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief executive officer makes decisions for the Company and its subsidiaries as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div>We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash and cash equivalents and investments of $286.4 million as of September 30, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued. 1 1 1 286400000 mary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue recognition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inventory;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty obligation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent accruals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expenditures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible assets; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leases; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 59% and 40% of the Company's total revenues for the three and nine months ended September 30, 2021. The Company monitors economic conditions, the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the FASB ASC Topic 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments — Debt Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments classified as held to maturity are carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income is recorded separately on the consolidated statements of operations.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of securities sold is based on the specific-identification method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to two specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More specifically, these adjustments include the following: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt pay discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&amp;A) expense. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates: </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services and pass-through costs that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If the license to the Company’s intellectual property (IP) is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s agreements may include research and development (R&amp;D) or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expenses are accounted for in accordance with ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and are expensed as incurred. R&amp;D costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, acquired licenses, subcontractors (such as contract research organizations) and materials used for R&amp;D activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the R&amp;D activities of the Company, including R&amp;D conducted by others on behalf of the Company, shall be included in R&amp;D costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. </span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's SG&amp;A expenses include commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These SG&amp;A costs include corporate facility operating expenses and allocated depreciation; commercial, marketing, pharmacovigilance, publications, tradeshows, advisory boards, samples and operations in support of LUPKYNIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense SG&amp;A expenses as they are incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to two specialty pharmacies and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in SG&amp;A expenses. </span></div>Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of September 30, 2021, accounts receivable, net are $9.8 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of September 30, 2021 and as of December 31, 2020<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses if fair value increases. The Company adopted the standard as of January 1, 2020 and did not have a material impact on the Company’s consolidated financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Topic 820 requires to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue recognition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inventory;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty obligation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent accruals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expenditures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible assets; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leases; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income taxes.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 59% and 40% of the Company's total revenues for the three and nine months ended September 30, 2021. The Company monitors economic conditions, the </span></div>creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses. 0.59 0.40 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the FASB ASC Topic 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments — Debt Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Investments classified as held to maturity are carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income is recorded separately on the consolidated statements of operations.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of securities sold is based on the specific-identification method.</span> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States (and territories), the Company sells LUPKYNIS primarily to two specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for discounts and allowances: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More specifically, these adjustments include the following: </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt pay discounts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer fees: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&amp;A) expense. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government rebates: </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims </span><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#282829;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License, Collaboration and Other Revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services and pass-through costs that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If the license to the Company’s intellectual property (IP) is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing supply services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research, Development and/or Manufacturing Services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s agreements may include research and development (R&amp;D) or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of sales: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.</span> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expenses are accounted for in accordance with ASC Topic 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span>, and are expensed as incurred. R&amp;D costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, acquired licenses, subcontractors (such as contract research organizations) and materials used for R&amp;D activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the R&amp;D activities of the Company, including R&amp;D conducted by others on behalf of the Company, shall be included in R&amp;D costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers. <span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's SG&amp;A expenses include commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These SG&amp;A costs include corporate facility operating expenses and allocated depreciation; commercial, marketing, pharmacovigilance, publications, tradeshows, advisory boards, samples and operations in support of LUPKYNIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense SG&amp;A expenses as they are incurred.</span>The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to two specialty pharmacies and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in SG&amp;A expenses. Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of September 30, 2021, accounts receivable, net are $9.8 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of September 30, 2021 and as of December 31, 2020 9800000 0 0 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses if fair value increases. The Company adopted the standard as of January 1, 2020 and did not have a material impact on the Company’s consolidated financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Topic 820 requires to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.</span></div> Investments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, the Company had $228.8 million and $nil and $126.0 million and $24.4 million of short and long-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of September 30, 2021, the Company classifies its investments as debt securities of which $21.5 million are held to maturity debt securities which are carried at amortized cost and are approximately equal to fair market value. As of September 30, 2021, $207.3 million are available-for-sale debt securities which are carried at fair market value and are approximately equal to amortized cost. As of December 31, 2020, $150.4 million were classified as held to maturity and $nil were available-for-sale. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashable Guaranteed Investment Certificate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">197,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bonds - total long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Currently, the Company does not intend to sell investments that are classified as held-to-maturity and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of September 30, 2021 and December 31, 2020, accrued interest receivable from the investments were $0.1 million and $0.5 million, respectively. During the three and nine months ended September 30, 2021, the Company had $2 thousand and $11 thousand unrealized losses and gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. The Company's investments as of September 30, 2021 mature at various dates through September 2022. 228800000 0 126000000 24400000 21500000 207300000 150400000 0 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashable Guaranteed Investment Certificate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,644</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">197,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,747 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury Bond</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yankee Bond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,979 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Bonds - total long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,380 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5644000 2000000 25435000 40372000 197734000 67747000 0 7999000 0 5045000 0 2816000 228813000 125979000 0 24380000 228813000 150359000 100000 500000 -2000 11000 Inventories<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For our product LUPKYNIS, the Company commenced capitalization of inventory once FDA approval was deemed to be probable, which occurred during the third quarter of 2020. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory as of September 30, 2021 and December 31, 2020 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,002</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory as of September 30, 2021 and December 31, 2020 are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,002</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,293</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,927 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2217000 0 12074000 13927000 5002000 0 19293000 13927000 Prepaid Expenses and Other Current Assets<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes prepaid expenses and other current assets.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes prepaid expenses and other current assets.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,871</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">728</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,712</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5871000 3701000 2524000 2054000 728000 1018000 4589000 398000 13712000 7171000 Intangible Assets<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,543)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,926</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,452 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,120)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,332 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended September 30, 2021 and 2020 was $0.5 million and $0.3 million, respectively, and for the nine months ended September 30, 2021 and 2020 was $1.6 million and $0.9 million, respectively.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,152)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,873</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,027</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,469</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,543)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,926</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,651 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intellectual property and reacquired rights</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software implementation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,452 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,120)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,332 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1471000 1152000 319000 15125000 8545000 6580000 2873000 846000 2027000 19469000 10543000 8926000 1651000 1203000 448000 15126000 7770000 7356000 1675000 147000 1528000 18452000 9120000 9332000 500000 300000 1600000 900000 Property and Equipment, net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment as of September 30, 2021 and December 31, 2020 are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,621</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,224</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense for the three month period ended September 30, 2021 and September 30, 2020 was $0.2 million and $nil, respectively, and for the nine months ended September 30, 2021 and 2020 was $0.5 million and $0.1 million. which is included in SG&amp;A expenses in the condensed consolidated statements of operations. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment as of September 30, 2021 and December 31, 2020 are as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">360</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,978</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,621</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">265</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,224</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 360000 4467000 2978000 34000 1621000 83000 265000 381000 5224000 4965000 673000 179000 4551000 4786000 200000 0 500000 100000 Lease Obligations<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the following lease obligations:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Victoria, British Columbia</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of September 30, 2021, the Company had $0.2 million right-of-use assets (ROU assets) and $0.2 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in SG&amp;A expense in the condensed consolidated statement of operations. The incremental borrowing rate applied to the lease liabilities was 4.08% based on financial position, geographical region and terms of leases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The lease term is expected to begin in 2022. The present value of the minimum lease payments for this lease are $2.7 million. As of September 30, 2021, the lease has not commenced and as a result there has been no accounting recognition associated with the lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rockville, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2020, the Company entered into a lease for its commercial office in Rockville, Maryland. The lease has a remaining term of approximately 11 years and has an option to extend for two five-year periods after the 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2021, the Company had a right-of-use asset of $5.3 million and lease liability of $8.7 million included in the condensed consolidated balance sheets. As of December 31, 2020, the Company had a right of use asset of $5.5 million and lease liability of $8.4 million included in the condensed consolidated balance sheets. During 2020, the Company received reimbursements for tenant leasehold improvements by the landlord in the amount of $2.3 million for the Maryland lease. The Company recorded these leasehold improvement incentives as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Edmonton, Alberta</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2020, the Company entered into an agreement to lease premises in Edmonton, Alberta, commencing on October 1, 2020 and ending September 30, 2021. During the third quarter of 2021, the lease was extended until September 30, 2022. The Company recognizes short-term leases on a straight-line basis and did not record a related lease asset or liability for the Edmonton lease. The Company recognized short-term rent expense for this lease, which is included in SG&amp;A expense in the condensed consolidated statement of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning January 1, 2021, the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs for the three and nine month periods ended September 30, 2021. The following provides a summary of the components of leasing costs and rent for the three and nine month periods ended September 30, 2021 and September 30, 2020. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office building</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20%</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of operating lease liabilities maturities for the next five years and thereafter:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,452</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finance Lease</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first capital expenditure payment was made in February 2021 of $11.8 million which was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $84.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.</span></div> 13206 200000 200000 0.0408 2700000 P11Y 2 P5Y P11Y P7Y 5300000 8700000 5500000 8400000 -2300000 0.052 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,489 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,111</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,795</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,619 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,407 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5532000 5489000 1111000 788000 7795000 7619000 8906000 8407000 <div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.432%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statement of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">261</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office Building</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office building</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">312</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">928</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20%</span></td></tr></table></div> 261000 196000 783000 456000 7000 74000 21000 215000 44000 1000 124000 3000 312000 271000 928000 674000 P9Y8M4D 0.0520 The following table provides a summary of operating lease liabilities maturities for the next five years and thereafter:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,143</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,061</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,109</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,773</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,452</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: lease imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 281000 1143000 1061000 1085000 1109000 6773000 11452000 2546000 8906000 11800000 84000000 84000000 Accounts Payable and Accrued Liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's accounts payable and accrued liabilities.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,865</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,520</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,797 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D projects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,865</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,520</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,797 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3263000 2635000 8322000 6616000 3865000 4185000 14520000 11361000 29970000 24797000 Non-current LiabilitiesThe Company recorded other non-current liabilities of $16.6 million and $16.3 million as of September 30, 2021 and December 31, 2020, respectively. The balance as of September 30, 2021 and December 31, 2020 primarily included obligations that are the result of a resolution of the board of directors of the Company dated March 8, 2012 whereby certain executive officers at that time were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. 16600000 16300000 Fair Value Measurements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short and long-term investments that are valued through third-party pricing services that use verifiable observable market data. The Company has no Level 3 instruments as of September 30, 2021 and December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1, Level 2 and Level 3 instruments in the periods presented.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">197,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,179</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,096 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,709 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, “Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the financial assets measured at fair value on a recurring basis:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,517</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">197,734</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,079</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228,813</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">252,221</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,179</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">286,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits held with banks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term highly liquid investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,746 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342,096 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,613 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,709 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 35070000 0 0 35070000 19417000 3100000 0 22517000 197734000 31079000 0 228813000 252221000 34179000 0 286400000 130807000 0 0 130807000 141543000 0 0 141543000 69746000 80613000 0 150359000 342096000 80613000 0 422709000 License and Collaboration Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Riptide License</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statement of operations. Additional milestone payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during the first half of 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Otsuka Contract</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS for the treatment of patients with active LN in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Aurinia received an upfront cash payment of $50.0 million for the license agreement and has the potential to receive up to $50.0 million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, voclosporin will be provided to Otsuka under a cost-plus supply agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional IP that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0 million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved, and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, there has been no additional consideration earned or received since the upfront payment of $50.0 million during the fourth quarter of 2020.</span></div> 6000000 50000000 50000000 0.10 0.20 50000000 0 50000000 Net Loss per Common Share<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(147,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,606)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.82)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,133 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:<div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(50,255)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,130)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(147,644)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,606)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,443</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,357 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,084</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,738 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share (expressed in $ per share)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.82)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:</span></div> -50255000 -42130000 -147644000 -94606000 128443000 128443000 122357000 122357000 128084000 128084000 115738000 115738000 -0.39 -0.39 -0.34 -0.34 -1.15 -1.15 -0.82 -0.82 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine months ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,443 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested performance awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">857</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,012</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,690 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,907</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,133 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 12837000 11443000 857000 0 201000 0 1012000 1690000 14907000 13133000 Share-based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of outstanding awards). Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code (the “Code”) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, 129.6 million and 126.7 million, common shares were issued and outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average assumptions were used to estimate the fair value of the options granted during the nine month periods ended September 30, 2021 and September 30, 2020:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity during the nine months ended September 30, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(945)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest - End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,244</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Awards and Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2021, the Company granted approximately 619,000 PAs and restricted stock units (RSUs). The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vest on the employee's first anniversary of the grant date and the employee must achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs have no performance metrics and will vest on the one year anniversary of the grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded approximately $0.7 million and $1.1 million of share-based compensation expense related to PAs and RSUs during the three and nine month periods ended September 30, 2021.</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2021 and September 30, 2020 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">276</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,611 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,309 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2021, there was $16.9 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.1 years.</span></div> 23800000 2500000 129600000 129600000 126700000 126700000 The following weighted average assumptions were used to estimate the fair value of the options granted during the nine month periods ended September 30, 2021 and September 30, 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per common share option</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.64</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0.66 0.43 0.0038 0.0070 P4Y P3Y 0.089 0.12 0.000 0.000 6.64 5.05 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the option award activity during the nine months ended September 30, 2021:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares (in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price $</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - Beginning of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,047</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.35</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,059</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(945)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,837</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.37</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest - End of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,635</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable - End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,244</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14047000 11.35 2059000 13.42 2324000 6.60 945000 13.72 12837000 12.37 2635000 14.54 5244000 10.81 439000 13.56 619000 14.42 700000 1100000 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2021 and September 30, 2020 as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,038</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,201</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,189</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized under inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">276</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,611 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,309 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1038000 814000 3201000 3111000 6000000 3750000 19189000 9151000 54000 47000 276000 47000 7092000 4611000 22666000 12309000 16900000 P1Y1M6D Income TaxesThe effective tax rates for the three and nine months ended September 30, 2021 and September 30, 2020 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $8 thousand and $34 thousand for the three and nine months ended September 30, 2021, respectively, and an income tax benefit of $15 thousand and $251 thousand for the three and nine months ended September 30, 2020, respectively. The expense recognized for the three and nine months ended September 30, <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 was a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit recognized for the three and nine months ended September 30, 2020 was a result of a discrete tax benefit recorded in the U.S. pursuant to certain tax provisions provided under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in the United States on March 27, 2020. The CARES Act permits the Company to carry back net operating losses to offset taxable income generated in the five preceding years, some of which were taxed at a federal income tax rate higher than the current enacted rate.</span></div> 8000 34000 -15000 -251000 Related Party Transactions<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ILJIN is considered to be a related party due to their equity ownership of over 5%. The outstanding related party amount payable to ILJIN is the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the first quarter of 2021, Aurinia paid $4.0 million upon achievement of specific milestones. The amount payable to ILJIN of $2.0 million and $6.0 million as of September 30, 2021 and December 31, 2020 was recorded in other current liabilities, respectively. The final $2.0 million outstanding amount payable has been achieved and will be paid during the fourth quarter 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stephen P. Robertson was a partner at Borden Ladner Gervais LLP (BLG) and acted as our corporate secretary through October 2020. We incurred legal fees in the normal course of business to BLG of $0.1 million and $0.3 million for the three and nine months ended September 30, 2020. We had no ongoing contractual or other commitments as a result of engaging Mr. Robertson to act as our corporate secretary and Mr. Robertson received no additional compensation for acting as the corporate secretary. On November 2, 2020 we announced the appointment of Stephen Robertson as our Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.</span></div> 4000000 2000000 6000000 2000000 100000 300000 Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's commitments and contingencies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Commitments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has various manufacturing agreements to support our commercial and clinical product supply requirements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial and clinical drug substance requirements. We have firm orders with Lonza, with remaining total non-cancellable future commitments of approximately $25.4 million through 2023 of which $3.5 million was paid during the second quarter of 2021. If we terminate certain firm orders with Lonza without cause, we will be required to pay for drug substance scheduled for manufacture under our arrangement.</span></div> 25400000 3500000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2021
Nov. 02, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-36421  
Entity Registrant Name Aurinia Pharmaceuticals Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Tax Identification Number 46-4129078  
Entity Address, Address Line One #1203-4464 Markham Street  
Entity Address, City or Town Victoria  
Entity Address, State or Province BC  
Entity Address, Postal Zip Code V8Z 7X8  
City Area Code (250)  
Local Phone Number 708-4272  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   129,670,345
Title of 12(b) Security Common shares, no par value  
Trading Symbol AUPH  
Security Exchange Name NASDAQ  
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001600620  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 57,587 $ 272,350
Short-term investments 228,813 125,979
Accounts receivable, net 9,814 0
Inventories, net 19,293 13,927
Prepaid expenses and other current assets 13,712 7,171
Total current assets 329,219 419,427
Non-current assets:    
Long-term investments 0 24,380
Other non-current assets 11,838 247
Property and equipment, net 4,551 4,786
Acquired intellectual property and other intangible assets, net 8,926 9,332
Right-of-use assets 5,532 5,489
Total assets 360,066 463,661
Current liabilities    
Accounts payable and accrued liabilities 29,970 24,797
Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively) 6,456 6,412
Operating lease liabilities 1,111 788
Total current liabilities 37,537 31,997
Non-current liabilities    
Other non-current liabilities 16,562 16,295
Operating lease liabilities 7,795 7,619
Total liabilities 61,894 55,911
Commitments and contingencies (Note 18)
SHAREHOLDER’S EQUITY    
Common shares - no par value, unlimited shares authorized, 129,570 and 126,725 shares issued and outstanding as at September 30, 2021 and December 31, 2020, respectively 967,159 944,328
Additional paid-in capital 54,607 39,383
Accumulated other comprehensive loss (794) (805)
Accumulated deficit (722,800) (575,156)
Total shareholder’s equity 298,172 407,750
Total liabilities and shareholders’ equity $ 360,066 $ 463,661
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Due to related party, current $ 2,000 $ 6,000
Common stock, issued (shares) 129,570,000 126,725,000
Common stock, outstanding (shares) 129,570,000 126,725,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Net revenue:        
Total revenues $ 14,667 $ 29 $ 22,201 $ 88
Operating expenses:        
Cost of sales 254 0 610 0
Selling, general and administrative 44,128 30,702 127,196 57,204
Research and development 20,066 12,243 39,990 37,154
Amortization of intangible assets 517 316 1,576 902
Other (income) expense, net 55 (917) 859 1,066
Total cost of sales and operating expenses 65,020 42,344 170,231 96,326
Loss from operations (50,353) (42,315) (148,030) (96,238)
Interest income 106 170 420 1,381
Net loss before income taxes (50,247) (42,145) (147,610) (94,857)
Income tax expense (benefit) 8 (15) 34 (251)
Net loss (50,255) (42,130) (147,644) (94,606)
Other comprehensive loss:        
Unrealized (loss) gain on available-for-sale securities, net of tax of nil (2) 0 11 0
Comprehensive loss $ (50,257) $ (42,130) $ (147,633) $ (94,606)
Basic loss per share (expressed in $ per share) $ (0.39) $ (0.34) $ (1.15) $ (0.82)
Diluted loss per share (expressed in $ per share) $ (0.39) $ (0.34) $ (1.15) $ (0.82)
Weighted-average common shares outstanding used in computation of basic loss per share 128,443 122,357 128,084 115,738
Weighted-average common shares outstanding used in computation of diluted loss per share 128,443 122,357 128,084 115,738
Product revenue, net        
Net revenue:        
Total revenues $ 14,638 $ 0 $ 22,113 $ 0
License revenue        
Net revenue:        
Total revenues $ 29 $ 29 $ 88 $ 88
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Unrealized gain on available-for-sale securities, tax $ 0.0 $ 0.0 $ 0.0 $ 0.0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Shares
Additional paid in capital
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Balance (in shares) at Dec. 31, 2019   111,798,000      
Balance at Dec. 31, 2019 $ 298,600 $ 746,487 $ 25,394 $ (805) $ (472,476)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options (in shares)   1,318,000      
Shares issued on exercise of stock options 5,400 $ 8,254 (2,854)    
Issuance of common shares (in shares)   13,333,000      
Issue of common shares 200,000 $ 200,000      
Share issue costs (12,268) $ (12,268)      
Exercise of warrants (in shares)   1,000      
Exercise of warrants 1 $ 2 (1)    
Share-based compensation 12,309   12,309    
Net loss (94,606)       (94,606)
Balance (in shares) at Sep. 30, 2020   126,450,000      
Balance at Sep. 30, 2020 409,436 $ 942,475 34,848 (805) (567,082)
Balance (in shares) at Jun. 30, 2020   112,705,000      
Balance at Jun. 30, 2020 257,698 $ 752,357 31,098 (805) (524,952)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options (in shares)   412,000      
Shares issued on exercise of stock options 1,525 $ 2,386 (861)    
Issuance of common shares (in shares)   13,333,000      
Issue of common shares 200,000 $ 200,000      
Share issue costs (12,268) $ (12,268)      
Share-based compensation 4,611   4,611    
Net loss (42,130)        
Balance (in shares) at Sep. 30, 2020   126,450,000      
Balance at Sep. 30, 2020 $ 409,436 $ 942,475 34,848 (805) (567,082)
Balance (in shares) at Dec. 31, 2020 126,725,000 126,725,000      
Balance at Dec. 31, 2020 $ 407,750 $ 944,328 39,383 (805) (575,156)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options (in shares)   2,324,000      
Shares issued on exercise of stock options 15,352 $ 22,097 (6,745)    
Exercise of warrants (in shares)   521,000      
Exercise of warrants 37 $ 734 (697)    
Share-based compensation 22,666   22,666    
Other comprehensive income 11     11  
Net loss $ (147,644)       (147,644)
Balance (in shares) at Sep. 30, 2021 129,570,000 129,570,000      
Balance at Sep. 30, 2021 $ 298,172 $ 967,159 54,607 (794) (722,800)
Balance (in shares) at Jun. 30, 2021   128,396,000      
Balance at Jun. 30, 2021 332,257 $ 954,572 51,022 (792) (672,545)
Increase (Decrease) in Stockholders' Equity          
Shares issued on exercise of stock options (in shares)   1,172,000      
Shares issued on exercise of stock options 9,074 $ 12,579 (3,505)    
Exercise of warrants (in shares)   2,000      
Exercise of warrants 6 $ 8 (2)    
Share-based compensation 7,092   7,092    
Other comprehensive income (2)     (2)  
Net loss $ (50,255)        
Balance (in shares) at Sep. 30, 2021 129,570,000 129,570,000      
Balance at Sep. 30, 2021 $ 298,172 $ 967,159 $ 54,607 $ (794) $ (722,800)
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows used in operating activities:    
Net loss $ (147,644) $ (94,606)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation of property and equipment 497 59
Amortization of intangible assets 1,576 902
Upfront license and milestone expense 10,000 0
Share-based compensation expense 22,666 12,309
Other, net 1,005 736
Net changes in operating assets and liabilities    
Accounts receivable (9,815) 0
Inventories (5,366) (471)
Prepaid expenses and other current assets (6,541) (3,725)
Non-current assets 247 0
Right of use assets (43) (5,576)
Accounts payable, accrued and other liabilities 1,149 9,012
Lease liabilities 499 8,298
Net cash used in operating activities (131,770) (73,062)
Cash flows used in investing activities:    
Purchase of investments (342,831) (202,951)
Proceeds from investments 263,752 30,779
Upfront lease payment (11,838) 0
Upfront license payment (6,000) 0
Purchase of long-lived assets (262) (4,095)
Additions to internal use-software implementation costs (1,198) (982)
Capitalized patent costs (6) (83)
Net cash used in investing activities (98,383) (177,332)
Cash flows from financing activities    
Proceeds from exercise of stock options 15,353 5,400
Proceeds from exercise of warrants 37 1
Net proceeds from issuance of common shares 0 187,732
Cash provided by financing activities 15,390 193,133
Net decrease in cash and cash equivalents (214,763) (57,261)
Cash and cash equivalents, beginning of period 272,350 306,019
Cash and cash equivalents, end of period 57,587 248,758
Supplemental cash flow information:    
Cash received for interest 671 891
Cash paid for taxes (236) (62)
Cash paid for amounts included in the measurement of lease liabilities (195) (68)
Supplemental disclosure of noncash transactions    
Initial recognition of operating lease right-of-use asset $ 419 $ 5,804
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Description of Business
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The Company has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program.
On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved LUPKYNIS in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN.
On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 is currently undergoing pre-clinical development with projected submission of an Investigational New Drug Application (IND) to the FDA by the end of 2022. It is anticipated that an IND for AUR300 is expected during the first half of 2023.
Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle, Rockville, Maryland, United States.
Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares traded on both the Nasdaq Global Market (Nasdaq) under the symbol AUPH and on the Toronto Stock Exchange (TSX) under the symbol AUP until July 30, 2021. As of July 30, 2021, the Company's common shares no longer trade on the TSX following the voluntary delisting by the Company and are solely traded on the Nasdaq.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.
These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.
The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, Segment Reporting. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief executive officer makes decisions for the Company and its subsidiaries as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.
These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.
We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash and cash equivalents and investments of $286.4 million as of September 30, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies mary of Significant Accounting Policies
Other than as described below, the Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Critical Accounting Estimates: The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial expenditures;
•Share-based compensation;
•Intangible assets;
•Leases; and
•Income taxes.
Concentration of Credit Risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.

The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 59% and 40% of the Company's total revenues for the three and nine months ended September 30, 2021. The Company monitors economic conditions, the
creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
Investments: The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the FASB ASC Topic 320, Investments — Debt Securities. Investments classified as held to maturity are carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method.
Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to two specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.
More specifically, these adjustments include the following:
Prompt pay discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Customer fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&A) expense.
Government rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.
Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
Co-payment assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.
License, Collaboration and Other Revenues
The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services and pass-through costs that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property (IP) is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Manufacturing supply services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.
Milestone payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-
evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.
Research, Development and/or Manufacturing Services. The Company’s agreements may include research and development (R&D) or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.
Cost of sales: Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.
Research and development expenses: R&D expenses are accounted for in accordance with ASC Topic 730, Research and Development, and are expensed as incurred. R&D costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, acquired licenses, subcontractors (such as contract research organizations) and materials used for R&D activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the R&D activities of the Company, including R&D conducted by others on behalf of the Company, shall be included in R&D costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers.
Selling, general and administrative expenses: The Company's SG&A expenses include commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These SG&A costs include corporate facility operating expenses and allocated depreciation; commercial, marketing, pharmacovigilance, publications, tradeshows, advisory boards, samples and operations in support of LUPKYNIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense SG&A expenses as they are incurred.
The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to two specialty pharmacies and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in SG&A expenses.
Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of September 30, 2021, accounts receivable, net are $9.8 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of September 30, 2021 and as of December 31, 2020
Recently adopted accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit
losses if fair value increases. The Company adopted the standard as of January 1, 2020 and did not have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement. Topic 820 requires to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Investments
 9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
As of September 30, 2021 and December 31, 2020, the Company had $228.8 million and $nil and $126.0 million and $24.4 million of short and long-term investments, respectively, mainly consisting of commercial paper and bonds as summarized below. As of September 30, 2021, the Company classifies its investments as debt securities of which $21.5 million are held to maturity debt securities which are carried at amortized cost and are approximately equal to fair market value. As of September 30, 2021, $207.3 million are available-for-sale debt securities which are carried at fair market value and are approximately equal to amortized cost. As of December 31, 2020, $150.4 million were classified as held to maturity and $nil were available-for-sale.
(in thousands)September 30, 2021December 31, 2020
Cashable Guaranteed Investment Certificate$5,644 $2,000 
Corporate Bond25,435 40,372 
Commercial Paper197,734 67,747 
Treasury Bill— 7,999 
Treasury Bond— 5,045 
Yankee Bond— 2,816 
Total short-term investments228,813 125,979 
Corporate Bonds - total long-term investments— 24,380 
Total investments$228,813 $150,359 
Currently, the Company does not intend to sell investments that are classified as held-to-maturity and has the ability and intent to hold these investments until maturity in order to collect interest payments over the life of the investments. As of September 30, 2021 and December 31, 2020, accrued interest receivable from the investments were $0.1 million and $0.5 million, respectively. During the three and nine months ended September 30, 2021, the Company had $2 thousand and $11 thousand unrealized losses and gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. The Company's investments as of September 30, 2021 mature at various dates through September 2022.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. For our product LUPKYNIS, the Company commenced capitalization of inventory once FDA approval was deemed to be probable, which occurred during the third quarter of 2020. Capitalized costs of inventories for LUPKYNIS mainly include third party manufacturing costs, transportation, storage, insurance, depreciation and allocated internal labor.

The components of inventory as of September 30, 2021 and December 31, 2020 are as follows:
(in thousands)September 30, 2021December 31, 2020
Raw materials$2,217 $— 
Work in process12,074 13,927 
Finished goods5,002 — 
Total inventories$19,293 $13,927 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Prepaid Expenses and Other Current Assets
 9 Months Ended
Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets
The following table summarizes prepaid expenses and other current assets.

(in thousands)September 30, 2021December 31, 2020
Prepaid assets$5,871 $3,701 
Prepaid insurance2,524 2,054 
Other current assets728 1,018 
Prepaid deposits4,589 398 
Total prepaid expenses and other current assets$13,712 $7,171 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets
 9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2021
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,471 $(1,152)$319 
Acquired intellectual property and reacquired rights15,125 (8,545)6,580 
Internal-use software implementation costs2,873 (846)2,027 
$19,469 $(10,543)$8,926 
December 31, 2020
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,651 $(1,203)$448 
Acquired intellectual property and reacquired rights15,126 (7,770)7,356 
Internal-use software implementation costs1,675 (147)1,528 
$18,452 $(9,120)$9,332 
Amortization expense for the three months ended September 30, 2021 and 2020 was $0.5 million and $0.3 million, respectively, and for the nine months ended September 30, 2021 and 2020 was $1.6 million and $0.9 million, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment, net
 9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, net Property and Equipment, net
Property and equipment as of September 30, 2021 and December 31, 2020 are as follows:
(in thousands)September 30, 2021December 31, 2020
Construction in progress$360 $4,467 
Leasehold improvements2,978 34 
Office equipment and furniture1,621 83 
Computer equipment265 381 
5,2244,965
Less accumulated depreciation(673)(179)
Property and equipment, net$4,551 $4,786 
Depreciation expense for the three month period ended September 30, 2021 and September 30, 2020 was $0.2 million and $nil, respectively, and for the nine months ended September 30, 2021 and 2020 was $0.5 million and $0.1 million. which is included in SG&A expenses in the condensed consolidated statements of operations.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Obligations
 9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Lease Obligations Lease Obligations
The Company has the following lease obligations:
Victoria, British Columbia
During the fourth quarter of 2020, the Company entered into facility and furniture leases for its head office located in Victoria, British Columbia for a total space of 13,206 square feet of office space for the facility lease. The lease terms commenced on January 1, 2021 for the facility and furniture leases. As of September 30, 2021, the Company had $0.2 million right-of-use assets (ROU assets) and $0.2 million lease liabilities related to the leases. The Company recognized operating lease costs that are included in SG&A expense in the condensed consolidated statement of operations. The incremental borrowing rate applied to the lease liabilities was 4.08% based on financial position, geographical region and terms of leases.
During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia. The lease term is expected to begin in 2022. The present value of the minimum lease payments for this lease are $2.7 million. As of September 30, 2021, the lease has not commenced and as a result there has been no accounting recognition associated with the lease.
Rockville, Maryland
During March 2020, the Company entered into a lease for its commercial office in Rockville, Maryland. The lease has a remaining term of approximately 11 years and has an option to extend for two five-year periods after the 11 years has elapsed and has an option to terminate after seven years. As of September 30, 2021, the Company had a right-of-use asset of $5.3 million and lease liability of $8.7 million included in the condensed consolidated balance sheets. As of December 31, 2020, the Company had a right of use asset of $5.5 million and lease liability of $8.4 million included in the condensed consolidated balance sheets. During 2020, the Company received reimbursements for tenant leasehold improvements by the landlord in the amount of $2.3 million for the Maryland lease. The Company recorded these leasehold improvement incentives as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease.
Edmonton, Alberta
During the fourth quarter of 2020, the Company entered into an agreement to lease premises in Edmonton, Alberta, commencing on October 1, 2020 and ending September 30, 2021. During the third quarter of 2021, the lease was extended until September 30, 2022. The Company recognizes short-term leases on a straight-line basis and did not record a related lease asset or liability for the Edmonton lease. The Company recognized short-term rent expense for this lease, which is included in SG&A expense in the condensed consolidated statement of operations.
The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:
(in thousands)Balance Sheet ClassificationSeptember 30, 2021December 31, 2020
Assets
Operating lease right of-use assetsRight-of-use assets$5,532 $5,489 
Liabilities
Current operating lease liabilitiesCurrent operating lease liabilities1,111 788 
Non-current operating lease liabilitiesNon-current operating lease liabilities7,795 7,619 
Total lease liabilities$8,906 $8,407 
Beginning January 1, 2021, the Company began to incur variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs for the three and nine month periods ended September 30, 2021. The following provides a summary of the components of leasing costs and rent for the three and nine month periods ended September 30, 2021 and September 30, 2020.
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)Consolidated Statement of Operations2021202020212020
Operating lease costs
Operating lease costsSelling, general and administrative$261 $196 $783 $456 
Short-term lease costs
Office BuildingSelling, general and administrative7 74 21 215 
Variable lease costs
Office buildingSelling, general and administrative44 1 124 3 
Total rent expense$312 $271 $928 $674 
The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2021:
As of September 30, 2021
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases9.685.20%
The following table provides a summary of operating lease liabilities maturities for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2021$281 
20221,143 
20231,061 
20241,085 
20251,109 
Thereafter6,773 
Total future minimum lease payments 11,452 
Less: lease imputed interest(2,546)
Total future minimum lease payments$8,906 
Finance Lease
On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing facility within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.
The first capital expenditure payment was made in February 2021 of $11.8 million which was treated as an upfront lease payment and recorded under other non-current assets on the condensed consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during 2023. Upon completion of the monoplant, the Company will have the right to maintain sole dedicated use of the monoplant by paying a quarterly fixed facility fee.
The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $84.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Accounts Payable and Accrued Liabilities
 9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities
The following table summarizes the Company's accounts payable and accrued liabilities.

(in thousands)September 30, 2021December 31, 2020
Trade payables$3,263 $2,635 
Other accrued liabilities8,322 6,616 
Accrued R&D projects3,865 4,185 
Employee accruals14,520 11,361 
Total accounts payable and accrued liabilities$29,970 $24,797 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Non-current Liabilities
 9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
Non-current Liabilities Non-current LiabilitiesThe Company recorded other non-current liabilities of $16.6 million and $16.3 million as of September 30, 2021 and December 31, 2020, respectively. The balance as of September 30, 2021 and December 31, 2020 primarily included obligations that are the result of a resolution of the board of directors of the Company dated March 8, 2012 whereby certain executive officers at that time were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair values of held to maturity and available-for-sale debt securities are generally based on prices obtained from commercial pricing services.
In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
•Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
•Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions.
The Company's Level 1 instruments include deposits held with banks and short-term investments that are valued using quoted market prices. Level 2 instruments include the Company's short and long-term investments that are valued through third-party pricing services that use verifiable observable market data. The Company has no Level 3 instruments as of September 30, 2021 and December 31, 2020.
There were no transfers between Level 1, Level 2 and Level 3 instruments in the periods presented.
The following tables present the financial assets measured at fair value on a recurring basis:
September 30, 2021
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$35,070 $— $— $35,070 
Short-term highly liquid investments19,417 3,100 — 22,517 
Investments197,734 31,079 — 228,813 
Total$252,221 $34,179 $— $286,400 
December 31, 2020
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$130,807 $— $— $130,807 
Short-term highly liquid investments141,543 — — 141,543 
Investments69,746 80,613 — 150,359 
Total$342,096 $80,613 $— $422,709 
Refer to Note 4, “Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
License and Collaboration Agreement
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
License and Collaboration Agreement License and Collaboration Agreements
Riptide License
On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated
statement of operations. Additional milestone payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during the first half of 2023.
Otsuka Contract

On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) for the development and commercialization of oral LUPKYNIS for the treatment of patients with active LN in the EU, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.

As part of the agreement, Aurinia received an upfront cash payment of $50.0 million for the license agreement and has the potential to receive up to $50.0 million in regulatory milestones. Aurinia will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on achievement of sale thresholds) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka. In addition, voclosporin will be provided to Otsuka under a cost-plus supply agreement.

The Company evaluated the Otsuka Agreement under ASC 606. Based on that evaluation, the license transferred was determined to be functional IP that has significant standalone functionality. That is, the treatment of LN and other diseases provides significant benefit to Otsuka at the point of transfer, and it is not expected that the utility of the IP will substantively change as a result of any remaining clinical trials or ongoing activities of Aurinia. The Company determined the upfront fee of $50.0 million was fixed consideration for the transfer of the license and was recognized upon transfer of the license in December 2020.

The remaining forms of consideration are variable because they are dependent on achieving milestones or are based on aggregate future net sales for the regions. None of the regulatory milestones have been included in the transaction price, as all milestone amounts were fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the magnitude of a potential reversal of revenue, uncertainty about if or when the milestone related performance obligations might be achieved, and that receipt of the milestones are outside the control of the Company since they are dependent on efforts to be undertaken by Otsuka and regulatory approval by various foreign government agencies. Any consideration related to sales-based royalties (and sales-based thresholds) will be recognized when the related sales occur.

As of September 30, 2021, there has been no additional consideration earned or received since the upfront payment of $50.0 million during the fourth quarter of 2020.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss per Common Share
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Net Loss per Common Share Net Loss per Common Share
Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2021202020212020
Net loss$(50,255)$(42,130)$(147,644)$(94,606)
Weighted average common shares outstanding128,443 122,357 128,084 115,738 
Net loss per common share (expressed in $ per share)$(0.39)$(0.34)$(1.15)$(0.82)
The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:
Nine months ended
September 30,
(in thousands)20212020
Stock options12,837 11,443 
Unvested performance awards857 — 
Unvested restricted units201 — 
Warrants1,012 1,690 
14,907 13,133 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Share-based Compensation
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Share-based Compensation Share-based Compensation
The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of outstanding awards). Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code (the “Code”) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price.
As of September 30, 2021 and December 31, 2020, 129.6 million and 126.7 million, common shares were issued and outstanding.

Stock Options

The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments.
The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average assumptions were used to estimate the fair value of the options granted during the nine month periods ended September 30, 2021 and September 30, 2020:
September 30, 2021September 30, 2020
Annualized volatility66 %43%
Risk-free interest rate0.38 %0.70 %
Expected life of options in years4.0 years3.0 years
Estimated forfeiture rate8.9 %12 %
Dividend rate0.0 %0.0%
Fair value per common share option$6.64 $5.05 
The following table summarizes the option award activity during the nine months ended September 30, 2021:

September 30, 2021
Number of shares (in thousands)Weighted average exercise price $
Outstanding - Beginning of Period14,047 11.35 
Granted2,059 13.42 
Exercised(2,324)6.60 
Cancelled/Forfeited(945)13.72 
Outstanding - End of Period12,837 12.37 
Vested and expected to vest - End of Period2,635 14.54 
Options exercisable - End of Period5,244 10.81 
Performance Awards and Restricted Stock Units
On October 23, 2020, the Company issued 439,000 performance awards (PAs) to executive management of the Company whose vesting is contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vests entitles the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56.
On August 6, 2021, the Company granted approximately 619,000 PAs and restricted stock units (RSUs). The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vest on the employee's first anniversary of the grant date and the employee must achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs have no performance metrics and will vest on the one year anniversary of the grant.
The Company recorded approximately $0.7 million and $1.1 million of share-based compensation expense related to PAs and RSUs during the three and nine month periods ended September 30, 2021.
Compensation Expense
The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2021 and September 30, 2020 as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Research and development$1,038 $814 $3,201 $3,111 
Selling, general and administrative6,000 3,750 19,189 9,151 
Capitalized under inventories54 47 276 47 
Share-based compensation expense$7,092 $4,611 $22,666 $12,309 
As of September 30, 2021, there was $16.9 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.1 years.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
 9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesThe effective tax rates for the three and nine months ended September 30, 2021 and September 30, 2020 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of $8 thousand and $34 thousand for the three and nine months ended September 30, 2021, respectively, and an income tax benefit of $15 thousand and $251 thousand for the three and nine months ended September 30, 2020, respectively. The expense recognized for the three and nine months ended September 30,
2021 was a result of income in certain jurisdictions. This tax expense is not offset by a tax benefit as the Company has losses which are fully offset by a valuation allowance in its significant jurisdictions.

The tax benefit recognized for the three and nine months ended September 30, 2020 was a result of a discrete tax benefit recorded in the U.S. pursuant to certain tax provisions provided under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in the United States on March 27, 2020. The CARES Act permits the Company to carry back net operating losses to offset taxable income generated in the five preceding years, some of which were taxed at a federal income tax rate higher than the current enacted rate.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Related-Party Transactions
 9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Related-Party Transactions Related Party Transactions
ILJIN is considered to be a related party due to their equity ownership of over 5%. The outstanding related party amount payable to ILJIN is the result of a settlement completed on September 20, 2013 between ILJIN and the Company. During the first quarter of 2021, Aurinia paid $4.0 million upon achievement of specific milestones. The amount payable to ILJIN of $2.0 million and $6.0 million as of September 30, 2021 and December 31, 2020 was recorded in other current liabilities, respectively. The final $2.0 million outstanding amount payable has been achieved and will be paid during the fourth quarter 2021.
Stephen P. Robertson was a partner at Borden Ladner Gervais LLP (BLG) and acted as our corporate secretary through October 2020. We incurred legal fees in the normal course of business to BLG of $0.1 million and $0.3 million for the three and nine months ended September 30, 2020. We had no ongoing contractual or other commitments as a result of engaging Mr. Robertson to act as our corporate secretary and Mr. Robertson received no additional compensation for acting as the corporate secretary. On November 2, 2020 we announced the appointment of Stephen Robertson as our Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Commitment and Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's commitments and contingencies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.
Manufacturing Commitments
The Company has various manufacturing agreements to support our commercial and clinical product supply requirements.

We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial and clinical drug substance requirements. We have firm orders with Lonza, with remaining total non-cancellable future commitments of approximately $25.4 million through 2023 of which $3.5 million was paid during the second quarter of 2021. If we terminate certain firm orders with Lonza without cause, we will be required to pay for drug substance scheduled for manufacture under our arrangement.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Critical Accounting Estimates
Critical Accounting Estimates: The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.
The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:
•Revenue recognition;
•Cost of sales;
•Inventory;
•Royalty obligation;
•Contingent accruals;
•Clinical trial expenditures;
•Share-based compensation;
•Intangible assets;
•Leases; and
•Income taxes.
Concentration of Credit Risk
Concentration of Credit Risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.

The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.

The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 59% and 40% of the Company's total revenues for the three and nine months ended September 30, 2021. The Company monitors economic conditions, the
creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
Investments Investments: The Company classifies its debt securities at acquisition as either held to maturity or available-for-sale in accordance with the FASB ASC Topic 320, Investments — Debt Securities. Investments classified as held to maturity are carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within shareholders’ equity. Realized gains and losses on held to maturity and available-for-sale securities are recorded in other income (expense), net. Interest income is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method.
Revenue Recognition
Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied.
Product Revenues
In the United States (and territories), the Company sells LUPKYNIS primarily to two specialty pharmacies and a specialty distributor. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer.
Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are generally calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment.
More specifically, these adjustments include the following:
Prompt pay discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized.
Customer fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as a selling, general and administrative (SG&A) expense.
Government rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet.
Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated potential future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period.
Co-payment assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual adjustment for co-payment assistance is based on the co-payments made on the Company's behalf by the specialty pharmacies; and estimated potential future claims that will be made for product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period.
License, Collaboration and Other Revenues
The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees, development, regulatory and commercial milestone payments, payments for manufacturing supply services and pass-through costs that the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues.
In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.
Licenses of intellectual property: If the license to the Company’s intellectual property (IP) is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Manufacturing supply services: Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations.
Milestone payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-
evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Any consideration related to sales-based royalties (and sales-based milestones) will be recognized when the related sales occur.
Research, Development and/or Manufacturing Services. The Company’s agreements may include research and development (R&D) or manufacturing services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date. If these services are determined not to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to the combined performance obligation as the related performance obligations are satisfied.
Cost of sales Cost of sales: Cost of sales consist primarily of cost of inventories for LUPKYNIS, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor and depreciation.
Research and development costs Research and development expenses: R&D expenses are accounted for in accordance with ASC Topic 730, Research and Development, and are expensed as incurred. R&D costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, acquired licenses, subcontractors (such as contract research organizations) and materials used for R&D activities, including nonclinical studies, clinical trials, clinical manufacturing costs and professional services. The costs of services performed by others in connection with the R&D activities of the Company, including R&D conducted by others on behalf of the Company, shall be included in R&D costs and expensed as the contracted work is performed. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial or project and the invoices received from its external service providers.
Selling, general and administrative expenses Selling, general and administrative expenses: The Company's SG&A expenses include commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These SG&A costs include corporate facility operating expenses and allocated depreciation; commercial, marketing, pharmacovigilance, publications, tradeshows, advisory boards, samples and operations in support of LUPKYNIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense SG&A expenses as they are incurred.The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to two specialty pharmacies and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in SG&A expenses.
Accounts receivable, net Accounts receivable, net: Accounts receivable are stated at their net realizable value. As of September 30, 2021, accounts receivable, net are $9.8 million. Estimates of the Company's allowance for doubtful accounts are determined based on existing contractual payment terms, historical payment patterns of our customers and individual customer circumstances. The allowance for doubtful accounts was $nil as of September 30, 2021 and as of December 31, 2020
Recently adopted accounting pronouncements
Recently adopted accounting pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit
losses if fair value increases. The Company adopted the standard as of January 1, 2020 and did not have a material impact on the Company’s consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement. Topic 820 requires to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements.
In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company elected to adopt the amendment as of January 1, 2021, which did not have a material impact on the consolidated financial statements.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Investments (Tables)
 9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments
(in thousands)September 30, 2021December 31, 2020
Cashable Guaranteed Investment Certificate$5,644 $2,000 
Corporate Bond25,435 40,372 
Commercial Paper197,734 67,747 
Treasury Bill— 7,999 
Treasury Bond— 5,045 
Yankee Bond— 2,816 
Total short-term investments228,813 125,979 
Corporate Bonds - total long-term investments— 24,380 
Total investments$228,813 $150,359 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventory
The components of inventory as of September 30, 2021 and December 31, 2020 are as follows:
(in thousands)September 30, 2021December 31, 2020
Raw materials$2,217 $— 
Work in process12,074 13,927 
Finished goods5,002 — 
Total inventories$19,293 $13,927 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Prepaid Expenses and Other Current Assets (Tables)
 9 Months Ended
Sep. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure
The following table summarizes prepaid expenses and other current assets.

(in thousands)September 30, 2021December 31, 2020
Prepaid assets$5,871 $3,701 
Prepaid insurance2,524 2,054 
Other current assets728 1,018 
Prepaid deposits4,589 398 
Total prepaid expenses and other current assets$13,712 $7,171 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
The following table summarizes the carrying amount of intangible assets, net of accumulated amortization.
September 30, 2021
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,471 $(1,152)$319 
Acquired intellectual property and reacquired rights15,125 (8,545)6,580 
Internal-use software implementation costs2,873 (846)2,027 
$19,469 $(10,543)$8,926 
December 31, 2020
(in thousands)Gross Carrying
Value		Accumulated
Amortization		Net Carrying
Amount
Patents$1,651 $(1,203)$448 
Acquired intellectual property and reacquired rights15,126 (7,770)7,356 
Internal-use software implementation costs1,675 (147)1,528 
$18,452 $(9,120)$9,332 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment, net (Tables)
 9 Months Ended
Sep. 30, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Property and equipment as of September 30, 2021 and December 31, 2020 are as follows:
(in thousands)September 30, 2021December 31, 2020
Construction in progress$360 $4,467 
Leasehold improvements2,978 34 
Office equipment and furniture1,621 83 
Computer equipment265 381 
5,2244,965
Less accumulated depreciation(673)(179)
Property and equipment, net$4,551 $4,786 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Obligations (Tables)
 9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Supplemental Balance Sheet Information
The following table provides supplemental balance sheet information related to the operating lease ROU assets and lease liabilities:
(in thousands)Balance Sheet ClassificationSeptember 30, 2021December 31, 2020
Assets
Operating lease right of-use assetsRight-of-use assets$5,532 $5,489 
Liabilities
Current operating lease liabilitiesCurrent operating lease liabilities1,111 788 
Non-current operating lease liabilitiesNon-current operating lease liabilities7,795 7,619 
Total lease liabilities$8,906 $8,407 
Lease, Cost
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)Consolidated Statement of Operations2021202020212020
Operating lease costs
Operating lease costsSelling, general and administrative$261 $196 $783 $456 
Short-term lease costs
Office BuildingSelling, general and administrative7 74 21 215 
Variable lease costs
Office buildingSelling, general and administrative44 1 124 3 
Total rent expense$312 $271 $928 $674 
The following table represents the weighted-average remaining lease term and discount rate as of September 30, 2021:
As of September 30, 2021
Weighted Average Remaining Lease Term (years)Weighted Average Discount Rate
Operating leases9.685.20%
Lessee, Operating Lease, Liability, Maturity The following table provides a summary of operating lease liabilities maturities for the next five years and thereafter:
(in thousands)Operating Lease Payments
Remainder of 2021$281 
20221,143 
20231,061 
20241,085 
20251,109 
Thereafter6,773 
Total future minimum lease payments 11,452 
Less: lease imputed interest(2,546)
Total future minimum lease payments$8,906 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Accounts Payable and Accrued Liabilities (Tables)
 9 Months Ended
Sep. 30, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
(in thousands)September 30, 2021December 31, 2020
Trade payables$3,263 $2,635 
Other accrued liabilities8,322 6,616 
Accrued R&D projects3,865 4,185 
Employee accruals14,520 11,361 
Total accounts payable and accrued liabilities$29,970 $24,797 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present the financial assets measured at fair value on a recurring basis:
September 30, 2021
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$35,070 $— $— $35,070 
Short-term highly liquid investments19,417 3,100 — 22,517 
Investments197,734 31,079 — 228,813 
Total$252,221 $34,179 $— $286,400 
December 31, 2020
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash and cash equivalents:
Deposits held with banks$130,807 $— $— $130,807 
Short-term highly liquid investments141,543 — — 141,543 
Investments69,746 80,613 — 150,359 
Total$342,096 $80,613 $— $422,709 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss per Common Share (Tables)
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands, except per share data)2021202020212020
Net loss$(50,255)$(42,130)$(147,644)$(94,606)
Weighted average common shares outstanding128,443 122,357 128,084 115,738 
Net loss per common share (expressed in $ per share)$(0.39)$(0.34)$(1.15)$(0.82)
The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Nine months ended
September 30,
(in thousands)20212020
Stock options12,837 11,443 
Unvested performance awards857 — 
Unvested restricted units201 — 
Warrants1,012 1,690 
14,907 13,133 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Share-based Compensation (Tables)
 9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award Valuation Assumptions The following weighted average assumptions were used to estimate the fair value of the options granted during the nine month periods ended September 30, 2021 and September 30, 2020:
September 30, 2021September 30, 2020
Annualized volatility66 %43%
Risk-free interest rate0.38 %0.70 %
Expected life of options in years4.0 years3.0 years
Estimated forfeiture rate8.9 %12 %
Dividend rate0.0 %0.0%
Fair value per common share option$6.64 $5.05 
Schedule of Performance Shares Activity
The following table summarizes the option award activity during the nine months ended September 30, 2021:

September 30, 2021
Number of shares (in thousands)Weighted average exercise price $
Outstanding - Beginning of Period14,047 11.35 
Granted2,059 13.42 
Exercised(2,324)6.60 
Cancelled/Forfeited(945)13.72 
Outstanding - End of Period12,837 12.37 
Vested and expected to vest - End of Period2,635 14.54 
Options exercisable - End of Period5,244 10.81 
Allocation of Share-Based Payments
The Company recognized share-based compensation expense for the three and nine month periods ended September 30, 2021 and September 30, 2020 as follows:
Three months ended
September 30,		Nine Months Ended
September 30,
(in thousands)2021202020212020
Research and development$1,038 $814 $3,201 $3,111 
Selling, general and administrative6,000 3,750 19,189 9,151 
Capitalized under inventories54 47 276 47 
Share-based compensation expense$7,092 $4,611 $22,666 $12,309 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2021
USD ($)
reportingUnit
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments | segment 1
Number of reporting units | reportingUnit 1
Cash and cash equivalents and investments | $ $ 286.4
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]      
Accounts receivable, net $ 9,814 $ 9,814 $ 0
Allowance for doubtful accounts $ 0 $ 0 $ 0
Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy One      
Property, Plant and Equipment [Line Items]      
Concentration risk 59.00%    
Customer Concentration Risk | Revenue Benchmark | Specialty Pharmacy Two      
Property, Plant and Equipment [Line Items]      
Concentration risk   40.00%  
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Investments (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]      
Debt Securities, Held-to-maturity $ 21,500 $ 21,500 $ 150,400
Debt Securities, Available-for-sale 207,300 207,300 0
Marketable Securities [Line Items]      
Short-term investments 228,813 228,813 125,979
Long-term investments 0 0 24,380
Total investments 228,813 228,813 150,359
Interest Receivable 100 100 500
Unrealized gains on available-for-sale securities (2) 11  
Cashable Guaranteed Investment Certificate      
Marketable Securities [Line Items]      
Short-term investments 5,644 5,644 2,000
Corporate Bond      
Marketable Securities [Line Items]      
Short-term investments 25,435 25,435 40,372
Commercial Paper      
Marketable Securities [Line Items]      
Short-term investments 197,734 197,734 67,747
Treasury Bill      
Marketable Securities [Line Items]      
Short-term investments 0 0 7,999
Treasury Bond      
Marketable Securities [Line Items]      
Short-term investments 0 0 5,045
Yankee Bond      
Marketable Securities [Line Items]      
Short-term investments 0 0 2,816
Corporate Bonds      
Marketable Securities [Line Items]      
Long-term investments $ 0 $ 0 $ 24,380
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Raw materials $ 2,217 $ 0
Work in process 12,074 13,927
Finished goods 5,002 0
Total inventories $ 19,293 $ 13,927
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid assets $ 5,871 $ 3,701
Prepaid insurance 2,524 2,054
Other current assets 728 1,018
Prepaid deposits 4,589 398
Prepaid expenses and other current assets $ 13,712 $ 7,171
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 19,469 $ 18,452
Accumulated Amortization (10,543) (9,120)
Net Carrying Amount 8,926 9,332
Patents    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 1,471 1,651
Accumulated Amortization (1,152) (1,203)
Net Carrying Amount 319 448
Acquired intellectual property and reacquired rights    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 15,125 15,126
Accumulated Amortization (8,545) (7,770)
Net Carrying Amount 6,580 7,356
Cloud computing arrangements    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2,873 1,675
Accumulated Amortization (846) (147)
Net Carrying Amount $ 2,027 $ 1,528
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 517 $ 316 $ 1,576 $ 902
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment, net (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross $ 5,224   $ 5,224   $ 4,965
Less accumulated depreciation (673)   (673)   (179)
Property and equipment, net 4,551   4,551   4,786
Depreciation of property and equipment 200 $ 0 497 $ 59  
Construction in progress          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross 360   360   4,467
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross 2,978   2,978   34
Office equipment and furniture          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross 1,621   1,621   83
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property, plant and equipment, gross $ 265   $ 265   $ 381
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Obligations - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2021
USD ($)
Mar. 31, 2020
extension_option
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
ft²
Aug. 31, 2020
USD ($)
Mar. 12, 2020
Lessee, Lease, Description [Line Items]                  
Right-of-use assets     $ 5,532   $ 5,532   $ 5,489    
Total lease liabilities     $ 8,906   $ 8,906   $ 8,407    
Incremental borrowing rate     5.20%   5.20%        
Total lease costs     $ 312 $ 271 $ 928 $ 674      
Capital expenditure payments $ (11,800)                
Minimum finance lease liability payments due     84,000   84,000        
Minimum lease payments     11,452   11,452        
Victoria, British Columbia                  
Lessee, Lease, Description [Line Items]                  
Area of property (in sqft) | ft²             13,206    
Right-of-use assets     200   200        
Total lease liabilities     $ 200   $ 200        
Incremental borrowing rate     4.08%   4.08%        
Minimum lease payments               $ 2,700  
Rockville, Maryland                  
Lessee, Lease, Description [Line Items]                  
Right-of-use assets     $ 5,300   $ 5,300   $ 5,500    
Total lease liabilities     $ 8,700   $ 8,700   8,400    
Incremental borrowing rate                 5.20%
Remaining lease term   11 years              
Number of extension options | extension_option   2              
Lease extension term   5 years              
Lease termination option term   7 years              
Proceeds from tenant improvements             $ 2,300    
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Obligations - Supplemental Balance Sheet Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Assets    
Right-of-use assets $ 5,532 $ 5,489
Current    
Current operating lease liabilities 1,111 788
Non-current    
Non-current operating lease liabilities 7,795 7,619
Total lease liabilities $ 8,906 $ 8,407
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Leases [Abstract]        
Operating lease costs $ 261 $ 196 $ 783 $ 456
Short-term lease costs 7 74 21 215
Variable lease costs 44 1 124 3
Total rent expense $ 312 $ 271 $ 928 $ 674
Weighted average remaining lease term - operating leases (in years) 9 years 8 months 4 days   9 years 8 months 4 days  
Weighted average discount rate - operating leases 5.20%   5.20%  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Leases [Abstract]    
Remainder of 2021 $ 281  
2022 1,143  
2023 1,061  
2024 1,085  
2025 1,109  
Thereafter 6,773  
Total 11,452  
Less: lease imputed interest (2,546)  
Total future minimum lease payments $ 8,906 $ 8,407
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Accounts Payable and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Trade payables $ 3,263 $ 2,635
Other accrued liabilities 8,322 6,616
Accrued R&D projects 3,865 4,185
Employee accruals 14,520 11,361
Total accounts payable and accrued liabilities $ 29,970 $ 24,797
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Non-current Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Other non-current liabilities $ 16,562 $ 16,295
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Assets:    
Investments $ 228,813 $ 150,359
Total 286,400 422,709
Deposits held with banks    
Assets:    
Cash and cash equivalents: 35,070 130,807
Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: 22,517 141,543
Level 1    
Assets:    
Investments 197,734 69,746
Total 252,221 342,096
Level 1 | Deposits held with banks    
Assets:    
Cash and cash equivalents: 35,070 130,807
Level 1 | Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: 19,417 141,543
Level 2    
Assets:    
Investments 31,079 80,613
Total 34,179 80,613
Level 2 | Deposits held with banks    
Assets:    
Cash and cash equivalents: 0 0
Level 2 | Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: 3,100 0
Level 3    
Assets:    
Investments 0 0
Total 0 0
Level 3 | Deposits held with banks    
Assets:    
Cash and cash equivalents: 0 0
Level 3 | Short-term highly liquid investments    
Assets:    
Cash and cash equivalents: $ 0 $ 0
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.2
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 17, 2021
Dec. 17, 2020
Dec. 31, 2020
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenues       $ 14,667   $ 29 $ 22,201 $ 88
License Agreement Terms | Otuska                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront payments received   $ 50,000         $ 0  
Potential regulatory milestone revenue   $ 50,000            
Revenues     $ 50,000   $ 50,000      
License Agreement Terms | Otuska | Minimum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   10.00%            
License Agreement Terms | Otuska | Maximum                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Tiered royalty percentages on future sales   20.00%            
License Agreement Terms | Riptide Bioscience, Inc.                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Upfront license fee $ 6,000              
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Earnings Per Share [Abstract]        
Net loss $ (50,255) $ (42,130) $ (147,644) $ (94,606)
Weighted-average common shares outstanding used in computation of basic loss per share 128,443 122,357 128,084 115,738
Basic loss per share (expressed in $ per share) $ (0.39) $ (0.34) $ (1.15) $ (0.82)
Weighted-average common shares outstanding used in computation of diluted loss per share 128,443 122,357 128,084 115,738
Diluted loss per share (expressed in $ per share) $ (0.39) $ (0.34) $ (1.15) $ (0.82)
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 14,907,000 13,133,000
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 12,837,000 11,443,000
Unvested performance awards    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 857,000 0
Unvested restricted units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 201,000 0
Warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 1,012,000 1,690,000
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Share-based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 06, 2021
Mar. 18, 2021
Oct. 23, 2020
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Common stock, issued (shares)         129,570,000   129,570,000   126,725,000
Common stock, outstanding (shares)         129,570,000   129,570,000   126,725,000
Share-based compensation expense         $ 7,092 $ 4,611 $ 22,666 $ 12,309  
Unrecognized share-based compensation expense         16,900   $ 16,900    
Unrecognized share-based compensation expense weighted average recognition period             1 year 1 month 6 days    
Amended and Restated Equity Incentive Plan                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of additional shares authorized       23,800,000          
Unvested performance awards | Officer                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Granted     439,000       2,059,000    
Granted, Weighted average exercise price (in usd per share)   $ 13.56         $ 13.42    
Share-based compensation expense         $ 700   $ 1,100    
Employee Stock                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Number of shares authorized         2,500,000   2,500,000    
Performance Share sand Restricted Stock Units (RSUs) | Officer                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Granted 619,000                
Granted, Weighted average exercise price (in usd per share) $ 14.42                
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Weighted Average Assumptions (Details) - USD ($)
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]    
Annualized volatility 66.00% 43.00%
Risk-free interest rate 0.38% 0.70%
Expected life of options in years 4 years 3 years
Estimated forfeiture rate 8.90% 12.00%
Dividend rate $ 0.000 $ 0.000
Fair value per common share option (in usd per share) $ 6.64 $ 5.05
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Share-based Compensation - Performance Shares Activity (Details) - Unvested performance awards - Officer - $ / shares
shares in Thousands
 9 Months Ended
Mar. 18, 2021
Oct. 23, 2020
Sep. 30, 2021
Number of shares      
Outstanding - Beginning of Period (in shares)     14,047
Granted (in shares)   439 2,059
Exercised (in shares)     (2,324)
Cancelled/Forfeited (in shares)     (945)
Outstanding - End of Period (in shares)     12,837
Vested and expected to vest - End of Period (in shares)     2,635
Options exercisable - End of Period (in shares)     5,244
Weighted average exercise price $      
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)     $ 11.35
Granted, Weighted average exercise price (in usd per share) $ 13.56   13.42
Vested, Weighted average exercise price (in usd per share)     6.60
Cancelled/Forfeited, Weighted average exercise price (in usd per share)     13.72
Outstanding, Weighted average exercise price - End of Period (in usd per share)     12.37
Vested and expected to vest - End of Period (in usd per share)     14.54
Options exercisable - End of Period (in usd per share)     $ 10.81
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 7,092 $ 4,611 $ 22,666 $ 12,309
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 1,038 814 3,201 3,111
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense 6,000 3,750 19,189 9,151
Capitalized under inventories        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation expense $ 54 $ 47 $ 276 $ 47
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]        
Income tax (benefit) expense $ 8 $ (15) $ 34 $ (251)
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Related-Party Transactions (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2020
Sep. 30, 2021
Dec. 31, 2020
Other Current Liabilities | ILJIN          
Related Party Transaction [Line Items]          
Due to related parties       $ 2.0 $ 6.0
Milestone Payment | Affiliated Shareholder | ILJIN          
Related Party Transaction [Line Items]          
Payments to related party $ 4.0        
Due to related parties       $ 2.0  
Legal Fees | Management          
Related Party Transaction [Line Items]          
Expenses from related party   $ 0.1 $ 0.3    
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Commitment and Contingencies (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Long-term Purchase Commitment [Line Items]      
Payments to Acquire Other Productive Assets   $ 262 $ 4,095
Lonza      
Long-term Purchase Commitment [Line Items]      
Non-cancellable future commitments   $ 25,400  
Payments to Acquire Other Productive Assets $ 3,500    
EXCEL 73 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 74 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 75 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 162 309 1 false 55 0 false 8 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.auriniapharma.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Organization and Description of Business Sheet http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 2102102 - Disclosure - Basis of Presentation Sheet http://www.auriniapharma.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 2104103 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 2107104 - Disclosure - Investments Sheet http://www.auriniapharma.com/role/Investments Investments Notes 11 false false R12.htm 2110105 - Disclosure - Inventories Sheet http://www.auriniapharma.com/role/Inventories Inventories Notes 12 false false R13.htm 2113106 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 13 false false R14.htm 2116107 - Disclosure - Intangible Assets Sheet http://www.auriniapharma.com/role/IntangibleAssets Intangible Assets Notes 14 false false R15.htm 2120108 - Disclosure - Property, Plant and Equipment, net Sheet http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet Property, Plant and Equipment, net Notes 15 false false R16.htm 2123109 - Disclosure - Lease Obligations Sheet http://www.auriniapharma.com/role/LeaseObligations Lease Obligations Notes 16 false false R17.htm 2129110 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 17 false false R18.htm 2132111 - Disclosure - Non-current Liabilities Sheet http://www.auriniapharma.com/role/NoncurrentLiabilities Non-current Liabilities Notes 18 false false R19.htm 2134112 - Disclosure - Fair Value Measurements Sheet http://www.auriniapharma.com/role/FairValueMeasurements Fair Value Measurements Notes 19 false false R20.htm 2137113 - Disclosure - License and Collaboration Agreement Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreement License and Collaboration Agreement Notes 20 false false R21.htm 2139114 - Disclosure - Net Loss per Common Share Sheet http://www.auriniapharma.com/role/NetLossperCommonShare Net Loss per Common Share Notes 21 false false R22.htm 2143115 - Disclosure - Share-based Compensation Sheet http://www.auriniapharma.com/role/SharebasedCompensation Share-based Compensation Notes 22 false false R23.htm 2149116 - Disclosure - Income Taxes Sheet http://www.auriniapharma.com/role/IncomeTaxes Income Taxes Notes 23 false false R24.htm 2151117 - Disclosure - Related-Party Transactions Sheet http://www.auriniapharma.com/role/RelatedPartyTransactions Related-Party Transactions Notes 24 false false R25.htm 2153118 - Disclosure - Commitment and Contingencies Sheet http://www.auriniapharma.com/role/CommitmentandContingencies Commitment and Contingencies Notes 25 false false R26.htm 2205201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies 26 false false R27.htm 2308301 - Disclosure - Investments (Tables) Sheet http://www.auriniapharma.com/role/InvestmentsTables Investments (Tables) Tables http://www.auriniapharma.com/role/Investments 27 false false R28.htm 2311302 - Disclosure - Inventories (Tables) Sheet http://www.auriniapharma.com/role/InventoriesTables Inventories (Tables) Tables http://www.auriniapharma.com/role/Inventories 28 false false R29.htm 2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets 29 false false R30.htm 2317304 - Disclosure - Intangible Assets (Tables) Sheet http://www.auriniapharma.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.auriniapharma.com/role/IntangibleAssets 30 false false R31.htm 2321305 - Disclosure - Property, Plant and Equipment, net (Tables) Sheet http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables Property, Plant and Equipment, net (Tables) Tables http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet 31 false false R32.htm 2324306 - Disclosure - Lease Obligations (Tables) Sheet http://www.auriniapharma.com/role/LeaseObligationsTables Lease Obligations (Tables) Tables http://www.auriniapharma.com/role/LeaseObligations 32 false false R33.htm 2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities 33 false false R34.htm 2335308 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.auriniapharma.com/role/FairValueMeasurements 34 false false R35.htm 2340309 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareTables Net Loss per Common Share (Tables) Tables http://www.auriniapharma.com/role/NetLossperCommonShare 35 false false R36.htm 2344310 - Disclosure - Share-based Compensation (Tables) Sheet http://www.auriniapharma.com/role/SharebasedCompensationTables Share-based Compensation (Tables) Tables http://www.auriniapharma.com/role/SharebasedCompensation 36 false false R37.htm 2403401 - Disclosure - Basis of Presentation (Details) Sheet http://www.auriniapharma.com/role/BasisofPresentationDetails Basis of Presentation (Details) Details http://www.auriniapharma.com/role/BasisofPresentation 37 false false R38.htm 2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 38 false false R39.htm 2409403 - Disclosure - Investments (Details) Sheet http://www.auriniapharma.com/role/InvestmentsDetails Investments (Details) Details http://www.auriniapharma.com/role/InvestmentsTables 39 false false R40.htm 2412404 - Disclosure - Inventories (Details) Sheet http://www.auriniapharma.com/role/InventoriesDetails Inventories (Details) Details http://www.auriniapharma.com/role/InventoriesTables 40 false false R41.htm 2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables 41 false false R42.htm 2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 42 false false R43.htm 2419407 - Disclosure - Intangible Assets - Narrative (Details) Sheet http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails Intangible Assets - Narrative (Details) Details 43 false false R44.htm 2422408 - Disclosure - Property, Plant and Equipment, net (Details) Sheet http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails Property, Plant and Equipment, net (Details) Details http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables 44 false false R45.htm 2425409 - Disclosure - Lease Obligations - Narrative (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails Lease Obligations - Narrative (Details) Details 45 false false R46.htm 2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails Lease Obligations - Supplemental Balance Sheet Information (Details) Details 46 false false R47.htm 2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) Details 47 false false R48.htm 2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Sheet http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) Details 48 false false R49.htm 2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables 49 false false R50.htm 2433414 - Disclosure - Non-current Liabilities (Details) Sheet http://www.auriniapharma.com/role/NoncurrentLiabilitiesDetails Non-current Liabilities (Details) Details http://www.auriniapharma.com/role/NoncurrentLiabilities 50 false false R51.htm 2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 51 false false R52.htm 2438416 - Disclosure - License and Collaboration Agreement (Details) Sheet http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails License and Collaboration Agreement (Details) Details http://www.auriniapharma.com/role/LicenseandCollaborationAgreement 52 false false R53.htm 2441417 - Disclosure - Net Loss per Common Share (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareDetails Net Loss per Common Share (Details) Details http://www.auriniapharma.com/role/NetLossperCommonShareTables 53 false false R54.htm 2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details) Sheet http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails Net Loss per Common Share - Anti-Dilutive Securities (Details) Details 54 false false R55.htm 2445419 - Disclosure - Share-based Compensation - Narrative (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails Share-based Compensation - Narrative (Details) Details 55 false false R56.htm 2446420 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails Share-Based Compensation - Weighted Average Assumptions (Details) Details 56 false false R57.htm 2447421 - Disclosure - Share-based Compensation - Performance Shares Activity (Details) Sheet http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails Share-based Compensation - Performance Shares Activity (Details) Details 57 false false R58.htm 2448422 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) Sheet http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) Details 58 false false R59.htm 2450423 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 59 false false R60.htm 2452424 - Disclosure - Related-Party Transactions (Details) Sheet http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.auriniapharma.com/role/RelatedPartyTransactions 60 false false R61.htm 2454425 - Disclosure - Commitment and Contingencies (Details) Sheet http://www.auriniapharma.com/role/CommitmentandContingenciesDetails Commitment and Contingencies (Details) Details http://www.auriniapharma.com/role/CommitmentandContingencies 61 false false All Reports Book All Reports auph-20210930.htm auph-20210930.xsd auph-20210930_cal.xml auph-20210930_def.xml auph-20210930_lab.xml auph-20210930_pre.xml auph-2021q3exx311.htm auph-2021q3exx312.htm auph-2021q3exx321.htm auph-2021q3exx322.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 true true JSON 78 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "auph-20210930.htm": { "axisCustom": 0, "axisStandard": 23, "contextCount": 162, "dts": { "calculationLink": { "local": [ "auph-20210930_cal.xml" ] }, "definitionLink": { "local": [ "auph-20210930_def.xml" ] }, "inline": { "local": [ "auph-20210930.htm" ] }, "labelLink": { "local": [ "auph-20210930_lab.xml" ] }, "presentationLink": { "local": [ "auph-20210930_pre.xml" ] }, "schema": { "local": [ "auph-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 409, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 17, "keyStandard": 292, "memberCustom": 15, "memberStandard": 39, "nsprefix": "auph", "nsuri": "http://www.auriniapharma.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.auriniapharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104103 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107104 - Disclosure - Investments", "role": "http://www.auriniapharma.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110105 - Disclosure - Inventories", "role": "http://www.auriniapharma.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113106 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116107 - Disclosure - Intangible Assets", "role": "http://www.auriniapharma.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120108 - Disclosure - Property, Plant and Equipment, net", "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet", "shortName": "Property, Plant and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123109 - Disclosure - Lease Obligations", "role": "http://www.auriniapharma.com/role/LeaseObligations", "shortName": "Lease Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129110 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132111 - Disclosure - Non-current Liabilities", "role": "http://www.auriniapharma.com/role/NoncurrentLiabilities", "shortName": "Non-current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134112 - Disclosure - Fair Value Measurements", "role": "http://www.auriniapharma.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137113 - Disclosure - License and Collaboration Agreement", "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement", "shortName": "License and Collaboration Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139114 - Disclosure - Net Loss per Common Share", "role": "http://www.auriniapharma.com/role/NetLossperCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143115 - Disclosure - Share-based Compensation", "role": "http://www.auriniapharma.com/role/SharebasedCompensation", "shortName": "Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149116 - Disclosure - Income Taxes", "role": "http://www.auriniapharma.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151117 - Disclosure - Related-Party Transactions", "role": "http://www.auriniapharma.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153118 - Disclosure - Commitment and Contingencies", "role": "http://www.auriniapharma.com/role/CommitmentandContingencies", "shortName": "Commitment and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2205201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Investments (Tables)", "role": "http://www.auriniapharma.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311302 - Disclosure - Inventories (Tables)", "role": "http://www.auriniapharma.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - Intangible Assets (Tables)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321305 - Disclosure - Property, Plant and Equipment, net (Tables)", "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables", "shortName": "Property, Plant and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "auph:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2324306 - Disclosure - Lease Obligations (Tables)", "role": "http://www.auriniapharma.com/role/LeaseObligationsTables", "shortName": "Lease Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "auph:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330307 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335308 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.auriniapharma.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340309 - Disclosure - Net Loss per Common Share (Tables)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344310 - Disclosure - Share-based Compensation (Tables)", "role": "http://www.auriniapharma.com/role/SharebasedCompensationTables", "shortName": "Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Basis of Presentation (Details)", "role": "http://www.auriniapharma.com/role/BasisofPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "role": "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AllowanceForDoubtfulAccountsReceivable", "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if427368d4c114547b0e4ef6081da2fdf_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Investments (Details)", "role": "http://www.auriniapharma.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if427368d4c114547b0e4ef6081da2fdf_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Inventories (Details)", "role": "http://www.auriniapharma.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidAdvertising", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PrepaidAdvertising", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418406 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - Intangible Assets - Narrative (Details)", "role": "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails", "shortName": "Intangible Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422408 - Disclosure - Property, Plant and Equipment, net (Details)", "role": "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails", "shortName": "Property, Plant and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if427368d4c114547b0e4ef6081da2fdf_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "auph:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425409 - Disclosure - Lease Obligations - Narrative (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "shortName": "Lease Obligations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i5ed7c451665a4102bce5b5bcb2d78f26_D20210201-20210228", "decimals": "-5", "lang": "en-US", "name": "us-gaap:FinanceLeasePrincipalPayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "auph:AssetsAndLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426410 - Disclosure - Lease Obligations - Supplemental Balance Sheet Information (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails", "shortName": "Lease Obligations - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427411 - Disclosure - Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails", "shortName": "Lease Obligations - Summary of Components of Leasing Costs and Rent (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428412 - Disclosure - Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "role": "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails", "shortName": "Lease Obligations - Schedule of Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431413 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "role": "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433414 - Disclosure - Non-current Liabilities (Details)", "role": "http://www.auriniapharma.com/role/NoncurrentLiabilitiesDetails", "shortName": "Non-current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436415 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "role": "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails", "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438416 - Disclosure - License and Collaboration Agreement (Details)", "role": "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "shortName": "License and Collaboration Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9a4c7e576c134a5580fd06e627c18cc3_D20201217-20201217", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441417 - Disclosure - Net Loss per Common Share (Details)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareDetails", "shortName": "Net Loss per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442418 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities (Details)", "role": "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails", "shortName": "Net Loss per Common Share - Anti-Dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i9b9167e1abb34eab9390ac596cbd139f_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445419 - Disclosure - Share-based Compensation - Narrative (Details)", "role": "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "shortName": "Share-based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446420 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i97198b8a1c3741439bc355f05b62f68f_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447421 - Disclosure - Share-based Compensation - Performance Shares Activity (Details)", "role": "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails", "shortName": "Share-based Compensation - Performance Shares Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i97198b8a1c3741439bc355f05b62f68f_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448422 - Disclosure - Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)", "role": "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "shortName": "Share-Based Compensation - Allocated Share-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "id9d9412c28ed45dd85bc1051650a8b83_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "if5647d01952e4cd19bafc0b9045d16b4_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450423 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i69026efb7b0b4d108ab15160645e155b_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i69026efb7b0b4d108ab15160645e155b_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i7b9d0bcde35741f58cb533eaed4fd931_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452424 - Disclosure - Related-Party Transactions (Details)", "role": "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i7b9d0bcde35741f58cb533eaed4fd931_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireOtherProductiveAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454425 - Disclosure - Commitment and Contingencies (Details)", "role": "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails", "shortName": "Commitment and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "i62634fd49e1441e2957a78a3b106e073_D20210101-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "auph:AcquiredUpfrontLicensePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Description of Business", "role": "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Basis of Presentation", "role": "http://www.auriniapharma.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "auph-20210930.htm", "contextRef": "ie1d4af69c2e4452c86857e09ee2a37de_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 55, "tag": { "auph_AccruedResearchCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Research, Current", "label": "Accrued Research, Current", "terseLabel": "Accrued R&D projects" } } }, "localname": "AccruedResearchCurrent", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "auph_AcquiredUpfrontLicensePayment": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquired Upfront License Payment", "label": "Acquired Upfront License Payment", "terseLabel": "Upfront license and milestone expense" } } }, "localname": "AcquiredUpfrontLicensePayment", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "auph_AmendedAndRestatedEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated Equity Incentive Plan", "label": "Amended and Restated Equity Incentive Plan [Member]", "terseLabel": "Amended and Restated Equity Incentive Plan" } } }, "localname": "AmendedAndRestatedEquityIncentivePlanMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "auph_CashCashEquivalentsAndDebtSecuritiesCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents and Debt Securities, Current", "label": "Cash, Cash Equivalents and Debt Securities, Current", "terseLabel": "Cash and cash equivalents and investments" } } }, "localname": "CashCashEquivalentsAndDebtSecuritiesCurrent", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "auph_CashableGuaranteedInvestmentCertificatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cashable Guaranteed Investment Certificates", "label": "Cashable Guaranteed Investment Certificates [Member]", "terseLabel": "Cashable Guaranteed Investment Certificate" } } }, "localname": "CashableGuaranteedInvestmentCertificatesMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "auph_DebtSecuritiesCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/InvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Current and Noncurrent", "label": "Debt Securities, Current and Noncurrent", "totalLabel": "Total investments" } } }, "localname": "DebtSecuritiesCurrentAndNoncurrent", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "auph_ILJINMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ILJIN", "label": "ILJIN [Member]", "terseLabel": "ILJIN" } } }, "localname": "ILJINMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease, Right-of-Use Assets", "label": "Increase (Decrease) in Operating Lease, Right-of-Use Assets", "negatedTerseLabel": "Right of use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "auph_LegalFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Fees", "label": "Legal Fees [Member]", "terseLabel": "Legal Fees" } } }, "localname": "LegalFeesMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_LesseeOperatingLeaseLeaseTerminationTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Termination Term", "label": "Lessee, Operating Lease, Lease Termination Term", "terseLabel": "Lease termination option term" } } }, "localname": "LesseeOperatingLeaseLeaseTerminationTerm", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "auph_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "auph_LesseeOperatingLeaseNumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number of Extension Options", "label": "Lessee, Operating Lease, Number of Extension Options", "terseLabel": "Number of extension options" } } }, "localname": "LesseeOperatingLeaseNumberOfExtensionOptions", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "integerItemType" }, "auph_LonzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lonza", "label": "Lonza [Member]", "terseLabel": "Lonza" } } }, "localname": "LonzaMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "auph_MilestonePaymentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone Payment", "label": "Milestone Payment [Member]", "terseLabel": "Milestone Payment" } } }, "localname": "MilestonePaymentMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "auph_OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Assets, Lessee", "label": "Operating Lease, Assets And Liabilities, Assets, Lessee [Abstract]", "terseLabel": "Assets" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesAssetsLesseeAbstract", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee", "label": "Operating Lease, Assets And Liabilities, Liabilities, Current, Lessee [Abstract]", "terseLabel": "Current" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLiabilitiesCurrentLesseeAbstract", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "auph_OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee", "label": "Operating Lease, Assets And Liabilities, Liabilities, Noncurrent, Lessee [Abstract]", "terseLabel": "Non-current" } } }, "localname": "OperatingLeaseAssetsAndLiabilitiesLiabilitiesNoncurrentLesseeAbstract", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "auph_OtuskaPharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Otuska Pharmaceutical Co., Ltd.", "label": "Otuska Pharmaceutical Co., Ltd. [Member]", "terseLabel": "Otuska" } } }, "localname": "OtuskaPharmaceuticalCoLtdMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "auph_PerformanceShareSandRestrictedStockUnitsRSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Share sand Restricted Stock Units (RSUs)", "label": "Performance Share sand Restricted Stock Units (RSUs) [Member]", "terseLabel": "Performance Share sand Restricted Stock Units (RSUs)" } } }, "localname": "PerformanceShareSandRestrictedStockUnitsRSUsMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_PrepaidRentAndPrepaidContinuingStudies": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid Rent and Prepaid Continuing Studies", "label": "Prepaid Rent and Prepaid Continuing Studies", "terseLabel": "Prepaid deposits" } } }, "localname": "PrepaidRentAndPrepaidContinuingStudies", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount", "label": "Research And Development Arrangement, Contract To Perform For Others, Performance Obligation, Potential Revenue Amount", "terseLabel": "Potential regulatory milestone revenue" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersPerformanceObligationPotentialRevenueAmount", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "auph_ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "label": "Research And Development Arrangement, Contract To Perform For Others, Tiered Royalty, Percent", "terseLabel": "Tiered royalty percentages on future sales" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTieredRoyaltyPercent", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "percentItemType" }, "auph_RiptideBioscienceIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Riptide Bioscience, Inc.", "label": "Riptide Bioscience, Inc. [Member]", "terseLabel": "Riptide Bioscience, Inc." } } }, "localname": "RiptideBioscienceIncMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "auph_RockvilleMarylandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rockville, Maryland", "label": "Rockville, Maryland [Member]", "terseLabel": "Rockville, Maryland" } } }, "localname": "RockvilleMarylandMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number", "terseLabel": "Options exercisable - End of Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable - End of Period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest - End of Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest - End of Period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "auph_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Forfeiture Rate", "terseLabel": "Estimated forfeiture rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "auph_ShortTermCorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-Term Corporate Debt Securities", "label": "Short-Term Corporate Debt Securities [Member]", "terseLabel": "Corporate Bond" } } }, "localname": "ShortTermCorporateDebtSecuritiesMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "auph_SpecialtyPharmacyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty Pharmacy One", "label": "Specialty Pharmacy One [Member]", "terseLabel": "Specialty Pharmacy One" } } }, "localname": "SpecialtyPharmacyOneMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_SpecialtyPharmacyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specialty Pharmacy Two", "label": "Specialty Pharmacy Two [Member]", "terseLabel": "Specialty Pharmacy Two" } } }, "localname": "SpecialtyPharmacyTwoMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_VictoriaBritishColumbiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Victoria, British Columbia", "label": "Victoria, British Columbia [Member]", "terseLabel": "Victoria, British Columbia" } } }, "localname": "VictoriaBritishColumbiaMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "auph_YankeeBondMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yankee Bond", "label": "Yankee Bond [Member]", "terseLabel": "Yankee Bond" } } }, "localname": "YankeeBondMember", "nsuri": "http://www.auriniapharma.com/20210930", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r282", "r394", "r395", "r398", "r511" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Shareholder" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r51", "r53", "r101", "r102", "r238", "r245" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r160", "r267", "r271", "r486" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ManagementMember": { "auth_ref": [ "r161", "r397" ], "lang": { "en-us": { "role": { "label": "Management [Member]", "terseLabel": "Management" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r237", "r244", "r284", "r285", "r410", "r411", "r412", "r413", "r414", "r415", "r434", "r483", "r487", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r237", "r244", "r284", "r285", "r410", "r411", "r412", "r413", "r414", "r415", "r434", "r483", "r487", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r160", "r267", "r271", "r486" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OfficerMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "label": "Officer [Member]", "terseLabel": "Officer" } } }, "localname": "OfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r157", "r267", "r269", "r436", "r482", "r484" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r157", "r267", "r269", "r436", "r482", "r484" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r237", "r244", "r274", "r284", "r285", "r410", "r411", "r412", "r413", "r414", "r415", "r434", "r483", "r487", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r237", "r244", "r274", "r284", "r285", "r410", "r411", "r412", "r413", "r414", "r415", "r434", "r483", "r487", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r52", "r53", "r101", "r102", "r238", "r245" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails", "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r158", "r159", "r267", "r270", "r485", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r158", "r159", "r267", "r270", "r485", "r496", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r161", "r397" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Accounts and Other Receivables, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as noncurrent at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Noncurrent [Text Block]", "terseLabel": "Non-current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NoncurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities", "totalLabel": "Total accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails", "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r13", "r38" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r36", "r213" ], "calculation": { "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r57", "r59", "r60", "r469", "r492", "r493" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r60", "r67", "r68", "r69", "r104", "r105", "r106", "r349", "r488", "r489", "r529" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r20" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r104", "r105", "r106", "r311", "r312", "r313", "r356" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r286", "r288", "r317", "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r247", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedTerseLabel": "Share issue costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r288", "r307", "r316" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r166", "r184", "r186", "r187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r88", "r203", "r208" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/IntangibleAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of property (in sqft)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r97", "r146", "r149", "r155", "r182", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r346", "r350", "r366", "r401", "r403", "r453", "r468" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r50", "r97", "r182", "r224", "r225", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r346", "r350", "r366", "r401", "r403" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r359" ], "calculation": { "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r171", "r173", "r192", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt Securities, Available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r289", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligationsIncurred": { "auth_ref": [ "r92", "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in lease obligation from new lease.", "label": "Lease Obligation Incurred", "negatedTerseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CapitalLeaseObligationsIncurred", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r34", "r90" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r85", "r90", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r367" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of noncash transactions" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r45", "r221", "r457", "r473" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 18)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r218", "r219", "r220", "r222", "r498" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r104", "r105", "r356" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r247" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r19" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common shares - no par value, unlimited shares authorized, 129,570 and 126,725 shares issued and outstanding as at September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r63", "r65", "r66", "r74", "r461", "r477" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r204", "r206", "r338" ], "lang": { "en-us": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Cloud computing arrangements" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r137", "r138", "r160", "r364", "r365", "r497" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r137", "r138", "r160", "r364", "r365", "r494", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r137", "r138", "r160", "r364", "r365", "r494", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r133", "r467" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r137", "r138", "r160", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r137", "r138", "r160", "r364", "r365", "r497" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r78", "r97", "r182", "r224", "r225", "r226", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r366" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of sales" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r77" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total cost of sales and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r136", "r160" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)", "terseLabel": "Unrealized gains on available-for-sale securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/InvestmentsDetails": { "order": 1.0, "parentTag": "auph_DebtSecuritiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.", "label": "Debt Securities, Current", "terseLabel": "Short-term investments" } } }, "localname": "DebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/InvestmentsDetails": { "order": 2.0, "parentTag": "auph_DebtSecuritiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Debt Securities, Noncurrent", "terseLabel": "Long-term investments" } } }, "localname": "DebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DemandDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.", "label": "Demand Deposits [Member]", "terseLabel": "Deposits held with banks" } } }, "localname": "DemandDepositsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r211" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation of property and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r38", "r100", "r227", "r229", "r230", "r234", "r235", "r236", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related party, current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r100", "r227", "r229", "r230", "r234", "r235", "r236", "r395", "r456", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r75", "r109", "r110", "r111", "r112", "r113", "r117", "r119", "r121", "r122", "r123", "r127", "r128", "r357", "r358", "r462", "r478" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic loss per share (expressed in $ per share)", "totalLabel": "Basic loss per share (expressed in $ per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r75", "r109", "r110", "r111", "r112", "r113", "r119", "r121", "r122", "r123", "r127", "r128", "r357", "r358", "r462", "r478" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted loss per share (expressed in $ per share)", "totalLabel": "Diluted loss per share (expressed in $ per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r124", "r125", "r126", "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized share-based compensation expense weighted average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r67", "r68", "r69", "r104", "r105", "r106", "r108", "r114", "r116", "r130", "r183", "r247", "r249", "r311", "r312", "r313", "r329", "r330", "r356", "r368", "r369", "r370", "r371", "r372", "r374", "r488", "r489", "r490", "r529" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r359", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r239", "r242", "r243", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r360", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r239", "r275", "r276", "r281", "r283", "r360", "r407" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r239", "r242", "r243", "r275", "r276", "r281", "r283", "r360", "r408" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r239", "r242", "r243", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r360", "r409" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r239", "r242", "r243", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r389" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "terseLabel": "Minimum finance lease liability payments due" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r377", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Capital expenditure payments" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r175", "r176", "r178", "r179", "r180", "r185", "r188", "r189", "r190", "r191", "r193", "r194", "r195", "r196", "r241", "r246", "r355", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r207" ], "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r204", "r205", "r207", "r209", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r207", "r438" ], "calculation": { "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r204", "r206" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r207", "r437" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Acquired intellectual property and other intangible assets, net", "totalLabel": "Net Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r168", "r174", "r184", "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "terseLabel": "Debt Securities, Held-to-maturity" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r146", "r148", "r151", "r154", "r156", "r451", "r458", "r463", "r480" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r215", "r217" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r98", "r326", "r327", "r328", "r331", "r333", "r335", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r115", "r116", "r145", "r325", "r332", "r334", "r481" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "negatedTerseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable, accrued and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Net changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r87", "r384" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r87" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Acquired intellectual property and reacquired rights" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Interest Receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Capitalized under inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r26", "r197" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r48", "r403" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r28", "r197" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r27", "r197" ], "calculation": { "http://www.auriniapharma.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r181", "r479" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r359" ], "calculation": { "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r177", "r452", "r465", "r495", "r527" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r388", "r390" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Total lease costs", "totalLabel": "Total rent expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r389" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Minimum lease payments", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r389" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r389" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r389" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r389" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r389" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r389" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: lease imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease Obligations" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41", "r97", "r150", "r182", "r224", "r225", "r226", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r347", "r350", "r351", "r366", "r401", "r402" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r97", "r182", "r366", "r403", "r454", "r471" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43", "r97", "r182", "r224", "r225", "r226", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r347", "r350", "r351", "r366", "r401", "r402", "r403" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "License Agreement Terms" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "terseLabel": "Non-cancellable future commitments" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment [Line Items]" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "Marketable Securities [Table Text Block]", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Short-term highly liquid investments" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows used in investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r86", "r89" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows used in operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r61", "r64", "r69", "r72", "r89", "r97", "r107", "r109", "r110", "r111", "r112", "r115", "r116", "r120", "r146", "r148", "r151", "r154", "r156", "r182", "r224", "r225", "r226", "r229", "r230", "r231", "r232", "r233", "r235", "r236", "r358", "r366", "r459", "r475" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of reporting units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/BasisofPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment and furniture" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r146", "r148", "r151", "r154", "r156" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r381", "r390" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r376" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities", "totalLabel": "Total lease liabilities", "verboseLabel": "Total future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsScheduleofMaturitiesofLeaseLiabilitiesDetails", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r376" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "verboseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r376" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities", "verboseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r375" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r387", "r390" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating leases", "verboseLabel": "Incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails", "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r386", "r390" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r14", "r42" ], "calculation": { "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r49", "r403" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r344", "r345", "r348" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized (loss) gain on available-for-sale securities, net of tax of nil" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "auth_ref": [ "r54", "r55", "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "terseLabel": "Unrealized gain on available-for-sale securities, tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r62", "r65", "r67", "r68", "r70", "r73", "r247", "r368", "r373", "r374", "r460", "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r42", "r403" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities (of which $2,000 and $6,000, due to related party in 2021 and 2020, respectively)" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "verboseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/NoncurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r89" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other (income) expense, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "auth_ref": [ "r80", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.", "label": "Payments for (Proceeds from) Tenant Allowance", "negatedTerseLabel": "Proceeds from tenant improvements" } } }, "localname": "PaymentsForProceedsFromTenantAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedTerseLabel": "Additions to internal use-software implementation costs" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Capitalized patent costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireLeaseReceivables": { "auth_ref": [ "r82" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of receivables arising from the lease of real estate, equipment or other fixed assets for a specified time in exchange for payment, usually in the form of rent.", "label": "Payments to Acquire Lease Receivables", "negatedTerseLabel": "Upfront lease payment" } } }, "localname": "PaymentsToAcquireLeaseReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r172" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchase of investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedTerseLabel": "Upfront license payment" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r81" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Purchase of long-lived assets", "terseLabel": "Payments to Acquire Other Productive Assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CommitmentandContingenciesDetails", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r81", "r341", "r342", "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Upfront license fee" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Unvested performance awards" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r289", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidAdvertising": { "auth_ref": [ "r7", "r200", "r202" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration paid in advance for advertising that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Advertising", "terseLabel": "Prepaid assets" } } }, "localname": "PrepaidAdvertising", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r8", "r32", "r33" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "totalLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r5", "r9", "r201", "r202" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r6", "r9", "r199", "r202" ], "calculation": { "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromInterestReceived": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received on loans and other debt instruments during the current period.", "label": "Proceeds from Interest Received", "terseLabel": "Cash received for interest" } } }, "localname": "ProceedsFromInterestReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r83" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from issuance of common shares" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r83", "r310" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r83" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenue, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r36", "r214" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r216", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r35", "r212" ], "calculation": { "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r214", "r403", "r466", "r472" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r212" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r282", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r394", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "terseLabel": "Payments to related party" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r282", "r394", "r395", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Expenses from related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r282", "r394", "r398", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r392", "r393", "r395", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "auth_ref": [ "r322", "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Upfront payments received" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r321", "r435", "r514" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested restricted units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r249", "r314", "r403", "r470", "r491", "r493" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r104", "r105", "r106", "r108", "r114", "r116", "r183", "r311", "r312", "r313", "r329", "r330", "r356", "r488", "r490" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "verboseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r143", "r144", "r147", "r152", "r153", "r157", "r158", "r160", "r266", "r267", "r436" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues", "verboseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r268", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "License and Collaboration Agreement" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Net revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r385", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Initial recognition of operating lease right-of-use asset" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r137", "r160" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/AccountsPayableandAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Allocation of Share-Based Payments" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r204", "r206", "r437" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r204", "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r15", "r29", "r30", "r31" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r36", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/PropertyPlantandEquipmentnetDetails", "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r396", "r398" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LicenseandCollaborationAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r289", "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Cancelled/Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Cancelled/Forfeited, Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding - End of Period (in shares)", "periodStartLabel": "Outstanding - Beginning of Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, Weighted average exercise price - End of Period (in usd per share)", "periodStartLabel": "Outstanding, Weighted average exercise price - Beginning of Period (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average exercise price $" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r303" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Annualized volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationAllocatedShareBasedCompensationExpenseDetails", "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Fair value per common share option (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r287", "r291" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationNarrativeDetails", "http://www.auriniapharma.com/role/SharebasedCompensationPerformanceSharesActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.", "label": "Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]", "terseLabel": "Schedule of Performance Shares Activity" } } }, "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SharebasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r301", "r315" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r382", "r390" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease costs" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r95", "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r47", "r67", "r68", "r69", "r104", "r105", "r106", "r108", "r114", "r116", "r130", "r183", "r247", "r249", "r311", "r312", "r313", "r329", "r330", "r356", "r368", "r369", "r370", "r371", "r372", "r374", "r488", "r489", "r490", "r529" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r104", "r105", "r106", "r130", "r436" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of preferred stock and warrants for common stock issued.", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "terseLabel": "Exercise of warrants" } } }, "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r46", "r240", "r247", "r248", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r247", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r247", "r249", "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Shares issued on exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r247", "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issue of common shares" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r47", "r247", "r249" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Shares issued on exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r97", "r169", "r182", "r366", "r403" ], "calculation": { "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholder\u2019s equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets", "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "SHAREHOLDER\u2019S EQUITY" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r162", "r163", "r164", "r165", "r167", "r170" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable, net" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r175", "r176", "r178", "r179", "r180", "r241", "r246", "r355", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r520", "r521", "r522", "r523", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBillSecuritiesMember": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bill Securities [Member]", "terseLabel": "Treasury Bill" } } }, "localname": "USTreasuryBillSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryBondSecuritiesMember": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bond Securities [Member]", "terseLabel": "Treasury Bond" } } }, "localname": "USTreasuryBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r131", "r132", "r134", "r135", "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Critical Accounting Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r383", "r390" ], "calculation": { "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/LeaseObligationsSummaryofComponentsofLeasingCostsandRentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/NetLossperCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r118", "r123" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding used in computation of diluted loss per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r117", "r123" ], "calculation": { "http://www.auriniapharma.com/role/NetLossperCommonShareDetails": { "order": 3.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted-average common shares outstanding used in computation of basic loss per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.auriniapharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.auriniapharma.com/role/NetLossperCommonShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r337": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r495": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r515": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r516": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r517": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r518": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r519": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r520": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r521": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r522": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r523": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r524": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r525": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r526": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r527": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r528": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(6)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 79 0001628280-21-021464-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-21-021464-xbrl.zip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

/J<*,P,SI>O5=PRP0(4>S? 5H0D<%,[H M;:_O ME?V.ZIN\QT(6Z]<(0XT%(=[J - +>=&>/)M8R/U"LQ'AV5:,JQ$W8EV4-U0] MC\TP#:I8FOLMHIQX7^9CSN1N4;4]XA8OXHTV9>:EEZI3L>])\_VCUW\?#$])3J)':!OMBG)78"P(_Q/L^XI%O)33)E#- MS=D%[7D[HJ^'_[W^K&=V+>+59+$U 9/F'OQ;4K7T-!?R/SX2[% R:4WE_ M+-2_"Q7B1>"/!&54V%*E3VDHS$:MMA>I)SX*WH*:UF%=$= MG2]X.^><1+*RSCL6E%*[8(3_@WB M0\8I/I>6$TXOF _]-=W2E6P1VH5Z-=;=Y?M^F?U@5XR/"122DSLLWL!>JN3Y MAHT*("X4I5*K,BYD=W'!^%R^[$36'>^6";"*TKN@/W5"N7C]J0>R"PD#!N(QZ+TG\_W6P'A+?R2#D M9OPE7-YH4:(1]8%>L(#QMF/&/W'PE9!SMLVWY=/M J/?)3C]8?,J!67XP1,H M0S+!_A79UL?GDNV"KM2:#+AXLVF&$N1=G&.(E>YF_/%9@%I#9HE>UIIG* =Y M&UVF@2 3PBNNT_\*AGF]7L2^E'7U&%#0AAE58$!U]7V2Q>(!FE)*.5I8 M[J^_'DHEY)XI*4)Y8,K*@,Q4GO-Y^!>^1'AX_/V_/A]-'GS$^6(\F_[RD/_$ M'C[ :9KE\?3]+P__>/<E/GLZ,&?L_E?XX\!X!_K7WHZ._XR'[__L'P@F. 7?SK_ M.18P9DN,.E.<2(B8!T2KO2XFZ2/]_WO\L#69I2@;OM 'ED(%G"B$HIH4I M,H>O3ITZ>?/L?YY*?9_/TC MP9A\=/KIAYN/?[[T^4]R_6GNO7^T_NG7CR[&5WV0'LL?_?NWEV_3!SP*,)XN MEF&:Z@L6XY\7ZV^^G*6P7(_YK;@>7/N)^A6_#@ M9#CFLPF^P?*@_OW'FQ?G7AE6\_%T'(X_A/E1^"G-CA[53SUZ.IMFG"XPTS\6 ML\DX5UT_"9,JQML/B,L%";-^^/++,?[R<#$^.I[@Z?<^S+'\\C"LCC] U3KS MDE5(_WF'IS[Z!CN%25I-UJ/TDK[>/+O"ZR$!?EXB_<;)N)U"F,S2N0]-JM9F M\]/?G(2(D_5W1ZL%O _A>/1R'.)X,EZ.<3%2BME2?:C.I:/<+) M5\/OB$U3YMC-\)SC!/EWAV?NIM/O%HL3HZ M6C\3QDL\.OW]:@G;\&(YZZF/$Q:0+/O2Y(QX3SA3G]02B=P5C@P M)@G%.9>1Y][L?WIW(HCOC A[CG@SS;]:?L#Y&3!GF(A:,N8$@D--OITK!B&) M"($C0T\RFXA]+,.UF.["!/F=,:&1!GK8@L?3_'8Y2W]]F$UH:!?/_F=%MFHD MK!1!>K)+:#TH37&21ARVEY( M"2E'KY-QRH;["9RWE^YQ2K,53;W7X4N($R0UTG?F*\Q7B)VMYD9F!UP'RELT M*Q"SYL MCU:S)&SH,PNV #E0A[H+F9! MI6C *70@E=5&.2\=UX=8AD%6' M8A-E1:$XEOO$8-< &JB?;4*+!BIHQH?'BP4NORV0%!:9RQI8,)0.2Y? !QE( M+)$BI=J96-K'Q9R%TC_4;3#C^6(WVXG=R$;S9/LDV7>"-R1'NCM'KO.A[333;"*\GN-Q&.=GGX_KIL@I%)T] M"50R&"*4,9!^+<"%I4?KXQBOA#,DSMB/!_B/?;JDJ+#[4I1#Z MJR:^'\-DO3BR?!KF\R\4S?TK3%8X*CHFE3W9)\](V,05.!8TQ?D4W5M3C)%] M]B[O!.\N)%'?'4G::Z89:5Y,/Q*6V?P+^;$1PQA$X1P,"XI@(((C&D.(/D<4 MSA"\+MPXB^(N%-#?'05V'N?&$?,(O3+H,G$K27IWS(RR-U**R5E1UJ\-.:N. MH7+;N)]+I;BQ"G)PI)'" S@C$%)(29 ?MB+T,68WQ/U#B'FWTO*E8'?G(6X8 MU,Z.<;[\\GH2IDNRG-5J'M>U_CI[T$9K.'E3I6Q=W;<>7$P,+/E6KFVV.?8) M:VY"-;P0=R\.-%- ,TH\'T])ZI?CCYA?3)=A^GY<%S/7DE9,6@:CO6; LXJ@ M6*:PNY *LTT>O4S9=')=-^,:7M"[%RT:*J%3[G.V1@)%SDPC6*XI""^:0BD3 M!?A<5)+9,5;Z5*EU>9&@R\)UV$=[4(7Q5_EB"MML&&P/UC:"1/)3W/()5#FM1 M%H?(4P!4(GJME+.\4V7K57#NP@+S';%@[R'O69*ADDL<0X(2&;DH45C-NA3% M+C'YI*T@ >^E)&.WTJ39=/W<]0+"J]6R'D>H)SQ&)O! EI;"=%MKA56DX<:8 M@&EA9!DF M9W".G(N6R\C **SR(N$*-$%Y*=:4Y*-T??;5;\X#*,IYB?A?F4K.'B#.A?L8S3>#DR M2?I2" VW%9?+A?A>$+PPUAC/F,A]?-7MV(:4L35F3V/%7"#,WQ]='+&7]'7[ MDXMOE_3GN@AX5C;I!_TTU(+@,Y.A3H/S0/>=Q5]D8'(LFN?#,R M(TV!#"7V ;1&3QE#*1!*#.!8]E8$R2WV690]!V/_W;#3)SVG^7=25+ZBV?%M M>)]@F?5[. YF"\33,O[P@A:RS'OI-4AR]YOV+Z1+GN%B.7&%) M*6&A2*3\MR0-T4<$88VUZ&V)MD])1D>AAA32[\['RWMUPV!!PTW>#=!-K

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

    ,!B$4E(Q_Y@Q)4 # O22OD$:$NS=R6NEA6I];? MIJN_WCR_47-Q_\"6?U6N.N8YS0C20$B$ "38^#904L 0$HA2D2KJ5?/GDL"Q M4=:!OHE5.-GI&[8LNH2XJ_L3#\?>_:!P" /\(3=<(CM&%X0.["&Y07#L*CG> M%UA,3-PKN9FI+[HC$+8NEJ6*$L$LHX P:APE04K 19H#HJC(TIR6//.J1^0N M>FSTL]7<5L[MCO .K%+F/BANO-0/U#TS5$24_0,6MS2:N_AARZ9YPW)4 M4LW_"0'AO%4XUQNV4M*N-)5QU2Q[WBZ7MBZ!76^^>=Y?TN0GW_[-EM(N2-?/ M'^>K];**&UQ5J8-W]VS^Y;%R]OY5K8P/>#N7[W_:LUDE[Q;V1ZTCKL^;.MB? M,RUQHUG"YD\LMT>\+O$W'\^IB[1#"_OI9C^F)82P&WIB9M.)(6'C;2 MJWU=@TE2@7*3U+ D+5R:XE!K@TS20'.3M%Z_]ZW7S_[X( #A)JE!^N=Z[SS" MMU]?6Y_W;Z!P\'_"]] OZ'P\H]X9Q#X"-8<+BA^!L:>"[$>DUCE'LCTI/IF_ M_:__LOV)^&ULW+U9DULYDB[XWK\BI^[KH!+[4M;=UY12 MJJYLE"F-I.RZ/2\T!^"0>)-!JDF&,M6_?AR,?>=RP(,HLZK("$;H'%\^.-P= M#O=__9]_GLQ^^(;+U70Q_[>_B+_RO_R \[3(T_GG?_O+;Y]>,_^7__GO__(O M__I_,?:_?_KP]H=7BW1Z@O/U#R^7"&O,/_PQ77_YX1\95[__4):+DQ_^L5C^ M/OT&C/W[YA^]7'S]OIQ^_K+^07(I;O]V^;=/'0VG?_^M_HEP@I_(.;F MJ\V/__:7+^OUU[_]^.,??_SQUS_C/%7__E_,__O//W?ZC- M7XL0PH^;WU[^Z6IZWQ_28\6/__N7MQ_3%SP!-IVOUC!/]06KZ=]6FP_?+A*L M-S)_DJX?'OR+^A.[^#-6/V)",B7^^NP^=*\^89Z^]?\=_^LIJ>?)U= M?O9EB>7?_@*G7[^PJEP>%*]O_A]7__C'*R*^+G%%N-DP_98^.']&?=L!!.&? M:YQG/./VXE6S1;KQ1[,JZ\7RXE_.(.)L\^DDXW2R>?*+N%HO(:TGQA=N0E*L M>)683CHR0/JBI-1&NV2BSS?YK[2OB/B-:E:8_OIY\>U'>O"/52;UFXUP-H*Y M\[HS >U']\5*_$1_._&0#=H,9UZ8+CPPXKRP&$L$YU+ 8@91_JT7;X4#V3\.#I%G)Y!XC\OI(O\\SZ]H M4YZ$G#DO,3&A 9BVW#)O(3!'TD ),7-I!P'$C==N!0?5/QSVEV4G8/BTA/EJ M6@5_#NB$68C"R37(B23BN6,^^,"RQ&P\9H=!#K,[W'KS5I#0_4/B((F.C(J? MY^OI^OOKZ0Q_/3V)N)QP+7R**3*/H9HW%9C7*!EBB5:&* C>!Z'A]ANW0H'I M%P4'2; +[7_ S],JA/GZ5SC!2?;%%Z<\<]F134/Z+M!7%@-B+(A>NS( FZ^ M=2L4V-Y1<( DNT#"&PKNEV3"-H+_2/+'EXO3^7KY_>4BX\0!MYBX9P U&H<@ MF$_$DU*1%^L=)\/)N0O8?((_WV02W[1,S_(6YY;0:>D5 M14@L*4O14PR*A1AH'S0>4B#Q6>X& ,P#K]\**KYWJ PAVRY \B)G4L'J_#]O MIW,4DYP(W2DA Y4)Z4C?>2;2&A)(%B\HF%C#F9)2TR1V6KWK@Q=NEKO@S0<6> NT) M$YNM\=WR_7+Q;3I/Y%"EI(TEK[H$@K76D?@P/#.I+#J?B-J8A@/&K;=OAXZ. M,YN#B;8GB+Q?K-8P^_^F7S>N4T;G9#3D,'&D71$-83QJS1(8@<:@'B9ZO>_= MV\&CXX3G0&(=&1S5ZKU8(FSHYLE++R1G+F7-=."<02Z!%739:L3J91]V7G/M M;=L!H.,4Y]ZB&UGE];1T]O[+8GZ1@4Q(8 M#U+[[3=NI_J.4YD'B;"+[>#EZ;**ZBP#.YU_KOO;Z6H2!#A93VN O%\*DZ(B M&"O:UF20T@I3M!HB9W'_V[>#1?>YS0%$VP5$WLSI:22.Z3=\!6LX9VM2LW%9 M(D5(HE:/2 W,A^@9*@-2#[M.7^PNR"QS\ M?(++S[3E_7VY^&/]Y>7BY"O,OT^RD\:I>J27I&?:.$N!49&,+[C.7APNV"WQ\_(*SV07U*F>?,V$:LR?JO20#AP1V*:/@TAI4\;"P MX^X[MRNRZCYCN;<8NP !$7Y2C_$6Z?>/7TANJW>GZUK36\ND)RE[)3>% )%< M99V(+RA(@M$\1S 25#ZL_.YI&K8#2?>)R\'$/#)H/F(Z71(_0L9/T_4,)W7S MT[D(EDU03!<76 C.L8#%I0S%NP,A=XCM.4>XOO$X6_<]_IB\P M_XQG]4%&A$R\LNR1Z!>.Z,?HF/)22P?"%*<'6?C7W[H=!CK.51XLRI&A\.($ MY[G6C;Z>P>>)P6Q]D(6!%)%I)/@&K1RQH$WFZ(PPAY5 W'C==LKO.".YO_ Z M*;]^/5TEF/TGPO(U?;*:)$'(U13C1$R!0IZ:&M%DS2PX=(7'& (>I/\'7KP= M$CI./ XAT*XP<7:SX(P)[F6100GFE"&AB"18 "PL3M,=)R%'$2D@\'B7W^\(\>W],&!E[0)Z?,59OIFM9A-<[V0_Q/, MZEWSCU\0UZN;;&Q[>_O)IPYYK7LW%@Z\[WVZ8I\!ODXVI7%U"WE77D_G]+(I M[2.+LQM>E\#CW%* @60TA,CUEH\CX G%O$D%!*DZ\B&L"-L=:;\ $<,MTQEKAZ!TC$QY0@',* MVVQJ]Y(S3K>,=D Z7.8= .=%2O5:YHI6Q+OU%UQ^P(2T)N(,5[_B^H*IS)W@ ML@1&]IQ"$+"*@?>>66,3%IT4^0-M]KAMR!NG[T8[8 VODPZ ]F;^C:A>++\3 M"Y.0O!."(M!-7*M](-IK$;:33OGB/*I&D<5U*L;IS=$.-GM+N -TO%_B5YCF MG__\6H/A"XACRM9+E4B+ 9B6M!.#X,A<%E*49)P6CUVNWA\F]Y(S3A>/=G@Y M7.8= .>&6"::8R23R%D)2+%I%(F(+YP609316!&,:>-)WR!CG$8?#?>CO66\ M/T 6:Y@-")!?%_-T6R(4BF8)%(TB4G!:A&20L5X!"Q$*<$66LR%6[E+4@W\\ M8.A^H,@[L"TW'?PK?B;)Q,B!0^U94ML?)<%\O5(,CGNC ])J>JR@8:BXZHJB M'F+T0_7]:'2UI_ [ -'&@[\MH4GQ,4NC/.,9!!E14"Q:CPQ+ :F]R-@HY7,O M.3U8GH'A<[C8.\#.^^7B*R[7W]_/@,0RSS5?];7FYZN'GZRRO!X&!FXAS_#!5/83B R-I,"5T *C7T_ETC6^GWS"_(;W,/T_C M#,^E1MQ([[02F3,7%7'CDZT-,B)+,8$J.>22VX3EC]/50Z ^,*@&5$0'L'I' M"P3JM>FW""O\4+O=ORN_K0H/HD6*8S6B]SD4TP8PVU(XKK/=O,2CB:(ZL$?7^+J=6T/4'K!P$I?2 MK);E$Q.6?$*2G/=21%X>NRL]".2Z*@-I@X&'@7:(0CJ UL5YWWOX7@_Y2&3T MR?*4Z+C#X@1]XLF0L*R5EFEM+ -.EM]*B3H%Y$8_=@'[\)/8+8CL!GP'X>*! M0]FAE=0!_C:YDGO8" 64]MJSDD5AFA,O/@K.R(FT'%(2(;8Y?GN H'%WSD:X M&D+X/6#H1NQQP<]%7ZV) 8\H/&?O<&,+-551LP UF0\4++Q )MY+Y->NI1LKJQ3$^J&*?\*9VE,+ M/>#I_DW\&D/$3BY0,D,=/-/6<))3]F2333%1FX#JL!<,C*KX# MV%_K^+BY>'BCX2/**(QP!+5:4E33-;YPSU22 4M&'^&QWFF'&=4'B!K[@OIX M6+G'] ZAN XP^"+GS?DOS-[#-+^9OX2O4W(:KG$X$3E9$YPF5Z60N(H5#$!: MIG@@*67#T;>!XM.TC7V>W@TB!U9C#\!,Z?3D=%9;HFPB^]H^>8E?<+Z:?L,Z M8/0$WRY6M6+N7?D$?T[ M3Y!MJ. .\/L!US"=8_X9EG,2W>H:NZ^P3--T/?'12U6,8\Y E1XGZ0DK*X-6 M(-MCGLOTO+. .P1PYZ=E) !]F@I\0TB1[ DRR8)YO-M)"11:$+K;B2C W2 MA=3FR/\IRL89FCU6EO%PY0P&MD8M .]OF_=^HXTON)XFF-UD9>LV@-L\>=!6 M@#NSK'9R6"K3+-4H2M9JO,)\;-:G6*>8"!KBZ3R;.L ($#. H3" $M0R8,IV.Z\Y!Z"QDZB- ;4$&KH M$4W7DXXB>\S!5%X$9SHJ#U$W2GXI8:;CV+C:5R'/K\WR MI6Q7BW)>&$&_A7H*>2V'4[,W>SI?![VR<8/F?9D?R%T[RXQ=$G%5W"*+=R4Y M@IBN(4,=/UI,G6%O$WH9=6GDJ3Q T.%IBO,'?JHYGHF!")ZB9(:=T-=&A*)04*G/0M<;+ (MU4)*(1@.W4'M>;8,3>L$UC-!/M_'Q$ 6=N.=[ M:',QH&C[@,8F 7+&P>K5X@2F\PD0#UJ+Q*R1]?:TXXE:>T M"S[NDC$.2(;1[%V8'"CF#ISKFR(Q!-)DB(GB M1T\K)GK4*%NEMZ^1,4[4;6[UWZ:D$\]U3\W>.;<_0,S]P.0UR:F6=E<6_C%= M?WEYNEI3"+C\^<_S>HC:T8?^EVN%C' %=#:>@4NQWF^IUM+0%BM1.16X3[Y- M"F /8L<%VV'HN!]JS52U-QJ_X3(NAKZ3=MXR_$IT.M:+XZ"KP&K!*\G/*UJJ M*2B3<@D9G6R"N@=)ZF2W&\:0#2/X#BS:R\5J_:Z<+Y:)"CI%^A_M^MK6\918 M)U@4EK7)17%: ;;5B<4U,L:U0@.I]LZYQ+YR[@ D?\8*P<4U.&R -J8L.H/6! M=$($U/E?KVAQS!:;1KX7S @/AD=;&.1:*"J49!Z-I.A3I.AXT13+-O*='B%K MW"/4-K :3@\=@.K%2:U'_N^-2MZ5V^U\)QF%C%P3^=K2QE\PLFA"861WC>?* M C2J\'Z(H?2C.9FU>#]A62S/KY!^@C]Q]?.?9,E)==,Y++]OI'K_C<&) M35E[2;Q;4(&B#[+. ,[6#N@@;0A1-O+7&S(UKE,V.*#[4'X7IO:A?G.63X MKWD9O-Z>]TXQ)ROT$_?,9Q#J$R)#$1)OJVAMDC'OW=V"D["_@#FS+-@T9 M[KV)?W9=\>I8-:6$6GO& 8AM5Z_7\&SK70BG%?@44IL2F($8&/>Z\-#AQ0A* M[#1Q]D?_/Z6I]/N;O*;%,E-=6@4,6LI=D^GU@ MOD3-R'?FL@B1(;;Q&1LS-O+9Z!A@W7+!C(&<#A;2/9*X;,Z3LT+' \E_ ZPH)1AV9B82PB6-QIN="\YVQD__DS <[C$.S _MYEX-9V= MKC%/,KG4&+EB7D:RHF@H;!?&LJ(HF/>@N=%M>J$_0-!VT'DN=;1#2+T#\/P# MZT14S"\HAH;/^.MIO6/PKMRYN'VV,BB8YQ8H1B-Y$7,@ @O!D^=@T* 264%J M4TB[$YG; >VYU#FVTU 7^98'V#M?3G<;"!103B-/-4VPV=/)-U0R,0.TP+#X MC*G-&UYS1'/Y M%)/#MS1\K,DF-R9KE*Q>2&7::TV.0O8,,2@GO0>OVMSBWHJ\@?OGE&**3%XS M90TRG6O6413%DN'9H.:@KR*%?]K^.:5]GI",X^H&+9DWJ[Y R+G &4._#G2SWD'4'8'E@ M^LTY,RDKX XH:,F^&F6>6-16,)=4HN""<].HW^ZC9(U[8W1X$ VG@QX ]?1L MFG/&+(E*EFB90)*6Y@88..YJ(EJI5 N[)+8!U[8DCGM%H@'0FNBF ]#='C5S ML71D!'0*F."HF2X.2%806/126Q400FC5U>4^>L:]'S$\G :0>A<'3/>]ME [)!HK3]Q-R!F2$3N:PSS%_A MV7_?S._F0CXL9K/7B^4?L,R30#MW]KXN C*@6D=3IZ8K9K4OUC@?A6U3VK4C MH9V$R-LZ^XG"[JN<%R/=#6>'<&%I#O!P", EVL M.]AG'^!P,[3\?@:5 ^Y\( 9C,-7 4\Q<7&$(9/H3%R3K5H<\.Y(Z;B#: 4X' MTF(GT>LC2_%7_&/S*W*II>4>)3 9::?0&4NM/W;,N5@P\B1]:7/7:COZQKUJ MWP$D#]%7Y^;RBBF7>0"NR?S[)&I+EL1";W2!%MKL(<0O6XM_Z/"=BCZ?;01G.?6EO4LWWBY6)./L1JT[#Q[/MU[=AX50$Z M\3G#IA%+X*5>4>.> ?K"5!9*FA2SC@W#]+WI'K=M0 I MCX[H8^FX TQOM2G5Y1QA4]A]4OL>;33_ 4GPJ^D:SV= G4GG Z;%Y_GF*1M! M38HLSBA/4L#:7LY)'<&%5#@3 MN1YP"&D9J&"9,A!EX1EC;%//>/CA^S_%F=1@RCGPM/3G^3#MYN\Y\S5<.*6# M8]$K3C+RP#SZS!)/%M(9)SV=O8M_GD.D_14Q*)Q&N6#[$E9?7L\6?ZQNLC30 MO=JKIQ_Q.NT#+ U_B_;R19>7)'TP3F*QC&N?F 9'4.1%,!&\\UA2+-#&N7V, MJ@&\JOK,]\O%MRG)[Z?OOY'PW\PO^_*_2.OIMTWFZK[.TY>R$6# )H/,";X9 M@AQ)-MR3E%(]_7+:RS8WE8:AOY-"RD-1=X_/=FSE=N#LW?14 VJP"FI&BKP( M3>XI\\H&PI$*')!BLP-\CPZ1+FJ: M7B&].TTW;&89NP/@@$H<$9(U M6IZ\2/]U.J5W_O:5Y%YO0:4:N;Z'[U7<$W)JC)$D%1*-KB.F+/,%+;/>1\Z= MUMK?&AEW-P1_^C7C5JYW@ZZ!]=&!L;MH6GWS:'&2<_:83&*<%V1:)& 0LV F M%IT@1U$:&;G[Z1FW(+T;^ VHM Z@MSD\K /#2'(WINA-',>4#6;FDRA,^VAH M#7< '$9U_=12WCTMN)3<>0G&E=@0I30Y,\>% M8%I3!!<3@4FBU@YEE-!HGM?V-(Y;I]X=6!LIMXM ^"YO)'&Q@T/ FZ?173LY5\,_]&(E\L M:\$QY\9Z=((%[Q5%^2X3=RHQ4V^O@X8@8IO9U8^2U=L5\".!;5_%] RV]TO\ M"M.+>>\3XTV*1#Z+T=$:VG000BV9-(8++\C7P&;#6!^EK+=;WD>"W 'JZ1EU MEZ[NZ7(S_>XL?V1Y A(>,F=YKLT5"@, R3P'1V!O-[B/A,'# ME34^%#A?36W(F8B $@8U!25-N MWYQ]( VXZYM[NY@]*-+:ZV)\O#TLRAZ9/E*1$XA3B= MG=TSBT:#D-&36&L_!"Y,'76GF NED)W.]Q',HR#J[*#_.%3 MZ_*"M>\3+U$E@9REPLD#]H8\8!LHYDK<;VL?:KP=06 =( MW+XN9!+ >HV9-H.4$W%6' OU"F/B*)UU6@O5K$QL2QK'C5\ZJ+%II,X.Y@,_ MP%G-%JQV$*Z&Z&P(DKE"VX.VEHQ M);EQ"5X+,'H-O9T&/H[Z9A[I"KG[O7R[-GY_*_P/)WW$R#O]8- 9(!=,8Q5*9>@G6;5:Q)\G<)'OO$6<>L^, M4+7%7*QU2;;>G_4JIQ1T5FV.;78FMS2O9RF/:V=9/FH>R.MG MR*OX"@\UVV&9*@ "#4G6MFF%_R1I73JRHYK5@Y37D4F]S=;V#DB2=3ZM0+Y+# MRO$DE2],J-HT458VB\MUS+GEP'5.I4WLM!U]XZ;SNX7G06H\%*.#PK/.@EZ4 M]1^DCXD,).0H) -,F6G%R1?1.3.+J'/!G+EJD[N_AYAQ$_,= 6]?!75L">]> MOS )K72.&5X\TR'$6B^:F%&6&$;N>#F2S[C7-9IFB?B.8#B,\OH!Y?:BG4CA M4BA:,.L4,9B#9M$79!F(X:",$++-+-WM:1RW#6H',&VDSGYS]*^GY4.IA;K:,@[2H2HHBM4DB#4/_N+'[L7/T+97;0Q+I>I;LWJD: MSDIKN2&&JA.MI; ,I,BL^)@1;9*A-/)$GR*MR]Q\4[P\EN(\6'F=H?&\M? % M+Q37!9,4A%1=[,*TB[9.AUW:^)]/DM9E1GTL(!ZNO [0N+U, M)SZ5;)SP#!6OZRPK,OC!UXE#JL2HD:>C]EZ[A\8ND^O'Q& IAM62LU!H*;H2 M2J$85D-NUGGF%BTCW_8X I8.E'\_9_3GEPTW5:KOXFSZ^2PS\N;L/G^>F*#! M.JEK,T6R[<4""2E;)I3PRI(S$!O=XWR"L)$/*X\ L2$UTQ/>SJ1UVZOUQ+NXANF\)GPODE2O%\L'[UASQ7T.F;EZ/*&+XRPZN2GH M,LESGLE6-,'N 42/ZQ<>%UV+<50]&*I;3*)ZM_P,\_.NWC#/KW"5EM--.<*B M_'2Z(H&L]II!M=5SAYL^M3L; \V=NO[BJ\E7=?G,\_MK/+TKYX"&V=50K"M' M(MLZ6UPQJY"?)5[ N\24@B R#T6I-AG@0<@_N&WQ(41<&85/I-*?9O7$V*"V M)1?)4$1:G0$U"]9J!KE>"-2"Q] FV3,T)^-:Y^-C^TY7Y#&1T;7=_@E6T]6B M7!?"/F;ZOL<,9Y6?)+(K(QQ4:YV;%72([X;"^O\Y&G-;5J]Y+@G6>(P#TX M EM\BI=&+=?3T\B+M^5RW#N(WX^NQFMHW'@:[=P%2+3!BWY G7@!T2!)8++ ML=$T^H=(^FVE9=%ZRXI)!5RQHV^9X\'YZQCW,Z0=N!VAI['%F]Q1]O*@YD+B^ZI+S\JQ_ M\\1(B#95-T36+GXY0[VZIVDUQ1 T>&4P/;7+[OK2<0]SQH-84^5T[=5]/#TY M@>7W1?DX_3R?EFF"^?K*>WU/*DBUMGP/#V_+)P_G[>W#RD">W]W77,)1&E=X M1,]XM$!(B9E!,(&E5(S)2G/3J%O^PS0=7,GUF'RO,CC>>IMC,0QLKK7\L9[# M"UZS2TE#\$Z%1G/TMJ)OY*FUPR#F3A77\*KY)S!?[ MOBPU5TQ>EPJEWGOU!I7(:-NDG-J9M=]6^*[\O%I/3\BG6$TB(+'"D;G@R8_P M=7(S1\42TK=:$J.V31NUFW1T:Z9V0(&GD\=AL(#:6$#O!T MU?]O(Z'O5_LT+\DZ'03+MDX<4(GV::XRXO,V=%29D$P6+,8=:*2M8D-*P M*, +GNI%7-ZF#&HG.D>>@-T&E=H5>W>;$1)-E"IGH][6O MGP,&R7M:5R$D6T04O$T>_V&:1IYPW6J#'$0%'8#I ^F#"/BRR<9]P]GB:S75 MY\,6SWB;)*0=7QC-T*M864IUY&=F-F=1' ].-$JS;$':3O4E8E MN+,5T@+9?\8]KXEHNYO1M.CML M.V/H]FH2"FRQO([&RZK.QRLLH*@E5.17".&ST&W"B5TIW0J#X9EAL*FZ_@D. M 7ZMO?/J9G! U=J>;SKVH<#CK+8_'"@8#*^7(4769.A,XBQ"4$RA!)U34EJT MJ>IO>.:9OF ^G>&[0DOK*R[7W]_/JNSGN98+;'S?3]743[0TB#D(EF(*M;&S M8J%X9 H\,>XQ!6ASM6Q;"KL]4-@%-7?\OQ;JZ6 /OI/E_NG[)_JG+_ZDBZR$&L7;F*O]!F:=<%A,4$(U:M/V,%$C-Z]H@H*G#A[V5$F/Z*J,O%J< MP'0^":5D[HB5[,D?T5I[YJT&AE*IA$;Q'-L<\#Y"U,A78(=2_%. VE,+/0#J M/'M]AZ5?L-9N3HH/1B-R)IV.3*<"+'C-F4$?C7505&ESGO4$89T!:U\ W ;6 M@-KH 5QWU]]/.$]?R"'^?;,(/8\6H2 30I$#P3,P;V1B#J.*RO-D8ANW\RG* M1F[#,]*NN+]RN@3;!3?G"S-%;T%*QW)PDO@1@D4?D<4L'"U*+1P<"VPW*>O, MEAV$@R=!=H!2.@#9YG#N_"#X5UR?FV4G33%*)Z9"'2DAA&: D1:D\<$6=$4W M:K]\+SF]P>D0C=\.&@\6_X@86BW7DU_@_RR6%[O\ZFQY:8X>T+"P:6N+)3,? MR*1C<3Q"C+'PK:H6Z?'7@$,_W0;-_>\?N1M8RYUN (&/#)=?X03K9.YK/%RL MHI"#=R0%8P09Y10ML>,CD]E"M$:4!,.AYD$RQC$U0^AU,;20Q[ZH]O$KUNM5 MM( V">CT_=TVD/OV,\ M( RDO<7PHNP.$9_^6)RS$:U4PHK:4C%RIB4M]U @D\J3E49&D+?CKFT1E_4#^(R"EJ0LVEO+R(6G: !R'46E:/D M]S9Y%T1I55OZ,%7C1E!#(^"ID'Q?=70 K8O"G8M"GJL"GE6=+75^]=L%DZ,M MP"3MW4PK2\&F#IQQ^KAD 2D5WP1C6Y$W;JJQ,=B&5U /J)O-%G_467JO%^19 MG,9U.9W=+2&;\,"S3,H1.F@#T((<#>^X9L;:4)3&0 )L [NMZ!LW\&^-N^%5 MU'5!U=5]J+VJI*[_\^%*GQXD:J!ZIFO/KST_SE&T_G[5_..R4B4:76QRDD4, M]5:8!N;1!(9"\920XKC8:L+#MC0.=R=Q]69^_JY?8/D[KBO4[[QUGE_2^J.H MJ%;"UE;0M4_SO7T]B_0^;.9N44A#/L%F.H.E$!A+LCJ7Q'F;WHVM.!K7O6N$ MVH=O2(X(A^=B,S=AVZ&6\_PA3>SG?00>WXH*SJ-ULLYIB:5&!XJ!I!T952[2 M>B_$=D<5'5O1JR5R]>PK[$NT=59-'744ZA"W4CN7%/FS8X$M&$4T@&R+OO.OIF36$ZKX#;%(J@4 MSY[6AJ#E0*YHH@6"63-5N"C*RYQLF^X3#Q T[JXYD+H7P\N^ PA]6L)\56J5 MT3Q_Q.6W:9V<=JVC\15WJWH-8'7_KRY*$*1(0G.RQ+[R7C0M2FXMRQPAF@)( M!KL)[H;D8ERP#@*KN^T QM'QV$5"M7UV7>A_/P42P1KKC+Z+':9F!#X M.J]VR4%9:8HC&5LR!Z#(T<646(ZVF@.GD6]7.+3;>\<%W'C@N-WLO)&FQ@;A MQR^+Y?H3+D]>+I9?%TOBXJ8[>\Z2Y=J)2 Z-U8(S'1$IM@HD/XJK3"XEQ=OS M:Q^J6MOJ?>-&%'V KH%F.MC17RY.3G!91?4>ON+RG F)Y"P;3_N'\#4["IRN<8LMNT'@@,KK"XJ+*MA;W+@8O"ZR M5K77]FJ.EIA/G$3FK*1/%);4J(7ZHW2-V^ZS1R@>JKRQ7;[_A/GOB)6-"Y.> MN0HZ.F9%KG7T"EFT.C)R([2%"$K%[9R[VT\>MY?GZ-@Y7-H=6*U+[_->W"N7 M'69R/)$K7D.=6'NPU3LZWHF=1W@\+X\Z=O+@M44 M@D:*>!BO;0"U]HEYKPJK=Y-)'#D!U_[PZ;V,( M(9,C:4-F>C. .*KJ7'H5BM8Z8YMS_?W'#![U>&)/=2^&EGUW /IU,4\7?"#7 M' /%Q5#J" )7R&YGR\#Q6'(JL80V-_D>HJ@_6]0"1GMJ8&R7_-ZU0.[#-7:* M-RH%89A*MC9\K'F7#(IY:13%%\"=MELYZ4^_:]S\U_!0:2'B_1&S6,-LH$E( MA#Y0>6$111Q4JS[R(Q & B5YH'62K$4BW:1DWA=7.WAPH]>[V MK-MU3;_-EPBSZ7]C_CO%'V\7J]6$JR("BLRX"8KXH^] 26#)2P0MZ ME=)Q\TBO__-AJ[#O)6K \NOZ_.]7=X"N[B5% \IQ M8)KK^L62:UR[7Q@TRE>,.=[FI.P1HH:X/G?KT=?O/"FO/1!)4LK:=Y-"@^($ ML2Z=](47L&VJ7Q^C:OQ"ZR'P<=^]M4'T\%Q,RF%WSVX^I(EY:7SW["$0B6)1 M@0\L.$>.L">%!U-4+5\-,N: J;2Y:]70R%QUD+E\R7D0L!'R%="UYZ)D!TS% M>I0#F%F,,M+>J83U-L30J&7%MA3V:WQVP[]90FIJCU M?;.',(5%.<$%9VK3]@TR,DBZ$*9DSK&@)J_ZN=FBRT=_@#]^ <+:%&:U*=MC$#9.2UW"!-G, 'E@V/DH3@PZJW+&OU;6%&<#::4GH+VN4R1I&__[8I%OL22B"UAL8&A3G9KF^?F18[9H#<]9 M0[OA[$\0-_ZULJ9 &T@K/0&-N)@DP#I[PS&+U=FLV2X(Z)F'Q'E*(KA&MZ^O M4S%NEKLY=':5\V"G(BW\[?=+_ K3?#'>%L[[XET:E]T=2FV*#0)%"/1(1D;3<8&C&28 MG2LV2Z\:+=@#"3_4:MU5SU4PZX0I.2=!$;.D51JS80&RJ!,9BDNJ@+5M!H<] M0M2X_OTQ47;;[@VEJ:[3#MO8C_T3HSL\_;@FL6$J]5#("G .01&TDE)U>D)B M(7#)I,G*)>6YVTN=\'4W9$4!^FE@YS-.0=OYB23VA6\TD\.FD\?$U8%Z&;L*_UQ$'\X*P\]_>KF8KZ?S4[*\']>G MN3;XBU*%X-&P+.NU\UP;<+L 3!1)_^%):[7=3+?MWC=NBGD,.+521@>6ZZ9_ M?%-Z%TO&0O+.(#)C,[%DR2)'90H+0A8?G W>M6FINP5QXU98=[!G#J:YKH]* MWM"#YI^G<8;['XO<><:094F/D3=0*%F/2_^8SF:DZMOONP=:/L:4:3'1*NARL36WN2.Q$Y@!7CAYXPU6")@F50!9"?8R&%D'DS*.P3$4H M20;ADFN3S=R"N'$#R7:(NN>2TJ!ZZCJ1=IO90ZJZ[WU2.\/5\%!B-["! F4] MMPP=4 "H:'5%)1(Y[%K3KF6\@C:+]JCFZZK&N-;$K/'M]!O>>>VMQS\F\[8*XAVO%V^CQ69F["V$LRAVI M'U)5ONM+VAG)'1DL;C2CH5/[.?$F M* %$X>>G[V=3 MZ&>P6FU:E/M2A _1DY.K M-%9>9Y5JP 1!E5T,78KW""Y\W=0"9KTMLSHH&TS!H-M<\MF1T-&'#K0! MS/; /%A['8#S/9!?M+[H_B>E+Z+6IZYD,TC7NN?TQ0#:27#A#V]W%1UG^0G&^)[J+A=[8I&0,, M99(4PZ-E]129A>23"Q)U%FV"BJW(&_?<_YBX&UY;'4#P$0&^O>SB%&4.F8(N MID 4IAVA!8A)@HP '\ %E]O4!VY#W;B&;_SP83\U]0V]OR]K/R\$(ZP*DI60 M:+%*DAIP3?Y"E+1FO8UDWX\-NPUEW3IP>V)A>[#MKIB^@?8BI=.3TQFYJ?G% MR6*YGO[W1HV3#(X'C/7PT9&K*B2R@*B9T)FCCB)C:7-Q>W=:NW7\FH-Q".7M M#L]P!L\Y?JXO_G0,E&XN))L,F*-BT6=:]"CZ& M^]<)IVYYGM#L\>)W^4LS)IB^+@$A-*4&B*RC!0 MFFQ4L3:5'(SB;6[M'?6L[+H=?G?GY'+BT4>9C&1*6;+,R2;F8RI,Y7H>;;(S MMDW>Y'&ZGM.9V"XXNC/-?3CM=%TL<)$5>C^#RN-F8OG7.E]F3AO6'I;LT><- M>8UP6[('LF W7OCBV@NORO$8E,I'R%87U:90;!>VJ0WGJ:M=RNV"VZVMF+[:>;9 MVJZ#&CP\_=CC6*^6H>73, 0N((406=18S]*-9EYL3CIM1NE+*(V:E3(\Y^>E['5NZ*;>2J&.A2)DIC[%.S,J,PF3+4HI05,JHL4TJ9POB>BFF M'!(5V^ZB>ZJH9]15ALY+%Y1%M,9&!E8ZIAW7)#)GF"9F J(1)+@C^VR7Q'5J MZ?8%Q-9NVW[:Z0!P+Q>;FRB3B^:DA1FPY(%XD6;P"(2:XJC MRN"*AT:W>A^CJE.([0N!.[5% ^FC VR]15CAE\4LOSGYNEQ\PY-K): Y11VC MRLSY>NLMD]_AO7 ,T4N/)0ML-,CK$:+&/4!OC:RAM-$!L-Z5,DUX*: +)J(V M3@O+7,1,3$1=KS@BPVA%H;!9B-AFYO"]Y(Q['MX:3(=KH ,87=1QWF;#HDO: M^\@P +D(M;VF#Y*^".M]4"(7V;;.=A\H-6N!U'['.UP+'8#I03&]O:P_R;5Q M:T+)DM.2:1DL\]IZEJ+5%I*-HM$LIZ=IZZ5V=HQH<3\%]0RYL^),F[,!2>LQ MI228)MG4<726"9]3R(E#]D?.#'90,SLT"K8%V>XJZ0!@U^HJ7R$1D:8;/='W M,]PH;'ZCWO)!YB=&1&%%2.1?1N(["-H?$CF9RI9L?%)"IC;W!H;BH-/08!C0 MCJ+F?NIM'^2G%G8&"K=51,4*5_6N!AH6A O,%D7!.#DZ/ATYQ3MZK>U8)G17 M=0Q69WM(/_:KY30).D@C"S ;;)TVIAPC,24F0S%1% N@VAQ37:>BTUAB&.CL M+>ZN#] WB9MW<3;]O'G>7J?E=YXQW-'XX^0-= Z^>@XV%Y62235%J^H..3V)7-V$75-YJR-Y%O!W'^ M1CZUJ_@M-EQ1(:,&1HX4^6(E&0:R:"8SF3]N0$;7<$W<)6C<*'P % TI\"YP M&F9"!:86*P<;?]E:Y*'2* MC896M8BW-L]\A:NTG'ZM$CT[6I)%Y.138E&&.E>L((O9193,!9-IY<0Y.]#ODI M!^;IUXR(BF%TN&@BT+&A\8%\\V_3V0Q_@>7W&4W7_N6%!6T%Q 4+VH$.,;4KW'Z*H1[=W3[7?KLP90@<=8.EFYNG#]/.7 M];ORV^JLWQ!)R&6/2C 4JG:1I/4&"0,3-;Z,QEB);4YS'R6K1R,U#*J&TT9W MT+I,:DZ"$Q)(1BS)6CXNK68@G6#@'-)F7DK2;0JW'B!H[%SRL>"TGP:Z ](_ ML"X+S"^^T:>?L7876IS.UQ^J$<9EJM6.&9.R=6ZDB/2%? 5R&STY#,XY[[6/ MQN4VWM6NE(Y;\W4\Z VLL[TQ2:^/BX9';!^P1C\7/WW"YQ].MIC8_?E9_K\=*J M=HWFF!62XSTZ(ZH@4< \L#ER5&X6[-<'H@[;#+6[>"DWU.<&HK M^ YVU_O7R1S_@-EF@62A2TWXLJ2$(Z$IQV(HB7'OLC-.)O1M6@T\0=A64'// M"6HM--*CR;HTOM/Y1E]G=EB8H%Q 9K'ZI% V%P@]"Q0P%ZDU1F?V-E?WO7$K M_/CGA)]V N_ 3+V'[YN^"*\7R_?+14+,J].?DS0 M=9XN,WD7/+TZQ8D4,@8LCB7A26 N61:(0Y:%PF1LC#ZU*0E_BK+M@/8L\_6# M*J4#._9H-?(-OC0O&9(G^ZP%TY%3>)NCJ2&O/KUZVQ3G0:SGV!6E^#'+XCK-_.RH']XUB)AL KR'=[6KK9\7Y;;5)T+ M8;,*>C.!IHYOJ(U^AV_1+&O!*WLT%=-\%LO,I99OE=LDZNE 2 MQ&K,L>:+I67><5K((=KL8BE0^%,(.^#]8U=4[ V#&TF*(\B^@]WT\=-\[@R7 M$H!EHRW362D60^0DP2*5C,Z!TDW6T.&U%8/CZVB@V*G>8A<-C9UG?5IXU[Y] M>;JLVK@ER"A5($=!,R\YK>8L#'V7':/82'GC3(FW4V=[6[:G:!F[PN=85FY0 MG71G\2Z=TG/>)CQ(;6K5;BX06*T!IFC("E:R0Q4RB5+%8U;^G-/5M6(63MCVIPE/$G:<[&( MPV!E.Z.XI^*ZJ%5[J! T"1E$T8IXR(G$!(Y%I23CKJA4A VA'",&V:T4MV$] MY,'F;DB!=SV-_&Y^ZN0$EM\7I38-7\QK"G)1ZA^1#.J)W@KF^0-].FA>;K=7 MMDS.'\<#1 S6%^+F.MH<#7M5 M>$ *PU,]3=% )(2DB-&Z7K,')2 N:KCB0F7;C$@U3%*^0$2^9 ?K$$'A!H9)5L4TIT%U:NLIG' *4 \7< 5#^ M Y;3>J'TB@&*<)50TC";2ZP,*.;!%"8MB24&+JUI3!#*RB#@S2 MSO?IZJ@G9;ED+FXF/L3$@N&<"1.-LU$9Y=HTAFMR![+AE:'C0/!0%3VO^ISS MJ5&+2]X-F0K8Z84-$P'[,]XF#SJQ\KG?R7M-J@]E_(BPG%)P 2P+XT=Y56V 5!>U4J'JZV#K;G;6LR?Z5E_ND/G'W#7Q;S]9?5 MI'@N=53UC*+.,\A@& 11Q^:DY%26$%W+1E"[4]Q5*J,Y. ]5V3."9EUVG_Y8 M3$!:JY77+%D')%.1F>>%LQQ,$:",0STN(L\)[2I9<@P@[J.@YX8_ A1.0LIH ML]7,6JPW4W,5IG%,(%+,EK/2L@,$5E*[2LT<#8,[*^F9H?#UXI0<$"LD>AV8 MB-92<$8Q82R^,.L4=P:\$8U.#W:EM*L4SK$PN+.*QJ[/?92Y3XN?\#U,\XM" M;[MD+UKB2]6[8Z[F(E2N,SLS,N\%+]XJ6?2M:LE=.B(\^NZNA/7YS4GR;<"-CT0@*I4NVN14SRVN3-6N!DNV51(^RB#Y$[ M=DN8XX!P$&4=>C&^:5FCB,9H*)&!B+5RS]1%1D*4H%2QRB=MVK2L.J2LL6'7 ME\%P-83 !RR([>XL8W++8A_A-&,B>CG/N,W\Y8G&CPYL#'0B=/["6D2_>2/,KFR!MS%SIY"%.DY.6]0L M>H=,:&5 .&&%;7,AZQ&B#NZ.?U/0+^X3=#V-G2U6I\MK4_6T2J8X+AF&2-$D MF2T6G/,431IMDC!-Q3HJ%0=:>O_A&TU_59^C9V8O\QT3L\_;BF MK^$XZ<>@*K@OOG#%%-8JH(R.8&,(0,H"*"07&-MXB@T-X,6F_:X\(.9K@]23 M-Q F!7&,QV\9,$&\@51:LC"!0I&VY1(;TUCOV9N%^S!2B 3K6]G2JUB:*G^"PH^C%G$TKT7LG49G#J\;R[3TO(>'%= M'4'3QE\G@T5)4:C'R#P7AH)2ES+6 >^I3=7M(T1U;+YV0,<37MK>6N@@A?YN M_067=]?L!3$7?>M:SF2YS28EKIN%G&M3(VXKA'D+P+$.=L.[) M\,1 SDZ,VKOH1:0][IG';7=!3^_)3ENZX&N\Z$W:OF3D@]?7H\QI;Q[&26X%K M[03MO^2=.48XY"P4K T%9 RUJL&'-LN_H9&\O1RNM1SST4"V03++761:@&*Q M-KT-LA2PY";8V*A3UX,T]6NV=L'&O3F(PW70>97+:Y@N_P-FI_@+0C6W9Q-A M]C ]]S]H.)NS!:$#&9O+-UUM0M>.M+5-)5C)BG*>::TEJ5Y;0I0W((52#E.3 MY?<850>/E+GGV5>[;49)K-7;Z9M^=5H5!EHB0PV!0RDBI3:9ST?)&M?H#(:1 M.X-D!E-%UX[/O:MY_VJ&QQ[7V 0UK%=X%&0NZ*BB<$QYD9@VLM:YF+K3R<(A M;J:Z/#M#='4:?OF6^QJ_GLL_OYM_P+HG3^>??X+5]/:!><10C#*TYT9"NW7AS"M ID/@,A41?:/!+D?Q%7_Z?GW\U-^7 MB].O)/'-NIP8;0OJ))B-&2CN"ID\(%]8O3KGN2)O!=K<]MF&NHX-ZBZ(>=!S M'$HQ'1QE7>/I\MO_-<5E/0#^_A:_X>S%G]/5!(0/2@?'K$82%A><1:,3.=RI M&&Z-\;KQ0GN4ODX -Q@N'@;>4$KJ"7K7]YV[_+U:U*9%$QDL16"6DQ-49Z_8 M>D('NC I$CC4 D2C@38[D=D-$ ?#R4-0'%QI/2'RS?SK:9U^1A(3O^!)Q.7$ M^CI%-DL&$@W33@ )S=4;>"5KI[QK5;_]"%&=H&UX*#P$N@/UTBG$Y#DK)JLL M=5",VU+'Z[G,?"U'$#)&;X,K3KBC04SN +%FU8_C0FP?O70*,77.2O 9.4"] M,[PYKI%UU "OK:VR,N#8U)Y\TL 3"R%*EC2M99^5 M1=MFE[V/FG$A=CPL+ 963 ?@^F4QQ^^_P/)W7+\^G><++HR5.>=:*)^]8EKI M2)L%[1@VA0# -0K?ID+B?GK&W5Y' ]@ RND 8E?>R3V^R>OIG#Z;PNPCZ7/C M&;^$KYMN-6^GXW'$IY)V%' M^YSQ$13; 9#/#BSO.?NY//H!E[T3FC.K:WXH)F3!*D-N:TKD+.2L&?F^!5"A MLJ*-\_@X7>,ZD6VA-J!&.L#7@[*:H!.F*)=9$"$Q[5UM1B8B>G^)K0^'(QW\#L']/UEY>GJ_7B!)>7T%.HT=EH&448M?VZ M!!:T,2P)*#*D)&)HXPUO2>#AN>1'7W.MG6',(90 C)MBF19%,G[)WK)V?EF\)[3_UC :-AFQEOTP3&% M6.,N],:VJ;4:A/QQ\3T6]NX>,Q\9",\;_97E\S(F7MM[@.&,9X5,UWM<8*UB MJ90H%)C"8RN?=P#RQ[;N1X?=<,#?$P,= /_%R.VY2 /I:T3HK9;KRR&R&_GEQ=_A'>+ M4YJ$E_-)"F>_S%[/\W76DY'*2<\HY"1]4RY'"%G4L:Z:8M#@76:;33M]XD7C M@:217&>-F#PV8-Y/OLXG&5],9A=I@M.$KZ9IN8S$A/;H$!AF0"3J;FQ/-8DFIHM1NKC M,YG$O%&GH,UQ,_H>M)O(5H6^ _]&%OO?)]/)E\LO2\(I3!3(O*JKM41NG1X0 MM 8M$T>?2TAQHW'8&PG^AU>/+/I=!#<;@HMCBS_\>8=P5,GKVK%=<.'JZ.U$ MA)L A5;C,-D2Q$8GC9N)_^ZK1W0KAA#_SESLX*QNCVWR]4U6,2\V,UHJL%3= M(]H8P446(7,O44;CBVR5H+(_]>,.\CC^"YK=8- !]-^%[U=-*V:E4Y9V43(JSDLF=."K">W/Y=4+/$Z-L+UDZ0=[9'UCFB9 MM11=!UC<@Z._S+Y\Q>G%0O@OP_D4\VF=P:-0U;&_M/,H(RQXYFJ2J8XI&1^E MZ>[.\/XR1B]6'!?CXT%B]#.NW5>^_%QKH][&L\FG!0O>S>;T2Y-PMLSV.?E2 M3XY.B]56+@KEDR8O+S)&L1[MEY+Q8-%I5*MCWM>=EQV$WG$/5D93AUX1<<1* M\G&"1.S[V?=P-O]./TQ8Y[J)HFQT"73MRZ5D1O H/900%$HLQF;36AL>(FQ< M]_QH8;^WC+MPBAY-SGSY9SJ[S)/II^KRT9_\,?QY2EK*!%+\KC6G("@'!HYK M!EQ*Y"&'XEB;^0P[$#ON++\.')RVXNVZJN -SE_/+BZ^XCDY:U]FTP_T\Y53 MX0VG7#WXH ''6SU-Z$#U =53)7'7'7OQDIODZ\B3-MYK,ENT&2M-(/.:,T F MK=9%,!O;Z/0ZBO:>>[ORW-NJ&:T9.N\4*%8+3.E+<,8A2+1>.I>"5VTZ8ZTE M:=R3AD$P<6_([2#L/S[SLOM(F<<>U]C4-!PILQ9<@BN*B)T&S-+51K58:]<, M"%ZTLEDP[]LT!6ME<&Y/F5??4(="I.H"3,XNYW6/_6&22!T2ITKBI&5*@S*\ M0" G$F30GB,I''=M#D!W)+A38[4-GM97#[4370>^_NTR3R@PSW5)DV_XHDSB61D.A MAE_+N$>AC7$]BL"/;_?>9Q+N8\]KO'^WK"A>[QV6*YE#T(& F:6 2.XB<%0Q M40#I=&%'M8$3:U]-B=%8&7QJN/)1IPR<$Q4J*03'K("L17'!V8RHFRSO!S(Z MW6RWD?VJ4=J=S1ULH?_$R:?/Y B!\,1!3EH4SY9ANXXL]2,ZX5VE-4+4_VP=K+S6X M!5L&./^DJSY;K.D7O.;.,?(!ZZZ @V%2#8)_O1<$#QWS/?Z6QI'@%DML'1\&K3CC7$%&LD&*2P<^, 3)2E1! ME")4FW/-]@>\^YZF+%*)40<>.2E7F7%48(E3QH+.0K^YC )16!.RQ>*U:*;Y,T MVW!1O32?.CQ65SOP=@*<;G7H3@&U9-SZS"1QM[9\D8;XS&@]AGLM90[DOK49 M$_(492/WN.\%0AM!>T=Y=H#/E^3=SKXC?IC/TA]O%P,LEJ5UY-R:D@,'S9"# M"LQ!L-Z"(/X[:U4JO$W3\K4D]8C(726_&H8-(H8.\'0G ?SJ6.*ZW-.C\J(F MP_I4ZW2% 2=JV6[P.1@?/.<;E;EO7]SU,$$CCU5HB:4A1- !DF[GERV4XO?I M9'[Q_L/OUW-A21,T2@1>DB,;[APX5_-37;:Q:"T\;S,CYE&R1AZKT!)5PXFC M VS],]3$Z_F2>*5,X $U9"<"J&PM1$'N07*D&)ZQH!M-?OF!C'&/K9MB9W=V M=X"5/3W1US?9^\8J)9)08.@E%%%ETA$5/(22G=->%YG:W,H-M8)>FBL>>WR[ M&R2.7Q66=7_6671.:B@L"/)H,8*ON=]6%.M$\?1OFZU[$/)[#$):(V]8^.\ M@Z[S!Q>+BN$"\]U*\%UND=8\:;B;HDU('>@VZ';LUMMR]V7O\2S4F<2SB_G% M+3G7+29N[S2C1*-3@:C(TU"RHH,[\A2292E9+E)J$R_N1_?>4],W??N+NV^_ M37:XRG,$#4=<*9\XB*YY1#FSRS/0D?UZH>$*OWIK$?4.!':$5W M+Z)Z]'FM+6K#,JH]L:J<8$X25D/PM.LJ17BI%;XE*^4-S\;(-N.>QK6KM\'# M/64Z^;]PGN^_%+($,5L!-@C'A!$LQC89>L.M8=Q3C3&58!P8]* -^I_ M=^65U[_-SN];A-LF'1^3H;OCDUK'! MXTOI(TIPS%INE0>15*Z3.0A7B=LZVD%'5DP)XCF>OCSD%MZEXJZROOC^L.MX M=;N@,2>R%!F2JH5D21MP3")YA,(EYI/EV+H:?L\E''5LL U^-XD-VH.@ Z_H MBO+K.8Q!Y2A*RH#(*::1GD.PB. <=Y8I6H-HDY3^ QF]I-0>% JKURT[RZ4# M4.W.N-ME3W-U>.[D(@2I&6.T:)XM@C+$S>""!(E">*%)^TN;4^X6JQGY0G%W M<&T43AY0TAV@?5WJ'=,IEN))\U5VH#0KX# 8\-8('5 *:]L+D$+=%'9A)8EPVH4+MJZ,2 PD*68DJH(&3E_ MJ#?4[2NNL7MBKVK-AS#-:[)$KQ7*9<^22QRL<.27,R5(EXHF-\@XGZUB8C4L M6M/V>OMWCSPIKQ?P'4)R(\_9^CB95Y?]U31/ODWR93B[FBM/"/(&!86$3-1! ME>3:J)RA9%.45<;9,MRB8B2&.4$"D8K38Z!-H-E5O!*8?7MT1 M5(84[FP(3G?@]5\[!0LUHCW:!FDL6%9':L?D(!ITD#*+B,$F8]IT-+]+12]# MB<<\M-M9*ATA:JE5T1HEE>)@>&6##A9"O6E$K<@9-,;$1J5V/9V3[2[/-<#8 M@;EC!WPG7Q97DR=7P4*]AWGYKTNROJ^F==[-Y!O6M2V-:+$FL6 D..ZP]J0* M$$12X)WFR)UD,:TD.ZR)]+9X:1\(V46PLP-PN0/#\J1!7F>/7]_4K3B6E5%* M I/U9D]21!H*&O!&.8SUF+I5C_R]:>]E].V8V^*!$7#,F+]N\GB2\Z3^2CA; MYN-=SC_/SB?_QGPJ?*Y]UA&DDN2IYNC(QB@&69:2HN8^8YO"Y8:+ZOQJ8F!\ M#J4> X/E.>C-/09$Y@()A\3!"D6'*.DKG@I(7V=Y9Q>5:=.F?O"E='Z1TKF. M[ 6,#C1CV>2SGM)?+>75Q<4E+2-;=-(D"4+;.AU0453".(++3F!)KIC0QC5: M0U#G-RYM43J$D'K$VMTNTUF(8@O74&(@_FCAP06*BHOW:=$3)#0:C/$852-[ MV9VA;E=Q=0"]G5EY'2Y?S,\O%^',8HSJQ\]ANJSH^EMM1G/QJI:Z3&9D_B6Z MZ(*&0&RO5YNL-DNGH"9[G8+ESOO._((M5SANV_)C=1=:PN@G4J^5T06+'_X: MYOA;F)S7TDH\U2PZH7/="&4='Y:)9R8*,D[1H+7:,'W<^O%DNMIS_<8^#+_^L7^)I"+X.@. 052"[Q&G;CUIH\%'%X-$(U^B0:#/Z M-L*^?:;8;R#"#H!YD]B(Y]\FRQ2S>VM[,[LN*:[LO/A81X&LECJ^F9E#DWFE-^B.5MI!;NF:I% M?P!ZSEIUM3W^-CM??JO^/WXJ,^9@B3'9>JR'8@HB"@O&RD#_QF :5:L?=IT; MZ9G_2\\.#:G^:]3O,6K%P;S3+F;?HO4=7C5P%?N^B^VCK!W16<^XJ;J2:IN2 M#$Y; R9'7H0P-K$V+L/(9>V[6IF;T.B.>%<$_X]9S<8\HT#L/:WD-'!,1M?< M ,;(4[7:@DLA0V%>**T%A5!MX.F%RVZUR[G/D/B)@RI1R>UF.TCGG_AIY$E[91>S*,P)*=:(B"Q@$S.5>^3 M!VS8IJ[)FHZZO];>>C,^3,9.QA[4?%"D5G R)W$N#$=6PF1!YH*IQ$ IVGE] M2 *D8=)&5:RUZJG I361X][SCX#_KJ3>RW;1R!V]-@N_UKHS"EQ/33+2."? M9YUJSC.K9X4*HA(J!8?1^S:I+H=.8.=_S$JVP$ M;.^T=OC;*3>J/<[-B^;- _>*_7) M-[7NG;K=4OLX=(Y>H^&!@92\4!3N+3@NZ:.*R!E&X7*;B[3GTDO5E\6H* X> M26T5YP*"X0PT(DL^1-G,]_JKE^J6^&W72W4;$'3@-?W85A'1:&:1>.9HSU2J MT!;DE0%:A=+98.2V33OE9]E+=2LH/-I+=1NY= "JW1GW2!,QSC$P3K&^1/2@ MG);@1(Q@%:NM/[40?J0:TB/OI;H5N [12W4;27> ]G5-.6T,O/;QADP;$^U' M@D$0#"'(9%6TTBC6QAWX>7JI;H64#7NI;B.VWOJ\+?0YNE1\X [0U^REPB,X M5T(MHLY16%1:F$UP]U<#P5TV\&'DTANPGNAGAB:G$HL#HU7=0H2%R DH(?+D M6"J&;5:Q_C,T$-P*!GLT$-Q&)ETU$&1!)PQ8(+L4B$&.XCC/:MZH\-H)5X3; M*#7K.3<0W$JX:QL(;L/I#ARM 9*0D=1-)E,=!C+K*J0$+OK:Q3IZ(5F6]/V^ M#NU?;]65Z0B:%>X3%1\8 <>,^2>+#F_2Y=_/SLY^FYW77SIE21;.N0*7,VU. MCM5]*0C H%Q@)KO*TWK4M:LE'JF:'0#GAU?)'4"WLS9^7=QX?YB'\WGG M.KG2&@.5B4'9 IIL*#G$5M2I)AI*$"+%)-%BFR$TAUKAD39D>TX:N0?D!LSZ MZ%$9_[&0X UG.&,8,UFIF(T%99#$YQ2';$))B8R5YTYZN1_P?@;57'7LI>9)998@4^H-LSFGPYS2/6HFWH2)Q,\TVAWJQ^ZTY;T^L W&83"R\0 MN0F5909"B@58]ME%9*;8E:R0H4O6!EO+D0:3^YVB=L+[K7!TM"6@3[+KY9]X MGB87]6)IR1==LC>UG:E<5%%D+<#74<@F&*.\Y:JLSA$^N'[=(_I( \&N%6D_ M9/P<%Q%/UB3=]4@D,Q&%,10;UQGCB5QQ%Y0 )[-C+J-0JDU/HLX8<:31X='< M'38#Y5\ZO:PS-*S(B!E\+.0YV&0A6DX6,5E3&&,IX?-5Y&=_)=E.?3HT!5MA M^:>[SGR:?<+SPK5,$!$5*.DRR1_IHS%,>9EQ,R%FQ&E+BY!DZ6<@SU!D$CUQACE''8TM_V)(%1QJ)_U3FH"6J MG[4YN&VCM=K[YP&N.:E$,8*L9I 65$D7UTK MM\1ONZZ5VX"@@S/25U,R:_B!A+Q8W.OZ"W6]M;\.;4Q:>47!G=$6*+:K%:X4 MZRF,M>.$2=CH$N,1HIY+1\NM8#)K([-^X;?LS>.PD)?G),2<(BCC&'B)]%%@ M\BYJ(;,\) ![Z#@YF/ W ]4.DN@ 5N]))D3 9PJ2?\5O>#;[6M>T=,&6+9N4 M\ I%+03)AGQR+@4QBQN(47H=0I"I$;@V(*Y+B.T"A5E;N70 M;_AE *^,UK1 M2?Y"T4)U1N:3;_CCHJ3-"7.4$++-=0)( &==AF2+P90-Z6:;EKL;D3=NZDX[ MN TOFPX ]VKZC;@T.Y_<]%D5S#@5G()LO"86D2_A<@KT42M%+$)LU(KM'BGC M)GVT ])^/.\ - ,E:"E8Q!KDD,RAA;>U9PT(';P%Q*V?$FN-Z,OB--L]\1 M-:NS&X878=?'ZU<[V,?P)^YT3'[WUX<[[EY+U$#'UC?/OSW_NSG3XUD[K#V= MD#D$)82'X"2"-$'0%SD6E1NY-FN)&N;,XX='?R16OJ#_\\>I%DI'6UL \%) M.:LIF!=D[,F?" YE8:GED,F[K'' M-3$YCQ-] !/$3-),>P4NH@,E:Y=Y7S1XC.]')TC,D'+'?0%!*UBM6D G3V-S^2%"_AF<;5*PU/'MPOVN;L[RP>Q?. MY]\_DJMX01RKZ1*[&)RUSQK.VFQ&[D"F9MW+;@>MLE)DI"!/.2%H2T,&/I-; MZQB71OG,*?9K="[].&7['\H__/R'ME^#ENG""L3%)"WF$X2L0FWMR:1+.4;3 MIJ/S%D2.:YP&Q=']<_HVHCI*J[6'M_34(]O;L)9>TY,09#H'S9@&Z[2GT#]' MVMHL PK*K?1&%MK=CM*4W1[IK7O3B^\__.1J7@>IA0O901 BDEI&!;'0=N]2 M2-Y+Y,JTGFJ[!;F=F[=ML+4^VZ>5^#HX_ERSM$6B0$X2@S8*?)$4XM9[#"]] M'? KD)Q0Q[4_J(_14V9/,TALML=N+9]^H;:\>,LB,*/(_6 FDZ9:Y\"9S*&H M1(NIY0B^30#]*%E=FK?MA;\9J':0Q-BE'W^?G.'%?#;%Y:W"]: U[F4V-D/R M2#$RUX664-/I%9>*\X)9/^F5/?+\+E&QB_1FP[)R;#2\QD_A[#>\N7[7*:.. M/H#'7&]\E(5H5#7EA.D/QS!MT MP%@]JS>NGLH%!*,T*\HK'EP;#WMS&GO)11C9S=E7>IWA\EI%62R8+ >+5H!2 MCD-$)Z$X;B4K(J?0IB'@?5JZW,GVEOHCX-I!!",/ZSTI97(VJ0MXN9A(NS3/ M(2DM, K0BWW9>@ZN< DLN:R*DP7#1JX=$XNA6.)";=18:N:A3PJ$DS*9X(.WPPVE7WU[/_[1GL#8BZT=;#XO MPEF8)OSP&?''&A!I34&5,GA?+Q$S@=QE::LY58%G[QEKTVUJ'46]3%L^E,,S MB&0Z1=A2Z;A/0J&CL($EBD2*MN"8+Q"2T*40+4RV23A?3].X.]8P,M\ 2#L( MH ,H+=HF_')Y7EGY>A(B;U1LOH#U"ZRG[42Q,A>T2^SRRD]Z6LUV6_"%UPH&]<,M?0(RO-2)_+6#EM" M0Q3:JU)$9'FC"H6-/*.'*!BYU>'!MKI!)# R@M[CU\OS]#EC+-*3BFQ4N[<1K#8F:QS[-(SD9ZW%,/9Q M]:O7__/JS=*JTO8?K8H.*, @]@15(%IOP*:4O;"Y4."RT5'UG8>.)_Q&\IH- MP+P.')TUAO?U33&,*D($0;MKH?6#B@8A.!8A(&WD)ABRM@>]>'^]58E8%6I93W5R>N&;5RODB#>-#DRH>( M[.<$_$9/O;B?_G,P_ MW_V54^D5ZL@T2 JAR7\M 9QF'J246K%L@L VB-R3\'%/5\>PDTU$VG5B^B^S M+U\F\^IJAVG^93:=3Z:?<)HFNQ4)/_*TX=+1-R5YH$STV]==G*R\[X':+9V2 M\YD3%(/R%+!J,FT<&01E+($S:F)6$UW?BLQ]+>)&+[LMXW",:S+W&D2.BZS# M!"'9 ED@@C+U[(49SM@&FZL ML!)!$Q)!<:MI5^:)=D:>C2(D:=>FL>=!#>#KV?331SS_\FYY8'7[\JOC@X#: M,(>F9E=C+5PKX(@MP),,S&,.4;6Y=WJ"L&,R<=L@:=7$#2F?$2.0C).K#-NK M#*/%:7C,N:CD T1+$93BS@+%3 Q0>"F]11?48]- +S#]YZ?9M_^B1U^ABKY8 M@&D!HP=>."YD!A7D;!BNC@R(*ZJ7)^$!K8U":* =NOH!E@*16M41L3BF611, M/^9O/HV&NV\;!PI[BVLV ._&OO4A/?AWN+Y+Y\H2T MH:^M=>NUZA2I"Y%)A M,*A5R4^Y+:L/'4^TNXMD-@!_.CA>6F_B;L\ZO$C*I40+*9G5ZPA/?!$%I$#. MHS.5/0?V)[:[WFEVH-EB@V@EF:[!=G5'<.JTC8PG#9P%6[M["W"ZCL.QEM21 M"2-MFS*7IRCKU0_9$0H;0VT'N72 L^L)&A]G)^E?EY-S7*2'O3N?YU:;5,;.1+^?K]"Z]0E4.5WFP"&4.489^,J%CAP M+KN?KN09C:UC9C0K:6R\OWZ?EL9@8W(QEU364)NJ&,^HU6IU/WJZ)>OXI].+ MWO"WRSZ;V"1FEY_>GPUZK%2IU3ZW>K7:Z?"4?1S^F8?0Z%N6&52B'54]EJ1J!_66Z.W[79[OSX2>WQ/ MO V:>^U1*)J'_VG R!K$?1]CY[%X5TID6ID(&K_3;E;W]S)[-).AG70:]?H_ M2T[TY#A2J<5X&OW]5Z]F39D5M[;"8SE..VY*)=]UT1RH6.G.J[K[=T0ME8@G M,IYWW@QE(@P[%S-VI1*>OBD;A*%BA):1%S3R#P&;8)Y[G'F3]Z$GEJE83*'1 M)*/[MQ,YDI:U&M7&JL7+$^=ZC+E;E:$7U"[9'L#90OLW,@WQU*DT#K*_:CJ] M_M5P\&'0ZPX'%^?LX@.[O!J<]P:7W3/6_[7?^S0<_+N/UY#H7P'=5]>?NN=# M-KQ :^]C]_SG/KOZ=-:_9HT6KS3:.WR7=<]/66,O]$]EUKUFW=.+RV'_=*7[ M=;_G1FS5FS3J\&.?77>OWG?/^]>5BU_/^K^Q;F](+P=%+F&BCNIC%CQ_]*.-A M"!ZLQ"+"FWIUC]PP8!,^%4R+J10S4*6=2,-^S[E&..(YWF=*6Z92]D'IA#7J ME7\Q%;%NKF4J.;N<<)WP0.16!CPV;) &503K\$4$J[EUP7K/#4*$8"1S=I.J M62S"L2C[F!61"A5,2!5R'T;@,F4\G;,\M3H7F &RH4N,""%G"9ZTY#&+>(!7 MFJD$W&V5EUL32$4@C.%Z3B()OQ$8=TFGP;L0QF#(V&55C$$"@=3(HA!+T1V6 MA%CFLXD,)LSD]''??R:T*)30!!)IP 3D!#:3=H()FDP$SD#2F\$T%6*:4W0+ MV6B^[(87@\'6\\&@8)%,$64"S'U4RP @Q-&LE]IE&H%..%5[^![$>0B=0,Y2 M",M G20*RA!XPBQA.8[O05G@P3P8&K@/71E9)HD\A@"0J 7-YQQ]@3<3%@4 MJYE9P%2+L306-:AEG%YZNV%E>0EM9F',FK4O!G#MK0/<<"4ZKU\=-!O[1Z: M5%$E$$FH*))XW#&[+G0#QK5P($'0Y2@6%$PF@,Q1+,V$>I!8 HXDGJ3G4)H@ M5B9'/V)/K6*/EDRK0(1X;=@.P!$*H,TCH'\;3'@Z%JP+8KK*8TBX8F]O1W@K M7+%'3_Y14GV;>I22?D;LM01>#R:R9>.!HI6!(@Q$\WP(:4A0GG]:(;4:CH/M M!BX*ZFU![MOJ88/\<"H,/(4 NDSW=725*0D'/#>;=Z%L.!) 2C&2SZ\JUU MSII*XY@04B)U>JBD6"O8=/N>!H:I3@4]AB5"Q#M[4FMUB-2Z/.][$YAT&85?M.F6H-F60QYSH/J32W1%D&[U5Z']L:TMH;PS0EQ8Z!C<4QE M2/CE1J6W!('2H3/ E;)CD:(C BXY@5N,+TY'* M[9?'WB1_\#MI055W]/6=$ALMZGFW'H7W >QQV*,!7BC^PBW"7\&I/L#K0*$M M?%'^N98'.'P"AU+R5T&0:P+"4J9=T9I?^10B5!+:&$3:[[#H +MC7$YOA+M?5BA8G?S^O1W[D?F]&Z-:@Z\D,$>;8MI>!U( (46FOML6S02_H=3KJS>7 M?%W=Z0Y)%R=)3\)=L8/Q1Q*/T!H/T=&(.U9[!*-%G0IAP WE9-EG?H.T;_($ M8(%[W#2*K/'H:=M+S^K;MU/J(GE'&H12!@:$(T"@R!UP%W K^VPHTZF*IX)2 M8LK'Q3F]+CA3)%FLY@*MLXGR+,E7P SP?6-U4-T4$HBM==NJHGD$, I=@9-C MGAG167PY H]G,9]W9.I'! /XI;C?_A8N#B]_*J^[V\9L/UMKUJJ_'EUGJU\<6V_Z6U#4;9?_O=U;:J MS>;WU]JN5^O>>5]56W/N]2Y&$$W&TW>E5FG1H8!WIYG=LL8J#Q#B'\;1A_#' M$X&[/G&*M;6:78O)/_-YG6/U)B,LX%;975OYMNFYNR);-;_W\^\0M>(:R3;- MZ_6K]OZ1<9\/KSJLS'7#)5AGKJ+9Q#_?5[3@>I<*,GB1CH$9N>]H6^.Q=K7' MQ>,YQ^!Y>;HWD2)B_5L1Y'2BQ2[\EN]OCW^+QYW&CK08+=@@!CN7_D@9Y=Y: M(';7(U%SE=HCA>"#^XJ9\AFO8+K+H"=_ E!+ P04 " !P@6-3?ANP+F0( #U*@ %0 &%U<&@M M,C R,7$S97AX,S$R+FAT;>U:;7/;-A+^?K\"5>82>T9OU(M?9,_M"_ MZHU^O1Z0V":27'_\<#'LD5*E5OO4[-5J_5&?_#CZ^8*TJO6 C#1-C;!"I536 M:H/+$BG%UF:=6FTVFU5GS:K2D]KHIH:J6C6IE.%59EGI[!2?P"^G[.Q?IS]4 M*J2OPCSAJ26AYM1R1G(CT@GYQ+BY(Y5*(=53V5R+26Q)H]X(R">E[\24^G8K MK.1G"SVG-7]_6G.#G(X5FY^=,C$E@KTOB7;4;C4B?GQ<'Q^V#NK']"!HUP]I M.SB.#EB;L?\&8&0-Q'T?8^>2OR\E(JW$',?OM!K5PW9F3V:"V;@3U.O_+CG1 ML]-(I1;&T]#?7WHU&\HLO[<5*L4D[;@IE7S717.HI-*=-W7W[P1;*A%-A)QW MWHU$P@VYY#-RHQ*:OBL;"$/%<"TB+VC$[QQL O/<[ MW,=B+"QI!M7&NL6K$Z=Z G.W*H->H';%]A"X&8T/!_VNJ/AU26Y M.B?7-\/+WO"Z>T'.AY==N(2KJW.0&-P EF]N/W8O1V1T16X^7@QN2="DE:"U M1_=)][)/@C;S=^7/^F%7YMV])=W^U?5HT%^;U>V@YQS1K#?0&:,?!^2V>_.A M>SFXK5S]YV+P*^GV1MC2J-?_4K#_EQLKHKE_)%(&/NA4@J/L[P=OZTD_#,OD M)R"5+"8_"RFY+I.0:[20V)C:MV_:1R>O89I!=3&+[S_Z2489 RJN2![!DWJU MC6X8DIA..=%\*O@,V-K&PI#?#$Q3#*8YA6Z,C.>K;G@U M&&R^' QR$HD4HHR 64:U# $<6C6*^TBC8!/*%:<!:.P>XT5ITWKXY:@2')Z: 5%$F($FH M*!)PNV?V7>B&A&KN0 )!%V/),9B$ S+'4I@8>Z!8 AR)/(GW3)A0*I-#/V1/ MK:1'2Z95R!D\-F0/P,$XH,TC8' ?QC2=<-(%8KK))4BX6K2]Q[T5KA;%.W\K ML-9,/4I1/T'V6@&O!Q/:LO5 T=I $0R$\WP,:9# 1/^\2FH]'$>[#5RH]W<% MN0?5XP#]T.<&/ 4!=)GNR^@J8Q(.:6ZV[X+9<,P!*<5(/K^J7(,"X*RI,(X) M08JG3@_6TTL.7>5AS25UT"L2[!(^Y8*CL5$ GX(M1DG!W/[>Y&,CF*!:X 2$ M+P-<9DA14VXP-;O%:EP>=[P)M3X8!#M[URF#OF!8 MK7/@:LQ1$!@9^G/V/ 9^6= >[Q"TFZU-:&]-:QL(WYX0MP8Z+(ZI8(A?:E1* MD?FI >QC 8J@IIHM :0%W0LI+!SK .>&A:7F\.B@YE?*6NB*P6L2S#WQ82R M7&< <^/JEC!4FCD#7"D[X2F4(Q+0#BT\PV6$(E"F>T3#=^N1>Q^ /0Y[., KQ1_;(?P5G.H#O D4W,(7Y9]K M>83#9W H)G\5AKE&(*QDVC5]B3(6GN#!*&@Q(:@H3H3(WH9P!"@&1GLD5Y@) MVRSNSAKP&"+-'VS9]Y;$U#R4(LB%#O6 MLKU[ ,J21%C+^9/T/U9026 +$V"3Z[X'P 6V-NA&H-?"4 <[@IQNUU*#@@I,C4#]NB&:=WF'I]]>:2KZL[ MW2'IXB3I6;@K=C#^2.()6J,,.AK^P&I/8+2H4T$8X ;E9-EG?@-IW^0)@ 7< MXZ919(TG3]M>>U;?O9U2%Y)WI(%0RH ![@@04.0.N NXE7TV%.E4R2G'E)C2 M27%.KPO.Y$DFU9Q#ZRQ6GB7I&I@!?%]9'52WA03$UKIM5=$\!C!R70$G2YH9 MWEEQ*L\P B_G$673^S#_!D'S7W3LU+S>OFD=GACWN_ZA MP]I,MUQ_=>+*F6V\\VU%"Z)W>2 #'^(9,$'GG>QJ-#:^NG'1>+D1>%E^[L6" M1^3\H=2X\KN]?SS^-1YW&CO"PFCA%C'8N_:GR>#^92!PE]!='C@7<=G?#$S- MU6Q/E(2/OI[,E/]\M.-?(DWYQO>42PYQ=5]]V86.@4ARN]GE"Y]@%K_^@U#W M:>K9'U!+ P04 " !P@6-3*3,H-J\$ #/% %0 &%U<&@M,C R,7$S M97AX,S(Q+FAT;>U8;6_;-A#^OE]Q=; T :Q7V[5C.P83T=0>-H#.^BG]]#T_4#B"0I%--,%(1[WN2T!K5,Z[+K>:O5 MRETU7"$OO.C<,Z::'A="43?126W0-T_P2DDR^*'_RG%@+.)E3@L-L:1$TP26 MBA47\"FAZ@LXSF;52)1KR2XR#:$?!O!)R"_LDE1RS32G@ZV=OE?=]SWKI+\0 MR7K03]@EL.2XQA8D;M,W1^TP;"^:[8Z_:!$_#CMAJY-VVLTP_#5 D!XNKW24 M7G-Z7,M9X634^.\V0[?=*G5OQ1*==0/?_[%FEP[ZJ2@T^I.H7_VLS.P8T_1* M.X2SBZ)K0ZI5JEMQ++B0W3W?_O6,Q$E)SOBZ^SIB.55P2E=P+G)2O*XKI,%1 M5+*T6JC8'Q0Q(3Q[NZH@M]$.9P7=AA"$!O3D*F,+IJ$1NL%=Q+<#)_("8]>B M1"TT>PM[C,FF\C\"/YJ<1].WT]$PFLY.L5C/YQ^'IQ%$LP2[(@PY\=.?N MR(7Y9&31!XV67X?A'(;CV5DT&;^H<+9!'/EO8/86HG<3F _/3X:GD[DS^^7] MY#,,1Y&1A+X?_I,R^VVI-$O73QY>\ZOA30N(15'0V/0Z6#&=@)PS]WDCD)2G6]B[H M'0(:?BMD#H'O?(!42.NA1+PB 5HDIAO.::EIOJ!R?R]XX_<:6"^V#Q(%*>/8 M-*^1S6F,.#3#%) B@ MJK#KZAK&=@L$1XTF$G?4,[7W\L@+GR5YK,">D!/+"/8B35 SP:>6C"VSA)EF M5$JJ#(EU(R:< ZHA&,*18E4BJZINM5)6D"(VS]%@8N ME/VE53,I'GUSLZ';>0JP+3=\I%G/IK=*,;*HL"R.:XW:5F%3R-VPO(+@[O8V MM7V?R(K#[[_C;:6,<7_/8KY5G%=[+^!JQ5 M<_.SBFM_K]GN*7N]/W3=B?616] W(=<>E9]ONW33[.V[H,0L"LX2,.GK/5<^ M=KYN+!\OF8.7E>D'OBC^S_B39?S@#+]78U;B%+B3]L/=O'MV,/O*W'?O7*P4 MU<%@5U).C,V=D[*;)F&'._]&A2RP4RSUKLK?'*YMKM51GSUT'/P)4$L#!!0 M ( '"!8U.1U4>!M 0 -<4 5 875P:"TR,#(Q<3-E>'@S,C(N:'1M M[5AM;]LV$/Z^7W%UL#0!K%"G_AO+@K&(JHSF"B))B:(Q5"7++^!33,LO8%GK M52-1K"2[2!7XKN_!)R&_L$M2RQ53G XV=OI.?=]WS";]A8A7@W[,+H'%[QKL MH$WV:6MOO^4E!\'!'L4O">(@H8'7]A9>\IN'(!U<7NN4:L7INT;&O]N MX-OMO4+UEBQ6:==SW9\;9NF@GXAN?M9D'QA2]4A;A["+O&I<:M>I& M' DN9'?+-9^>EE@)R1A?==^&+*,EG- EG(F,Y&^;)=)@E52RI%Y8LC\H8D)X MYG990VZC'6_ M!'XT.0NG1]/1,)S.3C!9S^;GPY,0PMFCGKP4Y%X'SNVY/;)A/AD9]%YKSVW" M< [#\>PTG(Q?E3L;)P['P9#*W9K\>3S[#^Z_RC- M?J]*Q9+5L[L7?-.]:0Z1R',:Z5X'2Z924"F%CQ61&'.^@C-:"*E )#"L),L9 M@=.4R(Q$M%(L(KR$:1[9L*.UMK*[U$1(A MS0X%XA4QT#S6W7!."T6S!97;6]Z^VVMAOI@^2$I(&,>F>8UL3B/$H1B&@.0Q M3*ZBE.07%!MHEK&RU%[@5Z^,L=M"2B5%[+?AU1YMT#5AVH1?L'\7*7Q@G%/9 MA%'*: )'+"=YQ B'69*PB$H=!&UG[5_3&%^L $7((")J0E')LB)(HQ)PJQ#6 MX:T+0:4$=]_K]%Y?MGCV!O./W[U7D%CGBL5IHKI^Q\:'5&,0(A_K%$TJCOD: M(3E<9\=UQDCZM6*2ZF=GJ2DLK]G8(9B<$KR]G7AW0^ZM_+K.K6%D"L [: 5( MW$%/9][K(\]_D>2Q'#M"1@PCV(D40B0M)2D]C48L(YH!J" MP0)%08&LEDVCE5P7+AJ,S11G>@6NJKAA4F#W,5N6]VK:?BJMR*$B"TXWXH60 M,9461I.3HJ3=S8]>S,J"DU67Y28F1JFW-K802HFLJZ>M2]U#L)VN,\4D32V^ M&<1LMQ[&%$Y@*M[LO!;;1N2H^*$LL-M!^U&I:WN/RO[2JF=W.OYW-^O;G>< MNV][?O DLXX);QUB9+'$M'C7:#4V"NM$[OK%%7AWRUOG]GTB:PY_?,6;3!EC M?=Q]TJR=?^5^G8A+,RQ JQX3_F/N':Z^ VGUT/RB_-K>"MJ]TESO3EQW/'UB M_;G:X<:3HO-]EZX[O7D0%!A#P5D,.GB]E\K&@Q<;P\;K9>!UQ?F1EXG_(_YL M$=\YQ1?5B!48[)NPZP%P&$6BRI5^X5RSL/N0!L>,:-^8 .^=CQ6B/B#L2LIQ MEKRD#T[,;CJ&&?/<&Q6RP+91J8&UL4$L! A0#% @ <(%C4[83?Z$U MM0 "K4' !4 ( !Z04" &%U<&@M,C R,3 Y,S!?;&%B+GAM M;%!+ 0(4 Q0 ( '"!8U._7+C3B6L -;L! 5 " 5&[ M @!A=7!H+3(P,C$P.3,P7W!R92YX;6Q02P$"% ,4 " !P@6-3@O0AF6H( M !G*@ %0 @ $-)P, 875P:"TR,#(Q<3-E>'@S,3$N:'1M M4$L! A0#% @ <(%C4WX;L"YD" ]2H !4 ( !JB\# M &%U<&@M,C R,7$S97AX,S$R+FAT;5!+ 0(4 Q0 ( '"!8U,I,R@VKP0 M ,\4 5 " 4$X P!A=7!H+3(P,C%Q,V5X>#,R,2YH=&U0 M2P$"% ,4 " !P@6-3D=5'@;0$ #7% %0 @ $C/0, K875P:"TR,#(Q<3-E>'@S,C(N:'1M4$L%!@ * H E@( I" P $! end